var title_f22_11_22704="Holoprosencephaly sonogram";
var content_f22_11_22704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64200&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Holoprosencephaly on sonogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Antenatal sonogram of a single ventricle a fetus with holoprosencephaly.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22704=[""].join("\n");
var outline_f22_11_22704=null;
var title_f22_11_22705="Normal appendix US";
var content_f22_11_22705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70354&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal appendix on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 274px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of a normal appendix (red arrow and markers). The appendix is located at the confluence of the taenia coli (white arrows) and is seen in relationship to the cecum (COE). Fluid filled small bowel (DD) and iliac vessels (VI) are also indicated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christoph F Dietrich, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22705=[""].join("\n");
var outline_f22_11_22705=null;
var title_f22_11_22706="Asbestosis lung gross";
var content_f22_11_22706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Whole lung section of freeze-dried lung from a person who died of asbestosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 243px; height: 434px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the peripheral honeycombing, which is most severe in the lower zones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Am J Respir Crit Care Med vol 170 pp 692, 2004; www.atsjournals.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22706=[""].join("\n");
var outline_f22_11_22706=null;
var title_f22_11_22707="Metacarpal head fractures";
var content_f22_11_22707=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metacarpal head fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22707/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22707/contributors\">",
"     Josh Bloom, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22707/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22707/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22707/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22707/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/11/22707/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal fractures are common injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22707/abstract/1\">",
"     1",
"    </a>",
"    ]. They account for 30 to 40 percent of all hand fractures. This topic will review issues related to metacarpal head fractures, which are usually the result of direct trauma.",
"   </p>",
"   <p>",
"    This topic will review issues related to metacarpal head fractures. A general overview of metacarpal fractures is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=see_link\">",
"     \"Overview of metacarpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metacarpal heads articulate with their corresponding phalanx. Thus, a fracture of the head is, by definition, an intraarticular fracture. The heads of the metacarpals are bulbous and \"cam\" shaped, thereby permitting adduction, abduction, flexion, extension and passive rotation of the fingers. The collateral ligaments join the metacarpal to the proximal phalanx and are taut in flexion, while having some laxity in extension (",
"    <a class=\"graphic graphic_figure graphicRef65855 \" href=\"UTD.htm?0/25/415\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the metacarpal heads are relatively rare and usually result from a direct blow, crush, or missile injury. The second metacarpal (ray of index finger) is most commonly involved, and the first metacarpal head (ray of thumb) is rarely fractured. In some patients, rupture of the collateral ligaments by torsional valgus or varus stress can result in avulsion fractures at the metacarpal head.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prominent swelling, decreased range of motion, and tenderness is found at the metacarpophalangeal (MCP) joint. Axial load to the MCP joint worsens pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rotational alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even small rotational deformities can produce significant disability. Rotational alignment should be carefully assessed with the MCP joint in flexion. The rotational alignment of the metacarpals can be assessed in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With a semi-clenched fist (flexion to 90 degrees at the MCP and PIP joints), normal alignment will enable each finger to point toward the scaphoid pole show convergence of the digits, but not necessarily to a single point (",
"      <a class=\"graphic graphic_picture graphicRef73269 graphicRef71612 \" href=\"UTD.htm?4/2/4134\">",
"       picture 1A-B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With the MCP joint flexed 90 degrees and the PIP and DIP joints in full extension, the plane of the fingernails should be aligned, and can be compared with the contralateral side (",
"      <a class=\"graphic graphic_picture graphicRef52326 \" href=\"UTD.htm?14/14/14575\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Skin integrity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special attention must be paid to skin integrity near the metacarpal head since this site is particularly prone to injury caused by a tooth during an altercation and are accordingly known as \"fight bites.\" Any evidence of laceration or skin breakdown requires aggressive decontamination to avoid potentially disastrous intraarticular infections. Prophylactic antibiotics appear to be beneficial with hand bites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=see_link\">",
"     \"Soft tissue infections due to human bites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A standard hand series (anteroposterior [AP], lateral, and oblique views) should be ordered if a metacarpal head fracture is suspected. Metacarpal head fractures often are significantly comminuted (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51598 \" href=\"UTD.htm?13/31/13823\">",
"     image 1",
"    </a>",
"    ) and may occur in conjunction with metacarpal neck fractures.",
"   </p>",
"   <p>",
"    If a collateral ligament avulsion fracture is suspected but not visualized on standard views, a Brewerton view (MCP joint flexed at 65 degrees with the proximal phalanx flat on the cassette and the beam directed 15 degrees ulnar) can be helpful. If plain films do not adequately assess the metacarpal heads, CT is the imaging study of choice to further define this injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most metacarpal head fractures require referral because they are intraarticular and typically comminuted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22707/abstract/2\">",
"     2",
"    </a>",
"    ]. If the fragments are small and multiple, non-operative management may be considered, but consultation should be sought before pursuing this approach. Any rotational deformity requires correction. (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Rotational alignment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Small avulsion fractures caused by collateral ligament injuries can be treated non-operatively if the fragment is small and displaced no more than 3mm. These injuries can be treated appropriately by the measures outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion describes the initial therapeutic approach in patients who do not require immediate fracture reduction or orthopedic referral as described in the previous section. Splinting is used in the initial immobilization of, and sometimes is the definitive treatment for, metacarpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22707/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. A detailed description of the techniques for applying splints is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute management of metacarpal head fractures involves use of an ulnar (",
"    <a class=\"graphic graphic_picture graphicRef65376 \" href=\"UTD.htm?28/12/28879\">",
"     picture 3",
"    </a>",
"    ) or radial gutter splint (MCP joints in 70 to 90 degrees of flexion, wrist in 20 to 30 degrees extension, proximal and distal interphalangeal joints in 5 to 10 degrees of flexion) or a bulky hand dressing in a position of function. Icing and elevation are employed during in the first 48 to 72 hours to minimize swelling. Metacarpal head fractures should be followed up within one week.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-displaced metacarpal head fractures typically are immobilized for two to three weeks using a gutter splint prior to initiation of range of motion exercises [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22707/abstract/3\">",
"     3",
"    </a>",
"    ]. Prolonged immobilization is avoided in order to prevent chronic stiffness, which is the most common complication of non-displaced metacarpal head fractures. Repeat radiographs should be performed at one week and at the time immobilization is completed (two to three weeks). If fragments displace at any time, orthopedic referral is indicated.",
"   </p>",
"   <p>",
"    While joint stiffness due to scarring of the ligamentous structures is a common complication, avascular necrosis (AVN) is the most significant morbidity associated with fractures of the metacarpal head. AVN occurs more often in displaced or horizontal fractures. We suggest obtaining radiographs one year following injury or if the patient is experiencing any suggestive symptoms to rule out AVN [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22707/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=see_link\">",
"     \"Osteonecrosis (avascular necrosis of bone)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Return to active use depends upon the type of activity in which the patient will engage. Advice differs for returning to sports and work.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Athletes should have full, pain-free range of motion and radiographic evidence of healing prior to return to sports. It is important to inform athletes that discontinuation of splinting at two to three weeks to allow range of motion does not mean that the fracture has completely healed. When evidence of bony healing is apparent, athletes can return to play, but should wear protective padding or an orthosis for four to six weeks after the initial period of immobilization is complete. They can expect to be out of competition for four to six weeks.",
"     </li>",
"     <li>",
"      Patients requiring regular use of the fractured hand at work can return to full duty when they have functional range of motion, are pain-free, and non-tender.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Metacarpal head fractures are typically intraarticular fractures that occur from crush injury or a direct blow. Avulsion fractures involving the metacarpal head result from torsional, varus, or valgus stress at the MCP joint.",
"     </li>",
"     <li>",
"      Metacarpal head fractures are often displaced",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      comminuted and accordingly warrant orthopedic referral.",
"     </li>",
"     <li>",
"      Small avulsion fractures caused by collateral ligament injuries can be treated non-operatively if the fragment is small and displaced no more than 3 mm.",
"     </li>",
"     <li>",
"      Non-displaced fractures can be splinted for two to three weeks, followed by rapid initiation of range of motion exercises to prevent stiffness.",
"     </li>",
"     <li>",
"      Puncture wounds or lacerations due to human teeth (\"fight bites\") warrant aggressive treatment to prevent serious intraarticular infection.",
"     </li>",
"     <li>",
"      Obtain plain radiographs at one year or if the patient is symptomatic during follow-up to evaluate for avascular necrosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14542386\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22707/abstract/1\">",
"      Ashkenaze DM, Ruby LK. Metacarpal fractures and dislocations. Orthop Clin North Am 1992; 23:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22707/abstract/2\">",
"      Light TR, Bednar MS. Management of intra-articular fractures of the metacarpophalangeal joint. Hand Clin 1994; 10:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22707/abstract/3\">",
"      Burkhalter WE. Closed treatment of hand fractures. J Hand Surg Am 1989; 14:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22707/abstract/4\">",
"      ElMaraghy AW, Devereaux MW, Panchapakesan V. Extracapsular extrusion of a horizontal metacarpal head fracture. Can J Surg 2009; 52:E10.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 257 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.96.59.103-3D38DFFA37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22707=[""].join("\n");
var outline_f22_11_22707=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rotational alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Skin integrity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14542386\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/257\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/257|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/31/13823\" title=\"diagnostic image 1\">",
"      Comminuted metacarpal head fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/257|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/25/415\" title=\"figure 1\">",
"      MCP collateral ligaments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/257|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40528\" title=\"picture 1A\">",
"      Examination metacarpal malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/20/39232\" title=\"picture 1B\">",
"      Metacarpal fracture with malrotation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/14/14575\" title=\"picture 2\">",
"      Examination metacarpal malrotation 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28879\" title=\"picture 3\">",
"      Ulnar gutter splint",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/43/28346?source=related_link\">",
"      Osteonecrosis (avascular necrosis of bone)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2149?source=related_link\">",
"      Overview of metacarpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31013?source=related_link\">",
"      Soft tissue infections due to human bites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22708="Colistin (colistimethate): Patient drug information";
var content_f22_11_22708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Colistin (colistimethate): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     see \"Colistin (colistimethate): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/10/32933?source=see_link\">",
"     see \"Colistin (colistimethate): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coly-Mycin&reg; M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Coly-Mycin&reg; M",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to colistimethate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Slurred speech.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid for breathing in:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may breathe in this drug from your mouth with a special machine (nebulizer).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10025381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use the solution within 24 hours.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10898 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22708=[""].join("\n");
var outline_f22_11_22708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154558\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154559\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025378\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025377\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025382\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025383\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025385\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025380\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025381\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025386\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025387\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=related_link\">",
"      Colistin (colistimethate): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/10/32933?source=related_link\">",
"      Colistin (colistimethate): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22709="Lichen planus hand";
var content_f22_11_22709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58361&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 396px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGMAToDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3NskkAk85xShSDwcDJ470uPmYnIB46UKccYB+ldiR82PizgEDjtk05ixJBHTsBSIykgAcc05CcZUfN2PTFA0xjh1JAJBKn5gOnvT0LDAVjk8ZJ5pPvMDjP1pBgN8uVPYD0plIlUNghz0NKCWySAPp60dHO3IGO3P50qqoGCOvpSLJUZsAjjjrTjydw4H16UxcAdMAdu1OJGBwQPSpC45RtAOc804HPPSowM4Gee2acc9TxikO5KAcjJxnrgdacoGB6DimJgAensaJZkgheWYhUQFiTxjFJlo53x/4kTw9obSq3+kzExxKOecdfwr54unk80y3UzvJOQzbTnHPU/5/nXQeMtfbxVr086yeXZxfJAMnGO5Pv/jWb9ixcKqsbjA+VSvBP1ryMTX9pKy2R9nleD+rwTl8T3/yK1syRzIEkkYkFR5nIGfStRZ0jQedNt5O0q+BjH/1qopbRSXBWe3kiQMC3kj5gB6Z4P41YsW+zEZSEtjHzfNnPT6CuVu569iUSRiYqz+eoGR8xOOKqTyxOAiPlVwN2OB7e/erQfarSyCWGNgFZkhwNvt69ajvVsoWRoJf3QUAswGQcdh+nNOJUdxto0PmK0s1wYh1CqTt9Pw9v61oS+SzFwqoi5VRIjbWPTPHvVTTHRkJVVlViF3iTB9enetKeWSJpfLhjWIjDRnDgHqMZ9aaWpMt9Clbywv5aQJGH3AHhlzz0J71pSx/6O6RQbGBLbDLk5PXH+FRb4Li2cyQTRuin95GQE9gR/Wsi3RIpiXcJGMnceXB7Dn3xVE2vqTXouI4JFu0eOJD/qyhU+nX1qnPIY5ITEZnRgDs3btnsfXmp2MkZlkmvmljY4KyIWIyBzj8qY8Mju8qktFgkBRsXHT8adiuhM1jPJpx1CMwtGpCtCHAb6lfz5qtuluFV/uqM5UZ4/z/ACqq0aKM7lcFdy/KeCKiSW5KsnltFAFyGL8tj0/z70rWEk7D7szom6J9pcblbcck+nPeqkrSqVWVJiOC+05Un6VIbgpuUbwc7o3DdD1DZ/z+tFn5TR7Mbw24tiT29KrVK4uVE9nCIPMa8LSFlzF5Z24bPX3Hf8acGMi7lG1Eyu9xkZqU2qtsYRFW28Mck9KgcHzCqqxUYY/N+v1qea4kky1e3NtFZp5Il+1lx8ycoVxjOPr/AEqNLyGR8PHM77fmz0468VAkQuElj81ohy27GMemB/n3psKCElnkaTJKnI7Y71aFy9ht1E+Fe2uWUEfdHIHP+f506Az7T5zPKhJAOTk06SwMiechLhsfKvBI9KSMmFD5XLDgKccHPU0K9hcpfaxsr/RZWQsl6rDKscEj2H+elcmkLpO1u7fJ/DvzjGcD9Mnn61b1C/mivN6FV+X+NTj8MVh6xcT+YpEkecn7nA9fzrSKMJRaTNaJBaiZfNV2yVC7s/p/nv2rVsPD11NY20ojlIeNWB85e4+lcPNdTXEWJAUZBt3LjHSvcvDquPD+mD7NcDFrFwFP9we9b0aXM3c8XH1XTseukjJGclfUUKwzkZ9yBSkAtjp/tHrTSvzc5zivUPkmOQbjjkDJ7VMvQHJpkY2rx8vPVjUoGdpAHORSuCQxF5wRxn1pyxgqQe569afGB91sAdQD/Wn7Tjkc47etFy1AaqEdeWwOnFSqAAWDNg9QaF+RgCD9fQU5VIHGKhs0SDGc524x0poHGGHHtUgX+6SR25pFGCR0B6UrhYcpA6daCu7OcEHqKTByO1PUZAzg+4oHa4qqAMDA7V5z8a/Ef9m6LFpds5F1dnLY6rGOv+frXolxLHbW8s8zKscSFmb0A618z+LNZm13XLrUpSohLgRKzZ2oOg9vX8a5cVU5I2W7PYyfCe3rczWkdf8AIo27IkWxgwAXAUYyx61bEwWMs6zHOQiZwFJ7kisqdjGwJeUTEfdC5HtzV6GaSSIA7OQOWPOff/P615UlY+1UCz5sDRKTc3EUxJKEkkYPBz61cjuJcRPDJHM8XTMYAx6k96padJdLatbxTRlSQTuA3H6E0IVluGy+VXsyke3alpYHE0ZZpbhg8ECrBs/eoZd3JPYdqZZxNOkqB7ONQSWjJG8nsMt1FA81IvMmJdXcgLFjJX0x2/H0qSaO2mQSSvIu7CqzQjk44HH+eKLpE20sWTvgkZILO3zjBE+FI4Iz6VBDFFJMrlLZCGUbRMArH13dO/U/1qAIbeIwpbxs74zKxJ+U84A5HB/nUeoAQQhZbkhAD8pUMACQfT/PeqVrhyvuWfKVZVEU623lkgvK6t34CsPb/Peql3PHZ7isss27cmfK3qRngg0v2l/LBS5Z7TqIiBjP4DiqFxd3EM58vyS2cAYwrjrgA9Kqw1F7sU3IcRqiiJR1ZU2ke+Dx61I6bY8C5LFiBwu1/wDP+T2qjLPLKib4vLOCSqjOeeuc4zUEuI2USpdOzMMfuzgZ6DPbB/z0q0inEtPGiNnDE4IG7gnvSsG8knrtx8ocHA9vf3qKSYMsYYT7zlcfMe3eoo2+z3cYlhMZXllzgEetTutBWLczSOqlYkkBHIbjAHcEfhTVlUyglWjcYUFR19MZqaBJ7tzJFOhiO4coB+X+fantHeq5DbXVVB3hcE98n0/yakgYLmcMTvbIBUrKME9hwKIZ3jypjRJdxLEdz04p6Su0J8xdrDjLdSo9Kcmnrcq0lrIg8oMzea2Fyem0HkcUeom0txs5jlUKGbeRhmOPm/w/+tThbSRbmTcQw+/jqD+lOtYJrzBRFDqufkI+fHXIq7YosUgiEjfN/AOh9TSbsF7bGZA1zHLtTcsg7qTn047VZltYTpzyzTh5y+DGq85x1+n+e1dJq0OkJpkMlleuuocB4Cgbv1Gawo7ZLgGVSVZiQRjG4due/wDnvTu+pCmpq+xitteLY8MLKRgqeTjr1/CsC90MyMeB83ZGIx7fh/ntXYDCzqJAQFxuAI6+341n6uHgbJ3lH+Zdy84//VWkZPoTM4VopTK1mDhyVGWA55AFfUWm6bJHp1qmwDbEgwACOg75r5kvvMXU7OQAfLNGQRk/xDjNfXFk+6zgLqu4xqTnPXFehhr6nyecycZxRdPykEE4x68VKNxYE/NgDqOtOMR5KjPfr2pVQEhg2B3AOa7bng2sL5Y/hbAHTPY0AYUZ55wMd/enL1IzxnNPIC4PUHp6UrjEQYCk9ckHipuoOOufyqEgOO/vUwHONpJ9zipZcWOAJOeo9uKAcluxH4UsZynygde1O459+Kk0SExlgelL82eD+FKuPmHGSeT1xS888igdho65XJpwGDg9TzinfqaMqqM7MAgGST2ouCieefGfxCdL0GPTbcg3V9kEZ5EY6n8en514Z9ndx8zSLk9MgLgDmtzxvrx8ReLLm6VjsUiOBeSNg9Pr1z9PSseMDyiju8cijIZyOCO+K8ivPnqXR9xleF+r0Unu9WZ6wPIQ5eR0XAK5Ib6+9attY+arbm5Zdx8yTkmnJEqgTtOhJYj92e/qfb3/AMKuwlk2SMQucffUMCeuTWEmz1d9ghtyVwix/Nn5iAef6DP86FRoCplViARkRpyfbjtRMFmhI3QuSuSkY2kkHrx1+grTGj6hDZi8mtpYBt6k5GPpmpvYUpJbleBrchylvI0n91jjqfX2449qjmuLqNDD5skcMjcIeRjPr/X8avW7CNpMTGJG+9lAQO+eff0oulhLIkklvIQoAPKqynkn17UJ6kJ66opxjA8yCcxyKfvdcj+fpVubVmis/IYsVkTa27a6lv7wIORx2/nVCFbea7xGjbUY7j5nBHTAb/GoI7hi8ywrsTJLQqFbkdMng9DVLctwu9RZ5vtGBcskYA2q3CDjtzwar39xLCZWF7BC5UhdygFsdM4ODUjTwsyrCs8SYAxImNh68djVd7OO8AC3EM04YlIfJAyMcgH19sd60ikNWKcMq3LhSBFMBkPDHweOSTmrtpEJYpCJ0lSM52s20g9P84p6yRwwhYlNux3bnLKRzxtXt059aW6ihHzNJFI0e0BWQLIQRn5B3xSJYkdzcR27mKJmcA5KneuM+g/Cmwu8khm8oGONeCjYwepODz/n6U+4iO8PbM7dAd37tj+VVp28sut1HLCY/vlVBJ+jD0xS0tYTEee137Y5nilfgrtO314HQVKJjKrCKRpZclypyCw9etVjcBl3RyNNGoZgSwGOPTv29u9KI1mLFowuQCoDZBpsXKWITKwAVCzYPDMRj+lSNpN+8SXMttmyDKrPuyFOPX8azpd20J91l+VXUFgR/Q/4VI+rarHYS2DXbPaSkSFUXAZgeDg/59qcRSTWxqRxSwp57GIAHGUlIOOvSryXDY3yTSSbs8YAOMYz/wDWrnReS3DKhnCkAnnAIA9BV+KPzJQqqGkI3HI9vWpcWTy6EglhbaEi2yISFJzggdMf5/lUst2qzJiIlWZdzI+eO59BVa2Jknjjlc20jHIkzgAe5pt3GsdwfKuhcAEhwAMH3H/1qOXUTtcZdM7vIUZmG3Cswzznj/P+NY+tMbiMGa7kBC4Cv16cfWrg3uD5cxi5JxtyfasXVLuOaVUu1O7hlPQ+9aRRM7W1Mm3EsmoWMcTFnknjCkk4+8Pb3r7GsIGFjbAwAERr3I7DtXy/8M7Uar49023hjMiRlp8g/cA6fqa+wY12xquOgA7V6WGdkz5DOHz1lHsjMICvhPpTgq8MD0PK07gSEkcYyKANxzjg9q6GeKLwB8vbvQqcIwGexxS4xginkDH+IoHYQKoXHRc9KcqZHBbjuaTB3ANycdTxUoHAHGaRSQKQOAAfYUudpHHHp3oCDZgA470bRuJ7/WkXqOXg5FOPHTuaanUc8enWnD5icUilsA5xyMmvPvjN4iGlaCdMtncXd6MEp1SMH5j+PSu9up47S1luZmVIoULuTxgCvl7xRrE3iXxLcahKpCFtqRv91V6AfyNc+IqckPNnqZZhfbVeaS0j/SMzyo3RCxcJGTz1569vWtGS2BRGWMNKuAFjJyc9+fwqSyihRgY2jkmB5t9jBcY5IOavM0EiSSAIygYMmWDD0464ryObU+yg3cz3hkLLgsdhHykDOT2xU5gSOKVSI2RFLPjOR659uaagMeQQHfIAyCWcfTsKnniQ2DQWe/c+Cu8Ank9PbvRe9ja+xDa20s1uzwW0kERySWkU5A67QSOK1Hu7lrK1ibVp5HU8QToRs5HQ/wAXFWNP1PR2tIV1eaaKWQMjK9viOEYwNrgE/iaua9p+kWF3EPtSXcDIvlR+ZuCYHVXU/hg+orWUOVbnK6zc+VooG6mgXaQk5DbseYBke1U9REl24kMixQnAKsB19z3q44ilVplSZ1Ktw5BVD17dhjp3qtEzTozMwjkILZQDaw46KaxXc2h3M0W8VvLmNQ0a8fuPuHnnj/P0q15M92rpaKy4DNJFIA7EZ+9jjin31w0iGO3HzFht+QICAMHp3H9aqsmoRhY5fKZycyMtw0bdupI49OKtK+5ert3JzOsEEhLWbSFdoTLKyH/gQPvx+tRF5ru3EUlyoiIX5VTfuIHHzde+KrRXMcEZ+1xC6lLERqtwTIxz0yMgj6/yq7aOgVJJLGaFXO5bjAJQH+MBTz/k1e2wrWVygfIV8M8cSHlC670PPAJHT8e9WWJV/L+128sWSPOhUSDPXr1471cNhFL5i2s8DkNghLcAnaDyRnkVVvtIa2kSfyvLlfBLPGBGSBjP+RSuJzUiPVJj5qSbLiNnAJO75WI4Bxxj0x+dU7m7DpsF4ELcujxhsg5OVx79qSS3vrYEzxxfaARtbO0jn0ORyM1SvTK02fLaNj9wecCWBGePX6fjVpX3HGKtoSzATPAJ0WKXbu3FQAOeDx+HFQXQIKbZ7iKMZYFAHB9vWmjzIz5TyNEhG7beP97sRu6EVJAbCJmUTLC5OQyoRtyR1HcfSpCwkU5n3vOEZEO1HUlGBxk0s8Hm2+9LsPBG43+ZgsPp/nvVi5liiDeY8MpXPzluDz1yPzrJvbSFog0cahmGVlD/ACcdM49//r1SJae6NKfmHNxHb3cKn74YArzxx9KpXtz5LxiCRWgPITJyB9ayH1KW2uQknlBUPyqmQR+J61PJcx3SiS3injkAOU79eoq+VrUz5ifeVV496qo4ZJW3OO+cUv2lYIiZFZGU/u3jXacn2/pUUmq3FpayRyF5XY4imZAzr7HI/wA81nG9F27JezyRz4AVTGFBIHtRyt+hm6ljQudciW2KFZVmwdpJ+8OnX+tYjag0pTy3cSJ8oL9fwPaq9/fswi8uUyMq8EcMDknHvVBZgULPuIJ5474/nW0YJIwqVe57v+zTpP2jV9Q1V1I8oLAmOnqa+jMj1H515H+zXYPaeBRPIhR7iRpCcYznp/SvXAVA+6fyrroxtE+LxVT2laUijtAw3P0PrTtwYDBGPbimrhR0/WnqAeT0/pWxyICAy/MATjt0pyjgdfxowQGHB9wKXaSc5yR70h2HAKSG6U7knrx396aM9ME/jT/pgUFokGSaaBuPJ5zx3poOO3QUoOcjqcdqRd0x69PT+tABzgd6UdeOR3xWN4w12Lw54fu9Rl2+YqFYkzje5BwP6/QUm7K7LjByaSPNvjV4yMUsehabJuAObrZ1Pome3rXmFtbu6skUqFn+fDZGPYg8H6fWoolnluGvrl2uPOkDSYHzZ65I71ZnuoHEkfnGSHO4KFwVHHB7/wCTXj1qvPLmPs8FhlQpqEd+vqTRIHgEdz5auFAaTkY45HH4c1bnXaqhzHIQoQGPLFB6kj8/1qmjT3ARXnJUH+IZIHb3q/HDC6o6iP5jgFm2Pn3HesJHopWHRqAqCNi+3K7iOcnpz169jRZxefKsZdVR8K1xuEaxAnkMD1PH1ptwqRs7eVKSyjaoO1s/3s4NbWkeEm1vwbatpd2kpEh86O4lGwLnn3HcfkaulBSd3sRVqKEbtmNa6eftFzGwuJ4EG6K5QrJEwxxuUHOD6+3Sn28IhmQJJbsACfMgG3n0J4rduBa6DpE1quoGyv8AcMwxkuygDhN23HesqcIzLHLGkXbdsJLE+nYGqqJLREUpyneTK6GaO/ufMidzvYRLIoZSPw9P0ptz9puGP76KO3UBGkCbsHk/w81XFyVvZY4Xk4+UruA55GQOhq1ZLNJzBJBEytkCRMMW6dTxUrTc6NYlfyLhbebcyPEQoGyQFjz/AAgnP1xVe/ubgxbINwlGAyXK5BB/u59sc5rSurcB0W9DXDrlchSu05+bHY5+tVbnyFtpfJFxHI/yiPDMNuMk9xxwacRxd+hRupr1EVbpLGW1RQo4Kk7eCcfwkDFQ/avJOy1aa1ONu5BncDngg5Bz6jHSpjJvaKSNoJiemYgCD0GADgjjv65rQuYJoNE86Se3+ytJnChUdD6DHOPatGVotGU4fPuoU3XEb24IBkmjG+MkdsHOMZ7UySyAiZ5V2lfuGG4Zvlxy2Og69e1JFaK9zve2meOHhp4ow5yR+ozz9Kiab7HJJ5jxgr8wBXbvGcjBIGRnH1xR6Eta2RR1FW3tDcXV4zbVAF224bccYx2/xFQwrJCOJIpWQbYoSxJxnqM8cVE88srSyLfKyZLGOXHyAnBAJ547Y7U9GvEkTZcpbshGHGChxz+ZqwtYme8t5raW32SpszmKaL16EHoOc1D59zMjmIJFDGBncqntjBx16VYijuQ0ckrSMkq/JtG8YzkjB689v61B9ktproeaPs8zNktnyoxz1we/1paIHohsMlyFaS3jDkkZCdB9QR2qpcuZFlX93GzZ4R8Kwz6dqtXCzWY2rLI4U7g2QpAPFYmp30TRtHNHGsj5AkQjDe5P1pxXNsZydkJeOVmEFxGiJu4kznHoM1Xh1n7BqStewmQpwCDw1Z63wVHiEiTQtldkhOaR2k+yBHhSSE5CuzDKnsM/StuXucU5lnXdWil2nymVJBu4GMMT6+grLuL24CqkvJxlHPzEj61WlWKJWhuF3Ix+Vt5IX2qkzvYsUTMtoeRnqB7VcYq2hxzqtPUlubuQhnc7gTtbaMHPt/nvVrSoJb8rHa+Y0ssqRIg6ncemDWaYmuQTCpLE5Ax/n2ru/g/ok934+0m1njIVJDM7IeyjIz7Z/wAKqW1kclWo1GUuiPsnwZp39l+GLCzChDFEq4HbArax7UW6hbeNBnhQOKU4z0NdS0Vj5tLS7KarkE8ZIzQwGeBnB9aRWxLgAAEEZHXg0/OWYZ75+lUZOzBT8oGc+oFPyRwDwB+NJtOOoyPTvSDOTjr14PagaHrnufy4py4UDGPemY4Oc/SnICw7+9IpXH9+lAIyM9SO1N2njH45pyL83bn2oKFkkjhhaWV1WJBuZm4AHXNfNPxP8XnxdraiAsNGtsrCoOGfnBf1Gf5fjXWfG7xhJcNL4c0a9SKNRi6kR8Fj/wA88/TrXkdpbi3kO1GVtpZFYEhsdelcGKqp+4j6XKcC1avNehcgcLAxMiwLGoBVgW7/AKVLDvwFmWQzDlGhxIGH8Oec46023jZxvS3Jkx87rOMDI5XB71Npzqs0aOJo1c4UtGBt65GR71wvY+jhEvwziOdHt4xLPEpBDoevOfxo+0GWWCJr+KNrg5LygrsHYnj3NJNmRmdlAVR8o6bfTJ7H2PtVeGe5hvVltyknlFT85IzgjKj16dPrmoS1szVrRtG5qNprOmaUbiOOQ2inHnKfL3dt20849Mdq2tE8J6LqPhqK6S9k8+QKss8cjICScgMoOVxyAefWrs2v6P4htBBBZONT8orhxiMkckHPfriuK0zS5mv3udPuJLG4iXzcB8IcHgeh+lapRiciVSpC0nytHYeI/Dd5pVok1pdQ31uEwf326TaThcHuMkAda5wyGYM379VHDBwSARnpz+v4VKdS1O8aO5u9cD3MCoFjESArycEEDBHrVISXkVmskLNKAx6Bd0q56be2OvFS7dDalTko2m9SREtUYNPbiZVGJCqjJ/3fTtVZVEsB+wrdAFMAB1+XJ9PrRc3UcKou1knfLLhNuBwCTnj0/KpG8vMbTiURlwQWXYwTjJJHB60tUb26jZLqYQ+VNLEkUnLiWAoPYZHf+lSRQRRJuLzRBPmVoPnSRge+On+elQXF9OD5em3AkgdgHJ2sGAJOeRjIH41DHLDBDG7TW/mgfu48GN245IGeRitFcOV2JLi0UbLiS32gAHzPKIxnPORkEfl1qpFb6fMkolihuRGwCF48lW/PHStI3t0qyKjva7y2zyTyT0OQRjv0/OrKb0uzIZYSGcKCzrskwO+eCPY+tTdibdtTKuvJtIRNAjLLKp2pbAug4wRg9Op/pzWfKJLgR7JoWZB8xnjAL47Z5I9OnatOeO1S4It/JEjHAdAY1VSRzkcHOf69qy9ahl02doXijMsDgF5eSeOzg46HpVRbFG3QrXVn9ndkcREkBoklfI3f7Jxxwe/41RVDCzeaidcZceZH74C9O9SPMso/e3jhscR7i0bAZJwfwx9aW0exiglS2UI5JdWeUhRnBwBg5ORye9aJj3JrKWaR4RazoxJyQUOFyOPu9M459KtT25t7qYamiM4XokhZTjqMVRtSQVkvoMwncUNuowT3yRyMe9T/AGm3lZUMFsmBtw/3ig4LbvfkYpNdiGMaK0vWSOQuI0b5l3dF9h6fX6Vg6/JpUGpSppAea3DEbG+bIHfmrOqwKCkkZLfLtWNmySPUEdRWRbag0E5H2IM2No2sCMHn8/8APNXCOlzlquzKFwEkwTCsi5wGAwcf41LcNp86KdMbyLgKPMikJwxHfmtFT9oEnkWqpHyzbnA2+nuB1rMu4Jrd/KeFJ8fckUjJH9a0TuckvIfEv9pW8kTRxI6jJ5+8P8/561k/ZERpIbhsY+XC9CBVxrqB58XaPbycBXHygkVpy6bLLZJLHLHIeu3v/n2pp8vzMuVSObgtksrtZEZ2gb+7x/n/AOtXvn7N2jNceJL3UgA0KxiFWI65wx/pXk80U/2U71hEb5OVHJ9x6f1xX1D8ANCfR/BMEk+RNcDzWDDGC3OPyxVU/fmjzMyap0eRdT08P69qXK+tRDp1Jp4QkcKa7Twk2ypjbkn5jnP0pe/19qcMcknFKuSM9j+OKDKw5OOvBprLuOcjinEDGOnalycEccUFeQgBPHPpTkyCR29KRV+bgZqVBnHTPrQ2VFCJnnpXGfFTxlH4T0FlgKnU7xSlun93jl/w/niun1zVbTQdJudS1B9tvCu4+rHso9STxXyn4j1q58U6/Jqt/ct5hY+Xb7chI+wBHp6/jXPXrKnHzPUy/BuvO8vhX9WKdpD9rlY3CSebJmRgGwWYnOcnv/Xmr7wq0QF0CzOC8DMSCwHGPY8Y5pNgKqHUPGDkKTtbOPvA59atLLbyJHGLie4ZSQ1tOv3T7Hr6c15TbZ9fCNrJFS4Ty2Voyzksu+BxneSOD2/H2xVt0SKV4py0I2hmjdcIMc8Ed/f3qtBD58aRN9odFJUEybiQDnt75/nWja3EkMchMnniQbS23cSOvTtx1/pS6HVFWGoGAaSEJJFGm4+p46ZPXniozGsh3ssYZyWX5fvdc4PQH/PappESeTZNItvChXMqjOBjuvoMU23ik3SG0czRMDuXaB14x/M4pWNI2NA6m8egDSnt0CiYSRz7fnGTnAPTrz+NN/d29sq5OBlQAwx9Sp+n1qI/aIZUEDKhHUS/eQeqn1FRtJIoV8KJWBydwkHr26HJ6fnTfkL2aWxah0qDVbtI9OtDNcurMqQpyoHVie3bqKNQhvNNcWt1YzCR2PMqHfjH8B4BOah8Ma9f+HtYlvba1S8DKsMisSrMAQwZSOnTpVrxTr934ivJL2+At8syW8DswdR06dCT/kVXKtyff9pyv4SBEO0G4ackDAWTh8/jnn2qFmhiQr5myQgHZG5yPTg/0+lQ6hbx+bbyI7CSOMbk2lWJ9Dzgmi3SMsnn+VtTI8pxjcR/tA9KEVbS5M6xlYwllujYbzKzh1z3wP8A63WqUgR0xbrG25vlbjKY9jzUzLDFLG8EU0WzL4jfGTn0PGKvyK7TSPA0MsxIaWN49px6HPuSP/rVWw72dipHdyJFGGgmRlBfhd0eD36/pilkktZnzEJowi8xGJhk46j5fX27CknmKbI5NOkC5yd670x6jBqaeXTVuJI9IvFkQ9DIj4B4zgkAgdeQcUt9TN7k8WntPbRx2UxnQkgtIhwD1I28EgcZqpbte6QZNIuBFb2t6RvRlTEihgcqSMDpwaY9zPZ4MQZJXyIzHKJcAnJwvUdqydc1XUNfEVtqF/GRbho4I1CoFDMCVC46k9+vvVxRnKE2/I9Vn+HWguPs2n3VxsmXzdpUSqp5wVcAYrybVNOm0jV7jStVsmS7iOVMmASGUBT7jvVjQvFHijwxCzaS0PkqudrLxg4BbB69OvrzWJfX2p6rq7atrU0purr5i0+TsA6Ae/sOlaNRtozChCtTk1N3RbSGOJS0kNwwGfMxGGHA5OB659aR7iCQpHaQCNGUKysDsP1B5HStfRvEt9oEqXNpZ/bHh3qGeLfkMAuWXvz/AIVh232G5ef7crw3AVhvZzE5fqBj06/lWcV1ZvdpmLqNuqxFSksAPzLKkhAPofaqtvNFFDMl3avdq4BjuFOdh9zWjq0N1HEp+2zTqQCc4cLx0Nc3JvtZAzxvIp53QnaT+Fbx95HHX0dzXESlo3lbD5UJPF7DuP8AOaS9luGiaG7gyQAUcKBkjofyqnC9tcK32a7liuPv4kPBPuP6irtvd3DSCC7RJWfhZl/z2pcvUwTuQII9SgME8KvMpwrBMY+tXNJkexMlu9s8jcAgHqOgIp95BNHceaCsciY5Ujaw+lWRF54im2xeYoyXOctjHX1qZPQaiT6dBDq2rWelpDLHHcSqu5+SM85B+gP/ANfFfY2iW0djo9tbxAbUQAY6CvnX4P6Mmp+NFvJFJNrGP4ONxx+uCa+lWGFULxjgV0YWN7yPnM2q81bl7IUHtmnDdgctTAOflxnvS8+9dbPLRCwA6df5U7nAApMbj7etPjX5s/jjsaZKQg6HORTiBkkGl25z/Sm9GxxzQVaw4dMjNOBAUlsBQOc8YFKo+XHQ14r8cfH5Qy+E9GLCaXAvLr+FV7xjHUnv7cVE5qCuzpw2HlXmoQ/4Y5D4ueNT4w1o6fpsrx6VZsQD/DK38Tn6Dp+Nc4ls9shnt2V7eAgFsgs+7sKqR2y28QMtzB5vDccBsnufWliEkdxMcxOF+cII/vAjr9RzXlTbm22fZ4bDKjBQidFBptobEtcu0ILfMhclYzwNzHt+HpWTqsGnWt7CI2me1YkrciNtuOuQxx3+tPju7uR4rRpBJayMZFSJSC/oM9yPrW3Dok09vDZi4lubw5eSGd87sjjAGeamNNy1R0cypP3mU4JXt3LGaV5ioClDtBB5GQOMe4qVNKubrTTcwzW5jjbayCbzH+uDgjPTP9Kjk8OS2TTMUUnKgxSlUCE94yTx6H159qlFu1g8CtMfMJ8sIzAuhHvghh19T+VQ1yvQ3jJS1iyubdo1DQRJbyHI/eH7owME88Hj/wDVipxJA0UnnRJKIm+WRCFbPTPqR/jWhokWnpcn7VBdyqVDE2uNjHJyTxk9uh7GqqyTSXzR6faGSPzgkkryBooycDDMeg6evvRa+pre/wAhUSSAKYgFm24EF1FgkeoI4ORzz6Y70xkKXEiyAo5BfZIpAfPbHft3qxbJfO0073tr5QbbNM92LpmB6bAADjHPsM+lFvdOyR2zMqxRgzRxq+9ck5OR97NN3FzX2KcUtp9mdgpimcgMol/9l9c+tV7OVbiRReS+csZyTIBlByen+HSrMssXmLIr27zbOVDf60nvyOw/lUM0UdtAFt4Vm3LzDPzg92Qj09M8ehotbQvQbARelsxTtISeYx1P3gOh7cfhTpIkeJyYvNVWw6PzkY+9gd+naoH3xRxmBDAkjD5beYN3GOT3/Kklv/LaX7RdypOn+rEsRDE56ZHHHPNHmh27E0MMYi2o7JJkKFSQZQkE5Ktzjqe1S3MLXFoIpLmCaLOxY5AyEY5GTnA5H6VA9014Vkms1uiVIeRB87Ad+wPXjnNNEsixOPNLxqpYQXKjaB3xnkjr6imS4t7lmzzbb0la4jynDQ5mDNjnIHIGM0jTSLP5xuIl3kr5V6GjLKQBgHp7fU+lZkDqZS8kM8DSkLvtzhBxnIUdvXrVqa8YIyxTRvjho7qIxsDntTS1Ja1LOoiK3t4y9jCiuPMDw3AJIH4gkHPGR2/CuduDYTKDP+9YAsu9AuT0x0yPX/69FzbS2M7SXukbw65RVkEgTJ4bg5+g71DaokqhbSadbsKZBvO8kdMAHnP09T6VeyITsmiUW0TQS3cbhFLEBbeQtjaRgMrc45U1ais7iaVVWxuLiWQlY2aQZ39B8hPH+NVZ023Ly3Vtbs3P7uT92cDjAyByM8YNbGmp5N6GXbM2SY8FWRSSGA6nPGec5yKTvbQmV0ijqGn31hO37ueSUAs8SxNHtx168EVTkvjqWrKb0ou4CJYVTkADGenXFeu/23ZQ+FoRLZXkkqYlkiiO7emASwYgg5BB68Vmat4KtdasotQ03SrhbiWMSGJ2Eci8kksOxxgD8O3FPVI4I4+N+WaseUa5izkuFtkcWqOQs0SkCVR0OD6/SudkntpHxHKAxOfLI2kY78j/APXXXaqj6fOItVtLpEj+UwSnc3H91hwRn+o61zc8Ju7l0ZAw5ZY5F6j2P1qoMqu76xCGyjlYG5hjaMjDO2PTrx/nvVSXTIzcYglnilz8rodyPU9mGClbeZYmjJX7NNz37Gty22yxIsiAAcHbwBjv/wDWq3JxMYxT3OdNzqmmSATIbmInIYDORWtpOqW97cncPLcDARyB7n/P861kkXYY7nyxEoOSFOW44Prmqy6ZaSq02AE2kqwPLH+mKmU01qgcXFXTPefgHprW2nXV3IgBnkZlx029B/I164CAOAM4z1rjfhVYfYvBtlHvLkRjLHvnn+tdiU5+XjHWu6hDlppM+NrzdStKfdi9sgfhSfL70h+6R268U3PuK1MrgCdxOMVIAWxwaU4OMHFOUHPHApXLjEQKVHA5oVemAakz6VgeOvEkXhfQnvXUSXDkpbx5xubGf6ZpOVtWaxpuTSjuYXxR8eWnhTTJLa1uIzrlwhEMIOWjB/jI9u3qa+aY2WUzPfPsvJCZHmYFi5689ee9M1W7bVNQudQvZV+1zuGYtkn5znIPX/CtXSXgtdciupI4pswlsGM+WCflyx74JU8etefVquo9Nj6vA4OOHj5mda3KsuTHMwQp5W4hVXccNnP1q4fJt5ZJRvb5gynJG9c4KZ7df5VSvpzdXkvmAl3wzJGMKpB2jbnnt/Kqt1G7yDzTJ9nZd8bbiMHPYnOTn09KwS1seuo2Og8NO736zuDBDGyxRsW3bB3I/Tr6Vu6eseqX73BupTd3EoLiFir7Mjdk9M/L29eeDWV4PvbvTVMSwLfbjkbHDNMhOMD6d8c8V33hy/itctOsNsqjEsTx7PIPY7d2SeSPp+Fb03ZHHiIzbbSMq80ZFee2nVry2kEht5ZpFVwwySuDycgAH3Fc5CHjuMSW1vGqOPK8shSpPyhu+R2/rXReJNTh1Fbe4uGiEkZ/dPAu447K3IwcDOfesAyE6ZdxRzu2EWNeQDgngjJ59cDvzWFR8zOrDxahqGoSE2VzCt1J5xHARwmEHdR1ySenXFdB4L1jw3awCJ9IfTbp49jT3DvslY8Md5zjkHtgVhrskspIZJPssirvn8xTiRc4Vd3Zl67e/wCVem6Hr1hc6TBpcPksIowpSdTjGwdNwGc89O9VBO2wsVO0ErHNCw8J6vdRtB9mWREZNyOMkg8Hgcjoff8ACuZnsCXvI4B9rgRsCVHAMbY42j06Ec881seL9EtNO1CWJLG3sdu545baLETr3J5znP161kWGo3LKTFGfLbEqqvyEEHBO0dx6cd6JNDopqPNF3XmQWjyS2a/aJFaIsikEEnp2Pr149BUGovFG0FslsFPIe43FQCxGOB+dSyTRBImSNQMFSYxgggcH06Zqxa28800Mdo6TyzFERZsLwRngjj2/HmstmdN7a7GfO0kgc2as0f3mXKyBgOMAED07GlXUI7MMt6skSb8OjxlCAOoGTgHvVj7KIJ50dZIp43C4iICEjIzken+eKgupZA/lfaFkkK8+avYjhck+uaFqynZ6IbFJb3EzyWsaGAc/K6xydCexx+FRM5LmDdbyTFSxWYgMpPbPOapuIIp3MkSKwIO9CBg9+P8APetKJWeHzWa2mjUruDp0xkgZHcDPbjNaWvsVstBhaNZ1in0+SKTcGLooYKeob5cHGPQUXepNFmCO6RoHOF+1Auc49/ujHTr0ouDuSUG6nCLyYJRnA9Ecj2HBxWYk4aN2glt5R8zFZU2lMdzjt/P0ppdzO3crPEoaTbcTwKeW2SKR0yBt5/8ArZ5qx9nMkqyxq0sKMFSSDClSeSMDv1z/AIVe0tdt0x1K12puEn7hkUkv0KZHTGOPavWIW0/TPCc9jYWkeq30qhy8LRpOoBwG4OSV4NP3nsctav7Oyte55DM80kkiG6cSq3NvdRfcGO7Y6H/GnRJLCj3NraRRRBN0hDgqc8bhxx0/n3rqdX07Vr7RhcyTD5IZAA0HlvGoPQkj5vr7c1zqnTNPiuk1A3Ed+vMJtmDRycAHIbHftj+dKzJhXjPbU6zQ/H9m+hQWmraZYXNuqlS4uUVh2Hy4GM+uazde+LGm2tl5Wg6R9muj925uGZgQRzwCcHPH4Vx16tvLGzz2UQwTi4hO3cR0xjGPxqhpVzY2momZIppyrBmRgrEqPqPrVxdtbHNUwdO/NYjvtf1bXbiFr64u5IVUhdib1VQSTtHbrWU89u0nzOAV6MAQck8n2rovEPiKXW5QltpskcUKbI2jUqqjPzFs9R681jT2TI4R3i3qcFSp2rwD97GM1SffQiWkdCK+tYQUa3me6RkV2kRNjRsRyB64PHvUthBdxvmzv1djnKuMEADOaopbYQkwFccb4W4JPfFXrRlgAMCzrMOdjdGz39qt3sRDU303RKE1CPbNwOvyn/Oat6VZxTT2pmV2gklVDEpwDlh+nPSsuHURcQCP7IPPzkh29+fpzWzaxTWRtrnYjSJKHEajPII/D2/GsJaGlRe47dj6y0iIR6bAiDaAOB3q52x71S0OVpdJtpHGCV6davN3HOTXq27HxC2GOQASRwPbNP2p3z+lISOPajNBSADJxnAzxT1Hzc96BnjNOVcsPekWkQXt5b6dZTXt7KsNrCpd5HOAAK+TPif41uvGOtNdsZI9Kts/Z41H3BkDdjuehJ/DtXUftAeOE1fV18O6TdObO1bbchOBJLnge4H88+1eTRbd8ccir5fOQDn6cH6VzVp391Hv5bg7L2s9yRppVVdsryRh9iuSM528ADsDxg/4VcCgxfJGHCqNxJYsARzgexHPHWqe5gZWgTAYLIpUbQCOencnirsCPEyyFRC0q4Yctlc8nAPcn2rlb0ue/TgRMyyGI3E8amSJf3SAkoOQRnGPQ47Z61p2aNsTzi0Dxcbux2nqR0JHU9KjtoI0s12MfMiIZG2gcfTHHAzWvZwSzCberCIp58RwDnJGR2GDkA/X61g5HVGnZakEMYkl3x2yTGM7spx1PJxnGOp6iuutLLSLvwsht/Kl1eUeaYnGxVVTj5iT8x4zx9PeuesrO/njvrkGzkWNnQI+I2lIA+ZQvHsc5p0MiRYmW6tVLDb5QnDg4Hd8gLwSaHIU482ztYvhJ42WGZltVXLtgkIvy5OM5+XJ49fzquEtElSd5IpoXwZChP31B429FGcD1otwEmZ4ppIyqqWk3qVDDB2g5OSSQecVZijAsRLMwin+YbxjBxkchegJOBnFJsa0JLDSY9W1Gz0xyUhkh81yxLC4lByRwQQMA5PTgV6LfeG0sNJQ+G7dTbg7jAJPOjQ45IVzwCBgEEGvM0vbvTrxreN3Cl96yodpRlUAYycAcnOOuK6ax8Z3JSG7l04C92ZYRT4V89H2FcAE8HB7mt4WRx4mnVlJcm3YyfGcEcF4sUQWyvJgzvAXZ4WcjkfMflbPTjHzDpXPTR3MlsIJzA7un7tyQWJAHBHUcHA78AVf1u8nu5ptQvYLtJLn5MNsaNCSAMYBwvb8BS2scjRJOo8y1fKiUAvgZ5xnkHPH61E3bU6KcXCCRVaCKHzISpcKvm7cbFX1wejevuajFoDahfKCmQlgu3GD7eh6dKdMoBkEifLb/wAXOwpzjJ6jGR+dSQ3aRxRqWwhAQtK5fgnJyp6f/W4qEaq9izDDCWggMiRSgqR5pOE7YORjGT+H41Y8VaPc6Nb51OK3kjdhgKdvzZzkD8e35Vh7W3lDcROPvBi4XH0Xv0z1qKW4upoDGJxMuPu7WDR/XcfTv+dPlHyS5k09CfeFWL7IVaQqRtWMMRzxlh+PWo0tVmEk09qkcauz77YnLHgDJHTDDj655pbS62QTfZpIo5JRjaAQPbJzT4IEigWcTMqFcM0Um4HHqp55P/1qaLa7ldjHHHGrX6CXaCcufmY56qwwSR+HP4Vmi6ljkQZtwn3cTqVyDnPzDjpirV19pPmlY5MBS7ELlQM45BGTWbE1xE52TRFQ2TE0YI4/pya0V7ES0RpS4nVUgsHEYbJubeTcBknGRx6MRxmo52FjcQXOn+c8qSYKbSJCuDkBtuVPXnn/ABSz81TsENs8cm0tH5u3Pdeo7e1PZ7t4BIy3lrIQUEliTKGj+6QycY/rTi7GM4XTiztdF8UBL6BpNQay0shUnsbh1Zi5xuclhwuQTwcjd3zxP8WE8JXXhqO8stZsJr4SZhWBlJYc5UhffHJ715+k97En+japZyoGJKXamKQEYHTP4Y//AF1l6zc3F+wuNUVJlAKRAmONcnuABk5/z61pdPVnnwwXs588WNhud+mxOYZiXyxIU7VPIGADzn6VTD2KyL9tmkjJIXaYyBkden9KeyKmR/Z821wVGyUja3HIAOOB/Op2iEkpeO6uxOnJM5+UN3wDnOTUto6pXaGwNZyxyRo8oxgIxkkUIufXp/8ArFM1JUeOOKwe6e2GDnzMozevP9fpUpa6UljdYt+ch0wFwMZx79qswTlZDdWa290EXL7toVRnHyhsZPfiotZ3RzTRU0+RrRJI5HMax/MQy5DHGMH8PT2qRbrzCjLGZXj5LKD8px19/wAfrV7Wr7TdQ2XFm6W7xqFkidcfn+fWq1m6KzHzNo24JAzn8avzaMoeQtzZvqdtvjt/IuEIHms2CpPY/WrekXOq211DBqdkktsXCs4PUHjPFWNKkEce50BJ+YEdCMcDNXVciPcA2+QhQmSeM8His3LpYqpG8GfVWiSxHS7fyiNuKtM3PHJIrC8KwtBocKsSSOvrmtgsMegr2LHwjlbQlOQDk8mk3r6/rUZfueh/Sj5v736UWDn7F3GScZFeafG/x7/wiWif2fphZ9bv1KRiMbmhToXOO/Yfn2rtPF+vw+GPDd7qk5UmFCIkZsCSQ/dXP1/TNfHmo6zfa3qdzealcs8txIrl8HIJGOo7DHTtXPVnyI9vAYT20uZ7IyrSO7kkkmZn85nBMn/LQ84IH4Z49vatDTF+z3RmmiiuPLDIkc5weTySeMkVLGIre1At3b5OQTF2K45P1Pc9/rWnpVvJOb1ZRDnhVIcAIQM4OOvJ5P0rglJ2Z9VTpqKKkWnkXLRqqtFGADEucE7enr2wfSprSFYYpRdJIy5EZdV6IehrRuIFkw/l+YLjO1o2DbXGcqc8k8fXmqu1llTzYQv2iUeXs+VFIGS2OuOByetYttvU7YJbss2cObmXzlkLYwuxgnAw2CRwTjGaDbiINOF37ZWwGJRh6ryc4749K0rXbLbW0LSSQSuh854lDAAnOAh69hj+mcLLZm1uJ1lW5kWMFUkVB85/vMM9TuwcdBxUXLT7jWsrq5ubfTybuKe8IV1MfUAbmOeSQRg8cdPStGXSILdXJt7fzxAzySSg74znOf69O3esrSYdSOrRNZWr38cG5nRWK716HOCTyM474Ga6rWNVjvLa0Ok28NtqEDFjEzPK5/u5yMbcc+2MVcWrGM3JTSWxyiC/eO1ubu1uo458lWchhIem/DAYHUgE85I9K1HjAmmH7pBdKpYG1KEAj72QTjOPXr9Kq3uqvq+si51K8klTysqrOgJLcbVwMAsfbgYrU03Rr2WxZ5Jbc2pYMzNONwKj7oxnOABwfQeuaT03G/dS5tyrpKLDDcteRLLE6qAiTMjDB4IUgA4HfPUmpNUupZxJJeG6lmZGjjd9oYKF5XgDODTbm5tUmjtm+1RebwuYhtHfO8HGTlutQz3aRHZIN4ciJgFDr7EdwfX8aspR1vYij09V0pY7ma5by8EjcV3fKM7uT09cVDJNbqWmtPNWxAEkLykb+R83QDIPPP50uo3haTzPJDKTgsmFZegAIHOD7g5+ta2oQWbaLFdxak0dtbptWG4hXiT72xdoGRluvHehpsUmotX6nOCUIsIE0ryYw4JO3d6c+5H+cVftLvTktrj7crLKrbocR7gMZ3Dk/Tgj6c1k2lzIIhPcEzxCRR5RVSVIPPGOmO+eKm1CQahAYBmNy6nc2SFHJxkjPt+tFtTRxvoW9Q0GW00lNVmhQRrgmRIypj3DuuOCO596yrUK7KxkM0cq5XD+WeOwzxV46nqaWVzEL6aaCSPDJvDcY6bjxjHGBzWaIfLZYbe4QuoBWOQlgQBk4PHrVO3ccVPeTJJvtFsFLq5jOVMkbDOOpyM46nqKuT20t9Ajy20c1urFhkhWAA5464x/SqlvC6OqOgDMBgxnJQdT3zV9khRWU3CyEdSyZYE9RkYOPrS9AeujMe5hcfvFt5Le3C43REnI4yCOoz/KqgitmnHnzJvjj3FIOJAeOMnvzWxqcgmt8RS7XQhhkbhu6Ekjp+tZjSgWTW/7mVnOS7puA4xkHr6/mKtXZE72saOmRI92sEjTpGwCsNqtsIGC3OO+O/c1e1O8jso/s7XMpYvt88bmUYHJxj645qvpElnHqZR4rwQSxkY80SOWHPI644H4V0Pinwx9l0EXUmrbI+v2WZGWYOcEYxwR68HGOvelo5HHUrxptKXU4bUZhcwssVyblgpEjPAoB+mD171lvDEZh5EaXB2ZEKqwbJHBPJH4VUgZr24kgBti7khVjOxs4457dKvf6qAIts+7OPMVRuGOTnb7D861ty6I0vzIeIbjz5ZHieBwQrhD5gQZ4U9/bgVo21rCljJM1ysBTDQoYs+Y4Hc56Z9aylt1dlWVruErtwIySSSfT6E/nVxUFsojNo0rbMsQP3gJHB54AxWdRid9jO1JYMBZZXluguSig7Mgk9uueKzbqOK5xLLeLAOQEdd3QDt1FdPfxvjMa3sByCFnwVQEEY//AFVkRFtwiDRN5fD7H5IPX2JojLqctSN2UYAYduySe8hTkvGm4LnpzWzFs2KoWSJGZdySR4BHQ/4VcsdU1DToriCyijjSddrKcOWHvxxUFrNJHdrdSSC6VG3NC5+VsdRn1obbISsmXoMxfLHI0eV3FkBxit3wWsE3imygvnd7fzS4U4wzYyD/AJ9Kz7m6iiuZC6wKkh+W3hlEm3uBuHB6jp3H1q/pRD6pZ3jHYiSKwVV5HNKOjVzCvf2Ukux9PW22OzhEYwpX64pWwynkf4VW0+QTWETgnAXFToctgjqcc17duqPg79BUOcjgY6jFSgpjrUahS3p6U/YPepZUbnzR8ZfGdz4v8Qy2FkCNDssxxsuT5j55bA6k44Hpn1ribR/IDoGxG0g2NIQASSo59uTUForWsbTW8m0+efkLZbIbHA6jrXSf2fcyaVeXkUcaSxyJ+6MOXLFgSRngAcfmK8upJyd2foOFoRpRUUUJNPMyTz26qSkJkkWPhxluPw5HFarlFgJjjTyC6kxo4Ujd8p4BOOoyT1x6cVnQPL50MBuCHdpFZw4xt3gnPbI5H1HpXY62thawW9rosNsoeUN9qQDdKx4Byei9/THGawmrHaviSMG2aG1m2lF3sgYMgCrtJ6EdxjjpmnwoJ4VExCjzcK4UgEFRld3Hbj6d6qxTGWNXRrVdrGNN5DGQAD6EjIznue1aFmZrd/MgkuoFKys8m042ABeMD09vWsrHQk/mEcKpaRbbZnCElUAOD1UdT6+vofWpHtII4E8hJAUYZZSSp75HfPT155qSBBPKDMxRCwk2xjbjgjBH8WBnJ960S5+3WzO2MjCkyHKDGeM9lUDnPoKTuNy6EGnvPZyzS20ojaVWVpFQouT2OPb+XtVS5kzC7v8AIsgJaWKRsEYAC5DHGTjrjrVq+ZjbeXaySCB9gaR5uVJJJBx8u4jPv69ayruWO2ZzEkSNEoSMOQQxBPzHHGF96pIUY3d0tSxo1rd6t4jmtNNjit3OyJzGd+1VUYGCCe7ZH19K2b+zNmbrTWmju4JWVRJFEF5PU7gOACB2PcVo+BdH1C30eXW7e60mdmY/KszRXDtn5trLxk88Ec1l3MkjzfPJJaqwLOMDdgZyvTPPTFUou+pjGpzzai9F+ZnW0yJO0SyqqwKclot4ZwfucdBz1qKK5leCYpBJDC7grhd6DnIPTPb1/lVloFbT4/MlDJIQBGMAgccZ9TgdPeoJSIndYTvaNCDGr8j0JPQYz3p2OqOuxnymK6imtnQXEYbEsro/3s5POMg9KhS3uFLQmW5MIyyx+YUDc4KlTxuwMgd8VZjkns7MSRzLJK24vGeremT6dPpS3VsLKWOOdVilMirIvmCQjPzHOecjBz71abtYCnHE/Ec7TKWO5ww2EDPA3dcHtjrUkbyaddpscxeW6u21jtBAPBz1x0q+CgkHmNDKXVGwwOGAPr1zzTkuLgSF5l88ksD++5UdyB6HFSVfuZuYZ5EYQjy5CdkkT7Ez1JJGR+GPc0+WSOK8+WeO5iTafmt/lxjJGRz39Oahd/OuATAqTStwYsx7ePbjJI9Mc01Ule48qSWCclgEjXEe1iOSTjkD14p2W47WJo5I4jHOvmx7ySHCZX6bTk47etB+xIDNcJFKyqSHDMrAn0z9M/yqSGcW6bFtpnj8shhGBkHsUz+OapySC3Q+ZdvGw+ZYSokyMADPfp0+nvTUdBSs0R3LHUER9kKIvAdUVWxnkkDBJrMaOOJCyqQ4Y4dHJLrz95e36Vdli8rDB45GPz/vU29uw7mmXEksMUYdEICqxMEoyQecHjg9/aqSZlNWWo17r7OyzPczFYnAUMgZSeS2COnJFY1xq2s38ktvcaizWErAvHDMOg7KH6HB6VDc3LGT5YDAxyQyLwVJzzjr2/Ordq08w2vBsRVLykoDvIBIOOo6mtfh1OSSUmR2du9tbukaQqjgqCZUdm+bPJ7cDtVpQoVmilP3eRAN3zdSDz7CpYNpWEqlq/O1N0XU9cEfj3/pWg1pZvIAYI5LwohhWBRHGB/EzEDnqOQepNQ33NlGy0KEbuihrlLjaNoEyIEZMbiQcDB4Pf2q1byy72jsbqSeVlJYysD0BJJJ9APxx9KrCaX5w0xERIAWJWB6HGCeuMinfZ7acP5xEW0kssqMXc89+/G3P4VEnfczZQuLkLMUluhIrsTsKchs8kkc8cU57yAyR/ZolaKJtx6q5IAA4x61G8k1sZHiabeVI+bgDB5Azzg8ClMs73Rkkuljny2TENq5IyOW4/z2oaOaV09C9DCDJK0kFy8rsTwCAT6dfarsyQwKolmWeTh/KX5mU+mO/GP8istWJcAtPOELHeJO569hx/jVtAkM6lHEKEhi0K5KnHcn8elS4g1oX7KCBboObXbNg8eXjHX/AOtWhBIrkCPh1Cg5/hPTvVCIRSopEhl2qQXJPXPFXVO1iX2s4PG33pMwep9D+Ar5r7QLdydx2KT6Z6GuiULuz0NcN8IbgS6KsSsW2FlOecd8Z+ld4Ytwzz9a9inPmgmfEYim4VZJdGyPbyccYOaXn3/OkIIJB6UnA/hNWYI+NL5YQrRvA8TNckm4EhKsCc5P456VpWMsYhjW5eSSWOZVLeYUDhXDZPOBwMcf0rKgvW+0eUVi4m8xfMVTnLDOfbt271PGrvP512GhczlzKuMEhR8oHrnjrxmvLlqfpsNC8lvNKsLCdtsjefkEsELbmwAfYDj/AOtXQm6eWfUZ8q0kMAKGVBjsOh4bnPHfrxWJbt9tS3ttMtriW9WHAk8wu4J7bVwowqkenU1eh2skyBpI/JJEcTEyMMgZ68AYJNYSLWuosYlCSXFuTHGymJJFZZQx6c+gHJ6fzqa3/d3cgdpHmidEy2BuIGdpB9WYfl3zV+1sLd7l7RNk0abFR4025HG7kj0AH1+tXBbwPdHCfeJYE4TBJJbJ9cADNZczTLUuhA9vLAzQxbTMzqjs4KlRjcdvOCMYH0ps88yRSkMskT7Y90ingluB9eASPTApkcMU97JP9kkkWFNyoGZwzc4IHoMAZ9qSe4H2pEt7hHePDgCPnzMZLH+HgDNPdlLVpCaqYbOOFllLmIk7SwO6QgKox3bJJPtWVpOlS6/qjadDeNbKse6ablwqg/cx6nOSQauahPK91A9qwWWJjJLIcDyieASMY7sf8irfw6e7vtZlihtkubEEyPLIm8qBjcBgjr/Wrj3JqycKTd9Tprrwzp7eGWAnEk8PzGW2ARJDtwHx1BABU+5z1rjhb308Ec4k2QRy7GIYF36/Ng88YGfqK7zxvLHpKxaXaxBLSVAySOA2zkkneefbmuEtJlmHm7AchoolTAMuWB3HPbj8quTsc+E5+Tm7stW96rXFyodZliOA7gKQAo6DPp2ptxGruDHE6AAEiVAzN0JweOpx9acTZWtjM8yQsm/fGJY8MxAxkd+TwB7g04Xl1LpdzHbIpuJGGWXBbB+8MY9uMdutQnc627aogvw0LwWYi8m4j/eyMisu7IyoOT/kVnXlq/nrLMrOEyhdWG4cjA9SB6+4q4zjdL5H2i4Fw6xSOzAtHgAnAxkEAde+akUh/KkmklttqghvLIyfqvHIHfr1p3a0Kh7pXRBFbkTXUkgfAL7AzqBxt5HpVW4luIN07MrsTsiUxAKUyeWwRjtnPU1ozXINvGLaVZo0yxCkhsnrkN+A49AapXU8axbRIZgr5KGNR5meOCBkjI5zxx70I0TIolvSVTzoiGILbzjYOeBjpxn65qNr0iVt8TM4BJdU56fwkdvz6Uv+sdEnijZ85OwlsZOeeh/n+lRJOnlyCQsZZNxiVmzgcAbfw9fWq30GRTzxokcjAKu0MCQ27aR8x/zx1qmJmlkYRrG7FgAzPggei9R/n6VZvpA8RCK4ck7AihWx36e34VVFu80oe6VUVGyMErtA6AkDqcdaqOpMl2HOxI3vHMY+h8xQwJ/z796W5ZJYYctC8mCgGcFcdOAcmrVpG4iLWj3EMRUDYo8wAc/xHpyT+dZGpswQMbdTgsoXBbHTnHUGmlciV7amGY5LnfKofK/K5UgcHjgHp3rXit5vsrTRxObZGxLcKmUTdztJHAzg8fXrVJY4yHdEDYb5Jclctjhcds8HHtWgs10lnJpyXu22kYGSEdJCDwffqa0euhyRWtyW1iPmtIJVmdkEhCuECk8j26kD8K0bXUBY2lwGsyZQxSRbhsLIvHBI6gHBGMdTmqWhtpUFxcnU2iLIhjgt5QGBdgQWwOuME9eu2hZhJsdrHeY1fPmFo0UnABGRxjr+HNZta6lXTuhZhfyzf6RqMasOqjIGe23HQc8YoW5hkkVUlkGY9u7A2ucgHknoB3qfdc7XSA23llS0uH+ZWbgYYDk4H1q7ZaFdatp15JpEwjg06LzJg5GGUEZwMZz/ADqG1bUJWS3OVjE81+PJljumyXEbgjCgZJ9Pf8qlgvWjt8SARso2xll3Lj+Lpjk/yqvJbSysxu5yikgQlTgkE916nIGKLWyLJvmhclVwpJ3B+DxyeB/9ardupyu9y1HcOZU8s+e56fvwF9jjHH19qlhT7bdQxMhs7QygAs+Sm7jI7Hqa6jTPCFrNokupNakwQhN4eLYSTzlCOozxk9uawGgsoH2Q7gGGYnKliPrk4qYyT2Ffmuky7JYPp95sgdLiFjhACADj05+tasEyrFsPyngMDgY9/pisqxtVhhiaN4PMYAlsHgkjP6dPr9a0UEE0hS6JDnkOBjPsal6majbc9d+DkyeVKEVgC27kY9v6V6pgjI5HsRjFeI/DEmw1Bdlw7RsNhjYdPQivb/vKp69Mc16GFleml2Pkswp8mIl56jHTg5NM2e9WcLjnNN3e4rfmONwR8OxytggnzJCwJYqR93GOR0xn8cnNX7ZlZ9jxiNd7bjHDksS+QOuc8VmW7ebcLGFaO4Zo0UlvlJ3Z/AjbWrC9xtQJKscm7zEYknAG7079elebI/RaeqLlpEDarOkkoeRMkvKFJYkqFbBLHuQDjoeK1liWK0xFKskhfJTyGGTzgDI7ZHfv3rHkt5ImkgdbeHbMsDKwIJKKCSAenc5xW5AymFpllD+SgA3vyzDv0z+X8qwnc2vZF7SoJ0njt54UnzCcGZigVlxlhg4BPQVLaSIsohztaYKkZDLlQG5OT14z+PeqySo8weJF8uGMBFDcHr/M5GKttIn2R47poN9xu8yTaWHTlcjjoSPaoKSZJ9oIiMkbLLJIdqSurnamMbW2nkYBOOPvGqLkSPBHJHbiLDPtZCrbQcc455JyPbitC1triS1NziG2to1PlBgN0nGOBngY5H0qjGqW8UjvBIlzI28kHDRqo+RCnUg/hSTsNW1sZN3ieTyRlEU+bMzsQSQPljHGO3X3r2P4NaMB4WM13ZIrndJveMAurHcMnuK8t02zuNS1WKzgX7RJ/rrmMkxhuctuB4x+PevXPFHjKw0nSoU0aa1UbBHNCU2BUI2/d7//AFq2pq7ucWYOc7UYLc8/8Y3E2pazcoh89Y3by40UlAAOWXntzn0rDtpJLi5juZWKWsSsLUZJ8wADcenPzduOlVXeLU70pFGVijwr/NkuenAB4B61L9qaabfHbmO0s8wWwK/8tM/M/Hvx9BzQ/eZ1048kVFF25mgiQRu+LpsOERGKdOG3n+7jnjqRS295dWdk620gQO3mStDtaSMjjI/u5BI4qbRPDV3eSQz6k072lySUjgnCevDnHynrj/CresaZc6OZbm1kks7SbCMZXByMYzhQcfnVcjeyJ9pDm5L3MDRQYnSKwtrm6ubiN3aMgZORlju79hj2rvvDfgm3urK31DVGuZZZE/eWjMUVODgBfwrzSy8i6mmnlJEACKCNyEAdW+mT+lek6H4v020tIYr6/u4Z+CrbMImMDJJ7d/xp04qW5ni3VjH90Z3jTQrGzin1C3+1RSwFc2RAdQOBxkg5B5xn2rgbOSS4mdkJACbRmLOS2eDz6c8V6N8RPGNjNpslvZPFcS3sbf6UGEoDA52gAdeMYPrXl+iyDy3WMZIcmV1OMcdCOnODz2qpxUVoaYWU3SXPuX5QTukbbCoO4g8hnwPl46cZNS3ltuuQHSJHWEsAJfugED0556Co4ES6PnqzREsWwhwcH07Y4pDZ2wj+0Ebt5zsYEkD7qjg5yf0rC51cxnXIgE5HnTpEoCyFTy/fAx15qKOJbaST7KbuPzTgiYbzhuBkkfWrd4skUr/LbBEAC7WJJAX0HTHv+tSC8MaqC8bbMZBJIL469sdf1rRPQHZ6lZUSQM0sioVJZVWXgED+IdM5PtWLqm0S+WpiZwOWiG7J9cjnvz9a6stM1mDGywlBtOyYNvz059c1yNwkaeZLM0qKflYoSe5yfT296pPuY1H7oqIqlDCsEpKmTDEgepxzyOKjit1SRtohYyBtzyZwDzkgdRjHen2xjmUySSRR28JyrTAY47BPQ+vSnvaRvAJkSJoWxjYgwSQflz24xmrTSMFrsX4Yls7mJVt4Y7oHKwlA2WOOrdRwfwrbbU7ye0it4YY1ECcy53OwJDFpGIyQMfKAOBWA9uLeF3ns7fldsjCINISWJPuMFfy+tW5XWVATJHa27O2yJHZJGO0FSxI5HQAe3pxUNIqK1uzTgtrm4jNz5Vui8OhjypLcYYjHH1+pqvrM9xmWJU2NN8reTKuCMZyQO2QOPYZpotFlAEk9ysSA7Y/tIy2c7SW4zgnpjrVa7FzAu2zgTHyoVxtA4xt4+8ev41KsVLzLXhbQrrWjcS2lrva2ZVZJZEXIx23HkZ4+lU7y0mhdorw7TglI1PCHOCuR7jFPsbu5sNk0rosp6oV3Dco4I59GOM16JqHjXw1N4MGny6Xi+VBjZEuWfGAxYc+pOeaSi27nHKUk1pdP8DE8H+LorPQrzT9UUIXz5SuTgMRy3HbOBxWDIn2mIi32+VC43LnjHAyM8856VSvgI3EkXlfOSSsjksATxn29qryi7ZYsQ2hj2gAZYZBPNNWsDoqLbRqW6LPFwzqVO0pjhvx/KtG2tmZA5jyqcg54HTkdz/8AXrN0x0QLbkv5gBJA+4OPWt7TN2/y5ZleEDgLk89qhpkt2Os8KkQqGDZY8/K2MY5A/nXuOmktYQlsZx3rxLw3cMZwXjKggcnByc817jYEfYo/pkVvg3rJHzeZxXtU/X9CQZxxg+1GB6U4cen403I9TXeedY+I9IRmkkAS3Fsrh2BBKvjIJ/UcDvVtIxb3cEd1IZkIYqY3B5IAwM9Pv9PypnhVVntUjgkVEkILLEGUL7d8kkD/AL5zV+ztobi9nzew25hi3iKaRFLrknbjAyflHHuK82T1aPvKXwXK0Mjxu80MjCWTfJvlb5wC+wZwf89ea6DSi8DKBO0kUK7d7R45wcc8Efz5rndPhthcwTNdJvlZAuyLaOm4jAHPOAOPWt1II5SIHd0dtzOWYqvTnA/rnkH2rKerOiKuzdPhXWrbRbfVJoB/ZkoXbKH2sygHaSOevY4rOvXN5FFHMse04WUJGWCxBgeo9+OB61K2sal/Z0dm2pXU9jGmFikYhVA6gdcDkdaoWkQWGTypV8yd/JBWUALGBu2nP4ZpJaF0ozSvU38jcSO3OmteNHseZvKgVt0QSFeh44IPueDWYIGfzLiAqz3APEkhJSP+FcnnAwD/ADq3DPOLBDDK0hcGCNSuVCkfvG/Lj8qq3kyvaAgruO7YZF/ec8AZHp1xSRcE0RqkbTlXCpboMsqNls9/05+tMvdrykh/NWTALZKsB79ee1PgmitQXhRzFGgQKy7/ADpMe/TvxQzxKq4g/eAgEDjJPQY6H/61GqbsVZplOSXZO/2Qu17jIkAwI8gYO7p+HtVixke2gRmnUxgiONWXkdyxPSok5eSPJKxgllOAST0x69P5VqRvZlGL7VAXaMIWCL6Ajkkc898U+Z9DOS8jpdC1f+z7YWV7KphCbhcQnczb/mIbPpwOORWZqesaVNOzvDMsKLvkBbHnAEBevqM/jWKLiKe0/wBGiY5bH74jO0ZAyAfxqrcRLcuqb2/e/eXG04HXJ/lirdd2sYww0b83UjiCyoEdniEj+aYnGSiZ+VW/Af5FDgLLEt68koBAjTyy25SMgYz24oS3i3ym1nmR7jKje2WOTgk/hn0q7Hp2be7kk1CGIQRnCTEIz7l/hPfOMVOt9DdtRXvMxYollv8AZBAJbyRhGnATySehxj61YNs+i6pNAymaSB3SVBh1z0xkjnrW54PsNOvFe41D5rdMxJCGO+STjrjnr75FZep2L2uoTwwq9wIU3OqoFKAHADEdQM/nScm2SpKUnHsVH8x5n+z+alzcYHlxLsDLjPTGOgpl1CI5pFaOd5FYRKzvkgj06fp6VHDHFcDbJctHKm4uwY4T29cH1p0ypFdGSWTeR8qsMszEdRjvg9ab30NFvYiRPJLZ3mUkopbqMjkDHT0zWgWuLe3jeWN/KyEZ9u5UA/h3Yx6cc9qjQ/6crs0SyAhECkoeeuT+fNTQPL9lkLFNiIPmdtyhsnnb68DmqCTKGsWwRW8mEO6gM0gQbV45A7msK4jEUxlF1HIudqlZM4P94AgdM4//AFVt3yzXIWMsWGFfYV+Q84AJH1x+NNs7S6utTMMDBJLVDjybfd5bHPykN6dM+9WnZGFRmXK6WxxiLzWACu+D5ajqQOmelQvdIjlYY/NuD8z7CUUNgY5GOmOcUl2ENzLbZB8osTIzA4467cc+4HqKktUjhkjhkkCYYMd5BYdPlUHg9aq1jJu7tEt2iCRnubImPEqJkEhSwBO8s3vz/wDqrSijM0KSXAujyDLIW3B8nJXHOAAH6dcioFtopyoMk+YlAWUP5SMSCd23tmtbwjok+s6s1sLOSTYN5UlmcqAFJGMZ5bOD0rOT6otyUI80tivbRxRO1ybaRowMfvIwQcAgN1ByOvb9KyZ75J71N8TIfLx5lw5jHAbPQnufz4rqNZ02606Q2t9Fdu6gvGgBCt2wGYZOM5zXPTuHkjeFnjucFiXGQi7cAn6+vvSjK5N1JXRnxx3NzEJN0cmWReIj8y/QDHT1/WrtnbW9qFn2H7QQPkB3HGCDkdsVBEssbtLa3Ek6r8gKLwW25OB1/wAKnaaGIxvM8xikwyFkKoeRk+uKTu9CbIn1BmmuHkmMSTF8bIIxHEAFGcrnknrz1P5VSMkKzmOK4kjvABjYvIOOi9scVradCuoXlrbxi0to2bZ50uABnqSD2Hqag1mKPT76e1icswJVLqBgyEg4OPbpTRMuxctoB9mC/aJPPJwQ/B+np/8Arq5aOn2hY5S28EEAHAOemG/z0rEWCQXEBvYkMGQBOJSMn6dz2/CtnTfsv2yEhpHhLhcMN2wZ4pPRXOeppex6Hpenwx3SecpLxHdtdcEHr2/CvXtGcvp0TAYyB17V45pEkMB+eTdIGZTKSVz2Ax0FeueHju06PJz8o75rfB6TaPnMz+yzWJzg4PHrTcH1p/ylTg5x7UzzAOMNXejzvU+KLa9fUrVQG3sCDEtspBxlySxPIPsMcEGtgXdxY6VIHtJ2M8YEpNsFBwuV3M3t79s85rl/DXlGK3QuybpV8xmQEYyRkc4x06981uSyrBEtpBPpU8eV+UJIGLZXGRzyf5V5sl7x93S1grljaXkeA26eaqZ809EyB2x1wg4681orcQlY4ZPmkYqxli+UuBz16dDiqhluHuo5I47fyXnYJIkDIrhQN2NxyRmtWASqjSfZTHbMpSIqu0sV5PA68kdeaykjohoitcvvh8tkjTdjeVjYMQCe5zjn/wCtVi1tImtbiVnhM23ZHgfe56DuM9DjjikBVgR82ZDwzLhScZyQT16j34FTQO0s/LQxQxAguyZ2ADltw6jsPWofZnT0shk0rRqluJEDbdi7TkKgznnJyPenQSyeU8y795kCJEVxtPrk9SeP5Co727MvmtGqbJx5UcZHRc8YHcDk/U1BdShkgiE0jPF8pXccDGeRnpyelNNvQqKckSurmeSUwxiaJSGx8odyQN34eo9amtInNxsjMfnbeZJVwozyTk9+OtRRyNvCQMjiMHhz0Ppk9P8AIprO8qRCeF974zsOUJ7kDvwaTT3YmtBHaWeNVMivGTsUpxlB3I9/rxzUe24jiYwxSO3CIyDEajuee9WmXzLUpEJSwwSc7FQZ+Ucc9a0/C+gz6reLJPem0txlSfvAkYyAKWzMpVVTV5GK7+VZGOKLy55FzI7qV+XPqKvlY4R5jnzA6/NKRuOPY8EAUeINJktrxrb7SZNv7z923DoCR8w9enFZkqus8M8iP58xXaOoBz/EAfTtRJApKauia4nS2jaRkV5QpyzngMf5Zx/SqV55c1si2rK0uPnRjxGe+e2MDGKsTuZWZJkgjEQ81i2THkZx79v0FM0yCSS3SRFiMzfOpf5cdz/LHPrVJdSk0loU2lniMhBcRqCFKjhmzyR/Wm6YJ7i/is4ofNmuzyjv5anPQk9+vFWLiSFkIjjZZxyC8m7cxOcBTwozn86pEsqEs2bnPmeYFySfQk9gP69KpibutNBl0rWF4bCdQpjKmX+I5+o688/hQski4Mhba+Rvdvlz346/Wo1ZXlfzAzSOu4sByzn19Km8kmVZY4laUjaB0D+vHbp+Qq7AmLHDbz3ahW8wvks2dpJPHy/06Vq6rbXWl6hNa6hmKZQiOqkNkkdAB7Y/OqllE1xdSbVjREAQeWflJXOcnqTyKluhbzxSTfaJZZSxYsqlskDp19ieaCW/eMe8kJdREjohbeXYFWweFPI9s1Iy38UE/wDZxmt/LXNzMrKuwE4z2LE+g9cVomFR5VxPHE1qGIYLJh5NgBKqp7Edzwaz7vUp5YTbxRuS0is7HLsSDnGDwf07VUSGrmHZ2V1LJtjt7c2/lMwkuJAOPUfUitGzijS+WGbMIRyu+PJxkEk/UAcfhT7NXIaKOJixUHEoAQ88DsOnarEkckc4kulM4wrtzsEXzjOw5Oe4GfWk5EqnyoW0tp0McRvkiVgMxydQRk/Pn8/xrY8O6jqWnalFeWMqJNLuH2tgRkEgcDoRwOD/AErJR4mJ3NKsLOGAIC4UMwAbucc9PfPpU8EggXzWCK6MqBMcqDzkBjz6ewzmoZTipKzRp6preqaoqJegNbw4ZnDlpMYOQe2emSO3SsueK5ZGGbcq7Bijghnfg4bjjA7dBSyyyeSUkkeRXkCglMbck7mAzz90c+2KsB5opN1rJ55O5nds5jz3OOAQBjjvSd90LlUdERw28iTuBJBMflBaFNgXOfx74/nVLUIJZ1l8qCZblWKly4KMB0AHf6//AK6VvsqoV5iiJDFA+C3HBz645z7nrUkyee0RsWWOEjbgENuwAM89M5P8+9NE2SA/ZGVI/sTtceaPLbyzt4X5gfzHsKrR7beURQYmV+GVlIIXPZe31/8ArVJDbY27ZoIm5B+Y4Jxg55/zn0qYQqyFbq1XOzLS25yAR7+n096d0tCXqiZ7WBLNwUimjfI8sHdt9/5DPvTNMupoNRCsqq6YIAORx+Ht3qVY2SNCZYlt+A6bhyfXd/npnFU5IZY97Wrplc7FjOQozgg/nQtjmqLueqaRKsVzAURnjmVWJdgPm9cV674ddXtAq7evbpXivg6Y3OmxMqyMsb4bzI8kEcYDenTivYvC6n7GTwB6CtcL/FfofO5orQT7M31U8belGV/vGjJwMdeuRSFST/DXoHk7Hwj4BuXt7KYRz7V85BJGwHzYYkfzrpbpCs8r3UlzfQpcbVZc28bdG543HO3v+FcR4SuR5d75LhTvyTs3E4NdtYtdX9rKrXukGNHeUCeRoXYkKvHXIy2QPrXnVL8zsfc4a3som9pVmIdLuUnWWB47fzHkYo65OTj7xIHy4FOjW3RLWPa0Rj24HmAFm7tkd8k0lsJpDIos9KkJugP3F5yBGgHykgAg7Sc55welLMxhLyBlMud4CtyM+o/GsmdlHXQiuDLIZo2mhlJOXxJuxk/w/h7VPG0c1tGkirHblt0saE/KgyNv6ZP1rLmuyL3yE8wFW3uSASPU8D0q210iQIu3LuOYwSA4xkdegx1qWmzrt0H3VwpfzQlxDafdgiHBwe49ye/piq93dRzSWYjtI1MSJE7ISN5DE7ic9ecfhUk3nSRteWrLsVCIosZYDucHgd8e1c8Z/LAjjiJkDgKpO45x/U/ypxWtxuyVzbvZQqQhSDGQSzbz8xye315/CrUd0LeNwwAzuUsGO4DHAA/D+lc/YvdXLG3CN5nAHORgHoD/AEq+k9wEDh5SgJymMZJ6/wCHNK1ifiNgmOZUMEm1QApcg5LYyc44H0rXstYurO2ezimHkgFQgxksQcuCB6Z/OuXt5tjPK5ljQkyAAkjB4wR6+9WUvZzK6O8flqCrME2k+3H0FSYVKPNobWpXFskbtA4TyQN4kIIDHrj1rn5PPkDypIHnJLnCn5d3p9BTy32qZQu141YF/lAy3XpVp5BO00q7UEeS2OWCgdcCmwjHkVihOirHMAUW1jwXTdu39MKMjqc5NVDJJbs6SW8b20e4ON3cnPB7+n1qZRHc+XG7hI1zM2eRhT39KXT0guINieYZHLMFOAM9dx49COtNaFN2Wo6HyUGZFDTnPOw4jzxn3PQDNVriRklaS4lDuAFYB8bMdj7Y9BWhJaXMOnCcWjS27DLSlSi5Y8ZOOeoFUbhswvuMbyhQD5ZAA9z3z/hTWqMlO+xHHcfY3je1BUY3KhXjBGTwevT1qN7y4nkDuyNO+5m3HaV+XqPTvUDMbmUOMEnlTIMZweSMdDUkahridRCJywHH931x6DNUtC0T2FjJfSxxwHYwG9ArAA8E8++BWoIYdG077XMsUryRgiNXI2Pn0PX0z60sOowafZxx29nE8qN5nmBcuevHPAAIHXNZWpedqt2bjUF3vMSxWNeQoGeOmBzzRvvsDTk/Iqarql7rF3FdatcO5IMaIFChU5HYYAqzYNbqCjh9rFvunJbkdM4wTtVfzqOxhACSySyeQUwSx7KCcA/UirdikkcUZDFBtRcZDZJO7BB7f59aqUilCyJRGYZFjuLZN7bAqqzKQuMkkeuOc0uopKY5riCEpbnMQw+CAF6EdzhhzVmNZbzY6zYcYAyRjJIBO4+vT8DWhpV7p7avDFq03lWKl/Pl5JC+ijB5PGcdhWfoTKfKrnMx2sgSUXLupjIMkR7nOSvHoTTY5yYogzYKrgGbLBuSTz1HX+VQXuoWiFlgkLoS2xz95wXG0kdRxzVeVxMDMwZo4wZFWQ7T2wc/UjHsOKtRZPOkWL2S3ujFIJJbghQjF8rhyTnnI4HX8auO1nDbbbWF2ZRkqzlBI2enHUAVnm8jkKp8skcJWNCV+Q7QTuOQOSPX0q7jyQqNcA3jplVcg+UMc5BOBxzj8KTIjK+4WkZcNMUIYR5YHDjB+6FzyelTv5EhSOe0lSGPJUyMM55Ixj6n6fjUbNGuTIpllckqpVhvznr7DAP4U6MRXPyyK23cSyk7csQMEcYAHH54pNdSmioGW2AW3VUeQD5icgA9VIzzUkLPmUWs0a3KNl4m3HC5IKc9B3qO+trd4t7RrcR9WbONhGe44/8A1VSkMcs0aK/lll2lyTiQZJx/Wmtdjmm7MuzXMcsjKrs1wvDLswrEnjA78d6uWaHIEYMYONyt1bnqPSsswBZgt1ZnzSdsbKxIA455+nfpUtozws7i4UMpyRyPwGRTMXd7np3huJrTZG2XjuV81G2kgsRgjHYYANe0+GApsAVAx6jivFPCccV5p9sVRleFwgk3HOBz6V7Z4UOdLXLBj7CtMPpVPn8y1ir9zZxjjnimkDPanHgYzSA/X8q9A8k/Ofwpcust3bgZB+fPYHPX3ru7CWzhW3dri6jctmRhKEGASflyMZyq85rzTRbg2urt0w5K8jOK9BsrwzWbqQ0saKGYBcgDIHHp1PHrmuKstbn2OXTvSUX0O/8ACckU5UQNEjQRqyyi/wAvuUDJ2v8AKSWc8YqKe4Kwg3E8khRyFdiMZP3yfx4/CsDR7a08l9RmlDSxIQsZjO0seEAOemT79MVZvZYftaQqxP8AAZRgjkZJHYD+Vc7XY9PD2vcdL5CeWlq7rI5LT4+YnjnHHAH19aqQCfKvvLR52ou7OQDwP0qBnkWAg71HdzySox69z6Vah8+eWIYwzHaieWT5ecZc4xk9Klux3KQ29uZZZ1hyfN3ANFGcZHX8qjWCOKaMl4d+05IOdvPQVrziHS0f/SgC4+Y7cyOSe3cVmu8MRLMhE8rBgG5+XHfIoV2O19yaB8uV3BB91MHj6/XrU00AuJYreMloh82N3PHQD8M1UVbdpN0cRYdsLjLe2e2fSryRJNIIzIVkYnduzgc5FDRVktUWogrW8e45VRg7Tu2c5HOPYU/zHu1bzUDh3YiZ48NnGOT7f1qq4HmeUS67yFdUI4X1H1qcXAMSKJUMaY2xDpn0J9ahxM5R7ESs1ncMwngZlygVmztJzk9OvvSkvCFjWSMCRv8AWKCcgc4PtxSTTAQ7Z47U9S5UHeMd8njnisu8umlaIpbLGi/dDtzj6VVjOSe4uoXa7UVpmPnKd8gXaFj3dv5CrWjOpuRMoMys/wA8ecZHGCAOfWsvUSZWW2XbG20GQtwVHUKfU/40wXLxJ5kMm2ZWG11H3M9x3J5rRLRGMtdD0/Utf+16A+kf2nLatHEHISFTG+D3Y9eccdQK8ra5hF9LbxbZJ9uA5THU8k4zwP16Vn65e3up3JV5opVRfL3qvljjuMdaNPt/s1qjWzliSQz45/XtWzSSOOlB09Im3bMiwCFmfzFy5yv3SM4Oc/59KsxRCFh9mR5iRlj5m0nv1H8hWWrNvaFZUIfJdjH171Zg3kB1kdXCBljRcEjOMnnisWjvii67KZ2ieRishwFyMKMcZJqrMxghEds/+uUq7nPTvj3xUE1wJkeMr5ZY7iRy2fY+nSmXLFpiQvywR8AYXqMg8e1HLoVoWEQx38jn5o/LUKvUc8AL+XWrUk0EGzyFBYZkLNzyOAB+f+FMRACnnkwEgSMZcn5R0xUE8SyWisIndBGMSMSvPJ49f8aT1YPbQtXeorENoaD5CCzyNvLcZHH6Y7Vz19qL3QCGaeYsc7VIjAz13E5+nXtVS/Qg7TsjGS2FUEjHYk063iMlu4V7h1AwPulVxjnGPyFbRgkcE5SbsjRjsUSURvPHHck8pArXMjHbhVGOOWIHB71VmQyRJPfKsZV1hCbGBYgY659f5dq1bW9iixbhLhlh3y7raNY5DKTjfK2CW2rnGMYZhVCEPcvsijA4+SPHIzySckD15qbtbkJN6E0UFxvi327OQhLyK6/KT8xwfXaMZPrjtWpaJgCYLJBBvaV3LK5YDkdepzWYS9xeJDLLbXRY8hvkiQgDOQOowoH41oralLT7ReT2+YSqwQgYABLfd9fXJ9qhvTU6KaHIwDiW3kkcs2eWLybNpzz2znOM8VbSNkxKyGCMZJjX5mZSOp7dO9WLyOytdPtBZXHmXbxN51s0eRn3xz/n61Xlt7gI0zyQ4ZgCcdM44Hbof61lc1VkZ2oNJMdi5iQcElsqT+HbFZs9xc+dsPkSpk8HiQdhjPWrF1aRT71ktsumWEskpCk9hjt/nNRQw2wgcC3hPGcs/QexzkitkrHDVbci5DdmdnAaZJBtErytwD6D+VWreKaYBnUqhBy7jeT83OBnisOCFQ+/zUBzgh1zkdeR3GBW/p1y9zs8tJFXG1fLxsZfXJ6e31pOyQlqjvPAkhhYRbptkoZnOcAMOORXuHhbi0K42j29PWvBvBgdb1kXZyuACueM8c/l+Jr3bwf/AMg3LHJyf5+laYV3qfI+ezVbepv4HPTNNwfWpMfIeflBpuF9RXoI8lo/Mm5lK37ScYD54+teiaI11PZMIp4FVyowVALDkgH/AOv7V5vef698DHJ/nXbeEpvtWmgOuFjzuZV9PX2rlqr3bn02WT/eyg+p2Oh6Vq1rtn+xPPbFgd1tEJDlMnOOwx14qpdXN3cySyOsoaTLyM8IUHnoAAAAAQMCrEcwsrHzLe78qRvlKx7lyp659R2x70lxPPNbrLqE8s1y2OhwF5+6FHGMD9K5k+p70Y8rsV3lWW2RcZKHKqpzkfStWK4aO3j8qzBDkFpXOM5H3fpxWY0aw3CsI1wB8rIcYPfNWmnfIS3uHMUYzhjgE+x9sdaiWux0R31JJ5ljgMtwoldOWweB6c/jUFnG8m92gmmuTkq24bVHHPP+eKie6kvZVg8qOJV+bLHcTx2+lOhkltZGXzwyKAN+MA98DP8AWmo2K59fI07RzMzFzJEkbbQinqccnPpT4rln/es5jKn+E5OAef17VlC7k5jIJiPYrzz/AExVqGQyh/LJ2Jjaqrk56flRY0U076k5Rh5jsW82Yhgw4wDxn29KS0P2ZHkCMzZKIwGQfX86SS6leBV2LE64yUYFyPX6f4VWlulJd42cCP5Fyx5Y9T9KdtBNpbkvmJJJIkk3yxqDhQcFuuPwp8Q8hwWhEkpAKR7x3HGff27UttOsT+UrKwwGdG4LEjt/hVW6dYpriRoNso4jPPJ6A5HFS9yW01cg3+Qr73YFgXc4+92wKbG6xrJJdRrMpUokTj7pbvx6VDdyGQxxw9VAaV2PDHOfwx6e1Ne6d7f94h2E7gAdu/PPI/Ort1OeTTdiJGNxiNwEiOFTsPr9KeFUMybgmB94Mfmx3P8Aniq73UaMxJDRyDC78/Jn0qezmDRuyq7IejZGenPNU9DOLTlYtrHHHZKZFJkDc78rxjoKn09IvNjEcAfe4TBP6c8YqG1YGJSz7sY3Z521JIo+weaHKtIWAAH04/pUHXFKxpTxWplDw2S2uRiMK5dn55PHHNUbXfNHNHHHJIJJCzOO65x1x04pbaXy7Yi5YqMfu/4S30qNrjyHItm/1SiIHJzuPX+lJLoDskPuJ5rq2IbfL5hwrSfNhBnPPbt+dWViaSxRbZncSuF2v0z22/lUCQeVbJIHTczCJFY4OO7e2MU+6mk+zyiJ1dVB2bBwcZ5/LNNkXVjmruRo7mVJsZJy7seSM4OPqaqxyTMIQgG3njPX3OOnSl1N/MuwVfaVUE9ABgZAxRYeb5mxHZfNG1WUZO3oTiuhaI85u8i5brJ5iyPLK2/5pHjIwowSeoJ9K09Jha7kkS1KRpcssT3F1l9gZhtUZ4BxyfyrPvZ/KlFpawS/cZXOCvLeufZah+2pYBA0jPdiQOscbZC+pGO//wBas7cyuDaj1Oo1rRLnQtUFhNNAyogYSI4CIpGeQfzwaRLaSSe3uJLeUrcRlonuW374vu7s/gccVjW5Dzxyz2sq4G9nlibMjD+Qzj8RXt0nhvwza/D173U9UMd8tuJLcM+whmG5QqHkg5OfxNZO6di1XVNxv1PN5GTav2drUxbQwYbmkU/XA56/5FY95qG4NC8k8pLHamSFzxjjvyMmrMOJIZJbgxRwN86MF2qOeAVP5/jWVfagl1dAxRyXknViiFVZR/IdOlEVqbVKisQ3UeH+S3kO4bi0cpBx6daijhAmDS2oTccBnYsfoRmoJpppUlkUQRQ5B2ybiw+nA64ojmuWUS2to8/mYy8siorHr6+/+TWtnY4ZyTLLIksu10UTA4wJDjHvjitzTYmklVFbyrhSMI6fKcHnA79q5WcatPOu97e2bB2BPmP0yO3+NaGmsthdhNannLHHl71whHfJHQ9vSlKLsKE9dj0vRJzBeQPKYneJgy+X8qlc9Rn05NfQPg7adKQqSc85PJPNfOmhXtswRoArovAMZB5x7f1/pX0J4EufP0wEFmUdC2MkYHpSwrtUPGzeOifmdN1OCDj+dJtPoaMnvxjgUHOepr0jxUfmJef69/qa67wEMWl25aRQGHzKfu8dSO9cdOcyufc11/gVh9mmUna3mhlJGRkAcEHjFc9X4D3ct1xK+Z3Etwp/d3E0QwqeWAoYsxGcn069e2amELRsxMltOG5XIK4Axx1rLYO93GZbiEAuCw8nOBn0HGMdvwq7qkCNczSy373BdiVfyBGGGcDufT9K5LH01/esLKJSA4XygMYcsCq4+vbmodRjW2jKvANw5EyjcrA8g57U+7hmNpshkhwRkiR8kevQYxVF4LkWqxg2jDB3bWPOPX9KmPc2bY24Y3MY89xGUHyuG556AY7UCe7gtgZFEsGf9evX8u/SqD3UsDbZ4rj5RtVtoZR/9artjqKzr5STwxxgchxnH4GtbaHMppvfUdamO4nLyORATkbfvPz09v8A69bNojwxOYJbdFxwjMcnsB+tYZimnMs1uyE9WSNdpYexqxZSQuksly88ITojMG57/jUyRpCpysl1GRoYxGZo2cnGRzsHc5qC2KfaU8lWkjjG4b+m73/z1qtGwkeeaW+CADgPFjcSfu5z+Oe2asWywNbymfcoxvbY2F9j9KLWQnPndzQtJm+z5tglrIwIOO/0J5qG2uGVQrSSTSgsFXAKjtkn365qC8eX7Okkj+WZBsjjBzsUd+Og7VAlwkTR2xbyVRctIo5yef8AP501G+we06FyeSUWhsxFGAzCSQ4x/nNQNJ5Y8xDFATgDvkHqajln8kF3jAiI/dhW79eaDP5sjIiqGK8CFVOPbHr/APqppEykilcyIdzNhpFb7y8q3vUltd4hOJSpYbWCpxT1BW5MU04KrneZE/zxUYuJMMlumYWAHIG361T7ER913LttfJCjrmNlAABVTyCPX+lOFxM0arGH2EhmYrxx6VXcvCuG8ve3GMfLSOJPMVZAdqjjbJ1HtU2R0c7SLiHzWbLMQg5bOeevHb/9dKhMRjVVV2IJKEfmD6D3qopcoEkkWON8cKeTz3P59KluC9ijSwtkSDapUZ684pNCctLl37SqyNK9krLGnlRKrbgXPcjPf+Qq7fMPsKSLKnl42Dy1A+Y4z/LisVk8s28e6RZB+8csAu09u9W5JZJIpHjxKg6SMAqrj379aTXUlT3uYN0pYEEfKM7eRnNTR7raxIlnEG9iq7BkqoOSx79QAKq3U8cdwBcSSOicjYuFBzzVIahG5EkpJ8s7Y0z65/qa2SujglNJl17vKO0czBN+JZ3yWbOSP61d0SSGK9kazskmyu1S7Hcx69T15x+VYu2SSSBJcqZztiQD+JmAH4c/55r3Of4fN4dsZNRttWgBsoCxyCCxYHgr0AHPX05pS00sZKouazepnaZ4QL6c9zf3o+03GGxE3nbl6khjxt6DPTPHYmsHxTYXOm6tJb3bylIyV+V1LDAwvb5eMcemK9E0/XLSEaj/AGmlxbJbg7mEBeNe5UqOduMDHcnp3ryvxHqL6pqqyQtBIRgu6MFUZI6+mBgc+lRy6s1o1JO9yaLPli4gia6jACyGYA7H7ke3SsG/aaa6ILFQASrKeeMYz7da1Q80h/eTp5aNwgU4Kjqc8f5ArF1meVbhJbKO3Kp08wlmxnkkDpn/AD0qYLU1qztEfBDEtwxu8MRwEDEeZ0xj0qxeTPKPscCxwwv8w85VDIx/2vQkdM965Mm4vLtY4rkO5BZhFCXK9eea0RaWUeY/Pub/AHZbcZCi/Qgc9x7VrKKOONfmuootQXqW+2CG3N7dKch0b5k+g/rV7TNmoSqm3fPkgrO2GIxz8ppbI29pIYolSOH1QY4xnDHrjmnTW1tKUecw7WwY2WQAhfXIPHHY1Lfkaxv1Z1Wk2kSXgUWpjlbHzxE557kdD/hX0L8Ly6WQil2FigOVGOOa+d/DdzNp0iTQut7aIuWZGxIoJ/XHrX0L8Mr1LqBjDICgVcfKffr+tZ0f4yPNzf8AhXO8zzyTx0pdp9Vpn8fPQelGT6V6h86mfmJN/rH+prsPCSotgDGx8xmO5c9ecVx03+tf6mu28M4axhBPlMBwQPvc1z1fhPocrV61/I6MFCiRyI8h34BB2k8Yq/dmRuEuXCKSVV1DBcejfjWfC2CVmIZ+GG1uV/Kr0skjxw4lEh3HqfmOMc4PBrj6n09luRzK6QYeSOQSEKwK4Yd+1ZVwdz4t0d0xw3p71eldNjef5kZOQAU2gkDkk/jVaSSIxskLN5WMYj4GT6+1OJM2rFI6xPbQPbNzHjAZ/mPp1qP+0pbqEo+nNc4XJkVAr47HI7UxmSFXXajo3AyOnaqfmyoh8uZmC5zHuOR9PatUuyOGcnHqXPLvkY/6POsX3lQOC4Hbj05FWZNQt3UzQube6RQNhTh/XIrLtJXfE8bsrZ28Mc8dqnvr9LhUF3GCVGFkX5XB9cjr170NO5KnZXuPEs5l2zLsZm4jAHryc/hVye5i8sQR749vBCtuBbtwe3+FZlvMbRSI9s7MvGeqj+RqWF4YLdywxO/3XHzbOeaGrhCbNC3Qxr9omh3RJkK8bZ5HOCOvehJ4lie8lhR5GcnY3GPw9KzoXVJDvcqu3+DjPtmhLoGY3VwpJQAqXTgjt160+Ur2li6PKG2aeULKeSqL8o9vTH+FJNdzQ/u4IUtScYlcEED1H51WtbhHPnSFmL5xGFYkds4HbtUu9i26W0vGxxgoQAM9Mn8aNgc00RWCLLJIszGeY5YuW4Hp+Oa1r1rdjtgDxQBRgOQW6DPTHfNYU8F0dQaKKFbdgDnDjt6DOPzqaFLWFy10Wnn5O2ViAPyNDVx06rStY0oi7OZIrjdFjbukB4/xxUBkEd2wiYyPjAKDg+tMubqc2waGIsiYA2kFfem2iypaibMeXAyucnP1qUtDVzu+VFmNIVaRrkZlXGBnAH+eKll2yyeaxVI4gAoI6/WqwgnBiCwl5n5wrKQR+f8AOpryLDeX9mjQAH7ykpg9uO9FtQ5tB0N0ssrSmIzkNkDaTsXoBT9RuZYLVN0pkVhgRP8AKc4/LjNU/wC0ZlQuWkVCAFWMYXrnHHT1qjds0uftErO6/wABc9aahd7GUqrSdjNumZLhhNxuzknsPrWhLdPLawSXcnmXJUIsQiGCB93kc9qxdkkl+VYPvzwvXaPU1s2z3MKsbAPNcPgSSoMqB6f59K1ehwUpNybLW9o1tDPHCJ1kEgGOVIIxknv7Vq6t4i8ReIy9pBO89sXCyoI1jJyc5bHU55yazVhkdRcXsiRLjDJzuPrk4461ZtJVgYPbyG3bYVUQtl29Sx685qLnU43fYq3eniyvUsre9S6nJ3l4p90ZO3Jxk445579qZFaXLFohGwUjfJJnaCuRx78mr95PJNOt7LIX1K4Kje6BTyBnIx0HAz6Vek02KC4jjvbmOTGBJLGeAeQVUcZx3P1xnik5aBGmrkkUUq2kkg+zxRQrhXmZtz846Y5Pf/IrldRElwQ5unSJyMBEClu3866y9lSVvJ0kEWyAMJZgcSNnHAPuTj+tcnq0kEGT5klxKc7NiEIee2R06/5yKVPcjEtW1Kokg01VaGMiZs8l8lvYmrNpp1zNdJdvdCFZmAYIuSp7Zz/TpUVtFOZVuJ+b6UkIhAwg6ZPv29q6G0tLaCJftO6Z2ALHOcnuABx+NVOSRz0KXtXeWiRHBpFo+Ek+13srHgiUopGMnIA6cVd0jSrK0uSTYJlXGQ4PH1P+f50+2Zpp5I3nKAHIZBjHbOR9a0o5VhgxFGqQqwLucknI6898D+frispN7HoKlFapG9YGMxruYRMnREjwCDz29a9z+FYAjlIUBXCtjOeSOTxXgFmxjRXzvUHG48jHuPxr374SweVYMT/GB0A9O3tU0Vaqjyc4f7r5noBC+meKdg+tN9RgAUAn0P5V6R84mj8wZf8AWv8AU13XhR1+xRDOW252HnNcLL/rX+pruvD8Kf2bCfLGQvLAnNc9b4T6TKb+1bXY6COBvMf7Oiybz/qn4J78HpUP2hFMUDxSxzISpjcbWH+NNdUS1OZZkY8YHTFVLeC5uDIi5uolXO1yA6+hHPPauZW6nv1JuL0NNrmVrfAbaqnG1hjHbB9eKyLuTFwHkjDZz80TYI459qWCdseTHC7uDwSwJ9wc0lwXWRXmgdQRkcZAPvinGPKYznzIoykXEieVOH9peMfjVa/SSFtwgcqvBwcinzp5kj7BuA5J+7+lQsWiB8mR/lGSOvPfrWmxxVHdEKXQkdjGVWUnA3Hb+B/z2p8M5hlfzo0ZnXO1huU/Q1XlRpy7L5bY5PHP1zS2kaSAIV3RKcMWOO/aq0OVSk3Y0LeNllSRMtnlgTjaPw7datGVXge4UAPnaMDjHpz/ADqsqImEtPuA5cuTlfx9qkvDuELSOW3D5QnUjPf9T+NTc6ouyG3CbIoyF4VssWOc1Jez7xG87EW44SP0A/pUWoXPnwZVQiA8qhPH4fpS28iz3SmNVSGNR95s5NUHMuayNvzbqJUkW8FqhUBV3c4xxx2/+vWVLNf+Q8jzySNNkhznB59+v+RV4LbSttnuY9/Z16Z6nJ79Kp3kLNIFEgkUc5TPy9wMVEWkayuyOD/QAzvHI0jgZLqSce1Wks0ljid1jhDnjf1A+lA1P/QltxvM4PzcZVhx/n8qekdxKoYWkvmrznAobLhy7BdS3ckX2bBdFBAdAAOarNDDDGgLtGxPIdt2eOelOvTK6/viqBRjC/ezVOBjNMiSEPFEeQRyR6fnVJEzmk7F+KQzTvLNtSPGY2XIGR6fjTrh2JVVm3s4xkcAc+tRy3TOfKhxsPBBUAIPT2pksgkYqi7xGvKqMDP9etCBzSVglTdeZHKwrlmlcHJAHTA+lU7iSW6gY2yLDGp+aRjgH/E9aki2RxPNKgYucAE9Of17/hS7mkT7RdRsIox+7jzjAx6en86paHPPVWKlq7RsY7YF5ZTjzGOCf8K6LTbUtbBIlVURd00jNt3MeT+XSsy2bZ/ptwCTKMLj9cA/lW/o9uYEN5eKoAOUiJwM+47/AEqJs1wtPUVHd0jFpBtjRizsB1JPv2/GoHit3t5bi7hSXeylEjG1uvTd649PWtFYXv8AzJrkpFbQKXMSkrv9FOf88HvS2lrdanLDLDalIY0+RhyqqBjc3vnkn3HrWVzqlHWxBHbzKVu72d2mmBIi5dwi9gcYBOQB+ZFWbdbfREe5utLjkkliKQtd/MQcg7hjoR9PX0q5HbSxXazQ3L/bHJ3T4CKoIJAX6qQe2N3NVbn7NZ2i3DXjzPtAeR5d5HUDaBwAcZx6Ci9yGlEyNRuJ7tNiuDwf3pXagA4yCeuf61zzKsd1I8MxmcnDTAbR17DpWrNeSXw8uee4FkFPlpuPzHOcDj6/ic1Ss44rvcIiqWcOHZBw0g6Zz3NbR0OGq+eRa0OAtJ9rmczbm+VAep55P58VtwRSG5KWwiaVgAXUhVRT15Hf/Cs2yjF8H8oPbwphCmCPNOOg98jpXQ21s8cUUKwmGMgBY8bSBgcn+dZTkdeHp+7psVDbpBM0aSJKysd+CQePfj/63409rgRCJihRFILM2c8duf5etV57uGObyNPVrm8z8oX51GOufSnNamOZZNRJnuGIxGwLrnPRVHX/ACKXqaSnfSJ01lMXZWVPKts8O2Dv55H/ANevo74dRldJIOQgxhcYIGB68182aMGjk3FGGCGCP1HOQPavpf4fTNNpW6WEwOTlkLZ7Cij/ABkeNnX8Nep054xzkU7A9f1NMfk4AxRg+pr07HzN2mfmLIMyt/vGvQdHfyrONDgALtI3da4KNN94FHd/6139uNltEnKjAzxnk9TXLV2PrMoVnKRoStPaJEVVHSROdxyHXurD6g/lWbPHAZGNurK2fmjP8PbKn0rTFsbi0MluyySKceUzcso7g/lxVCdUaZchoXxg55H/ANesE7HsTQkqMzKhEkcvTccY49cVGFhjPlXCyRtnP7tsA/SrxKQ/LKuJF67gAD3pk7KIvLuCjKTnO0ZH9aVyXT0uZN3GfNUW0wYEABZgFb6bh1rOu1uLaUC7tmhDfMW+8MfUVsfZ4TKEM0MqNjaR3FNaFocugnaJfusynA59KtSscdSi3rcowq0kW2AoVODuXHAqaCAxruQ7sZDLjn/eFOe3OC8aLGWywZBx+QoEaEYdnjkC/XcfYelO5HLbdEkcfymSAogyCSwwzfT26VHJNuvlaAhhGudoO446Z/X+dPkYxOszBd+wOsfGMdMn9az1unVZLjOXlPl7emMd89O+KEiZTSsSW0S3LXKtMPK6sc4Jx2FX9PW2lm81YQLRDsCqCSfr/nvUC7orae3QgjhpJFySDyOvp/gOatWQ8qxjKGeQsuQsR6Env/n9KbY4KzRe1C7ggjFukManqAi4YH0Ix/nmoYre4uI/MllNrHniIKfMfA4+g5NQRMYXlxFEkoXOd+Tj6nnv60yJjOyowGCORyOPT6VOxunfct+XHCFt/NEQYjc23nr3qu14oyjy3EijO0lS2D3q1Idu/iQADr1/Csa4RnYZkcBjwuQKEr7jnJxXukN5ftJPvRWCnowBFV2mBZYYHw54aTpRJNPK4gjZU/hz2xn9KsWFjG0oiXzHjPL+WvzMfb2rXRHDedSWhZtdyoRAN4Py5bufxodCzLBCGZ25bHr/AIgVtrZW1tHHCvnSTkBVHmj5c9sfXsayrjbFK0JL+eScEYwBjJqFK51ThyRSY27MAnSBCxkHG9vQf/WpJfs6EPeHfCAdqA8se2TUMLByY4YjO5wHYoAC3pk9OaseUsUyvKyyTZ+7nABz+v1pkayJNOTfP9puYXOMFI17d+c9K6NYDChmuhHJNIT5YeQgDnrjHoKp2EdvpW271Fo3fnbERvUH0+vHXpx3rbghn8ptSvon3ygi3iK5AUgENt6bcZ5+p7VjN3Z3UIqK13E1PTxbxNc6nfwSyTJmO1iJkIz93II9Dn+dMuL5oLBI0ZEhlYsYFx5vljIUMexIzx159xWZLfRm5UkyJKAxB2gu3pyOBzj6VNDAt3AJppYrCEHLPK+6d+/yqMY/E+1S13HKaUtC7YO8tyGmspJ7qYBbe3BClcY3NnIAz/T3rI1qF3u3ykl9qat85Dq0UQ6Y44Jyev6ejL67FtbulvI9rZsVZ2Y755u+Cw+6OnHv71mtdCSGJokgggiwoVeCxA+8fetIxe5yVanNoxl/5sc8lsXFzcEfvABwgGM4Pt6D0NS2sEdydvmSzWNuoLscIpY9RweevA64Ge1Up5Io0kWOX7OsoAZ2+bd2JA7ZOSPYVv24t4UUyPcC1zlPMQLuOOWOOBnA4/WqdzmguaVy9pM62FmlzLK8QQlYjGuSoOMbVxkVm6jrjXibY5pEs2bIB+aeT2HoPaqkU114m11rbSI1KMP3lxPgqnctxwDx9QM+5rUisLOwdfskYv7tPlaRSGz1P0Uf/WqXFLfc3jUnW0h8KK9nNcTRA2NvFp0bLtMhTczenGP1P9K2rOzhtrZrme4jglYfNNcShWc9eOOvTpSpp2HSW6v2jaRsta2ybCFGfvOc47cj+dazaPZ6fYteSJbKWIBeeQyNjGR83vx05rOUk9jqhRlFFfRr1r6+8nTo5rgZ++w2xdO5P1r6a8AxPBpohZkfaigFWGOmK+d/DLyTajGbZDHDjaHcAKACM4B6/wCfWvorwOENs5UAAY5AxkYxV0P4qPDzq6gl5nT9BxxS5PZhRkdO3v1pdn+zXonziPzR0qLztWRTjAYk5rtiVRl6c8rjtXI6EuL6WQdVyBxmulSVWly//wBc1x1NWfYZauWlfuzWt/MKIY9xjHJw3Un1NQ3sZjlEQbeoGT+PvT7XzBb+W0hWFjkDA5OOCaliheRmVItw/hbOO9ZXseslzIjiijeAGVWdNwABxz+P9KsR28ltEJLeMvao2W3AMR6/UVZtLMzXALHI6AJkhT0OferTW6eZlF3sWI/eA7TjPOOlZuVjeFK6M65I1Ihpk2ouFTyo1BXHrgdqjmMtvMVffIpPyOowvPHI6Cta409n3vayMJDy8asFVsdcHsantJLAW8iyJvBUCZGOGX1Pv0PNK/YiVJLfc5i50icStNZNHC4G9o5XwGHpWBeXEDxkLGY7tCQxB49ua6DUIWi3tZyDY3VHYg9ex78YrlPEHlbfMXfHOGxtZdpI9fT8q3p6s8fGN002ipLdSRMFjkZnbIJPI69afYPI8p+bMEXLBjjPpx3/APrVlTy+Y5bucY7Yq5CMW4LlvKJHyA9a3tY8qFRykblrE00EgYONxDIMkKV96vx3DC2iYXrQ4XhQpRM56cZ/P8KoRztPst3LqijgIMtt46k9q1bVLSC3t2EMzy5IZd2DnsNvQj61lI9WnrsQq7lQEjeYsT96PC55/iOKmgsrqSEFLy1jLMVMaZdgPc9KlCPeo73d6tvCiYj847nYj+FUHA+pxUAt7NJVSV724nJHzRyLEuM9DgHqMUM15XcbNGltu+0xtNIDyXPt0wB61m3SvMm4Qm1i24yCQSM46Gpry3KAxSCa4d2AX9/kD8P6mpUsfmWOZLv+HafOUqOnXimrLUiac/dsV7OxhYM6rJGjDAQnLOfQnsK1NIHlXHm3DyxrGMLHGfmb2PoOtJIi20aNAWTPAVwrs35dqz5mkBx5Tpjpt/wHNL4h2VJI1NX1NFG51ESluQgG7j3rDtJnLFEAKTkAyO2OOuD/AJ7Vl301wC/mjCg8BhzVizlLRZMbtz8yj7uPbHc1aikjjliXOobX21m2QxqrIhARVH3jnjPrn+tdGNO/sgrvS3bVZG2xxZzIhGM/L/k8EVz+nSCzZZkCy6keEhbBjiX1J7n+Va+iI0slxcWkwQJ811ePKPlzkYQ9eefc4rOojtovuaWgXJ0XXF1C8t4b++RWEiS/MkPHGB0yKPiB4yGuypDawy7yArJGu0Ej0HoM1mXrG4jIsh9ntgcPOxGJCMgEA88020SytCWf7RPdMBtAUbmz3zjj/PWoSXxPc2a193TzKOn2dyYMukaL/GGbgehJ6nFSXIGYAYY55ZRtVwcAdFG0H+daFzHMMQzqGkyMW8SHaueu4gcnpxVW1s3kZnifEjcbmGAefmK+vHt0Bqk77kSjy6Iz9QhuIJWNyyXLoGzHu3gY7kj+f0qgshvYmE21EixtgXk4z6k5Hc1ptFHCk4sJvLkkwJVkUq2PQDPTjJ98CsC5CJuSTEMo5LD+L3/+tWkdTjrXjq9ja06z8uc3d40Uaw8hSQ2RwAEHQkD/AD0rO1fVr3X742tmmSSflU4GAPfgYHeqN7qNzNbWljHLJOQNsaKM43HPA9Sf6elew/CfwS+jJLqGraXGb4xED7cxCpuHACjv/tHp/OZyVNcz3MacZYl+zh8PUyfC/g+S10xWupJb5VG97axTbED1zJI2AxAPQZroGiNmVs5GtLeJ+Y4LZRPK2QMLlfwP4V2bI98DHGTPA8YjligJtojkn5cnk4PHPXp9MObRZYLZkWSC0bJGyFAvGeMuRyeP0rklPm1Z9DhqEKa5Y9DHuYZbJoo5bKOxnIAaa8YTSPg5GxOQD1q6kd2wmuxYLcTsgf7ZqbbARnA2AgcYwMLjHBqvALNZPLa4sIrlAXF3cylpCc9M5xnip430u7VpGN9qsioTJtheUKR0IBAUDPoe9FzStBR33MyzLG+DX83nRiQfubZcKwP3lDf5/lX0f8OpN+l4WF4VwGUP1xgYP1r50iv57dTJ/ZN2kW8LltqYJHXk59T9PpX0H8Mr5r+xEjoqb0DBVlEmOP8A61b0H+8Vz5jPFeCa7naKoDZBA70uB7UMAGGee+PalBPoK9I+YSPzh0RAPOfvvx9K2Y2YEEfLjADAZxVLRoF2uMtwxFakaBD8hI+XI9jmuOW59phbKlEvOssduyecjKh3AcjP+c0W94Y5Edi8RPI6jB78nrTJLcfZo2WSRXXJ3A8n69qdcjbEAGJXBcKeQCcZwO2azsdsanVGmJ0MbFpTGy4AYZ3NntgVctdVtd0Mcsgt5UA+Zzw5PTFc3OhghVVkdlMW/DYPP+FLDZxFYlbLB5Npyf8AaAqfZpmqxUlpE6me5a0bdGEaNwWDRYDZH+cVh6jqtvqBMd0qqAMA4w4Prx29fpVOS3EV6lokknkE4wTnA9M1cvrGEnb8w28A556A0lFRInXckzPfzZIj5FzHeQKP9W7bXUfj1rF1WUmHbPBPHjuYwQPx5rYuEBCDA5OSQB2rNu5ZoEKpPJt9CeK1iup5+Jdo6nJTY8xtvTtWtpVncXwEowsKHG4+v+TVa4t0aUsScnk4rqvDWnW407eQxZstye4zitZu0bnmYKmqlSz2IoYEjZQ14FU8HyuWb2J/pWxotvvEj2lvdsejNFHuLNycf5+tBiENwjQnyyQPugD39K1YrVPJjhLOScP5hPzg8559+PyrmlM96nBJmbfafGHZ5RNBcNgGON8tnvuB4/KnpazrGQ0lsB93EhKH6kZ64q9qjNaOI4WYbsEsTk/rU39lQTJDNctLPui8wo7/ACZ2jsMcU02a2V7IwoUtWmEVr5styfvLB8+cdc5/xqeayuLeUSTLDCORwNxPBzk9BW8iiWPkBVVQqqihQAPoKbaabA6wzSF3d9qnecjk+lS5F+ystTnVs45VaSyEhz/GpDKfZs4A/CsC7ujZswuNu08fuz96uz8SLiCKIsWD8ZPUAdh2rj9Xs4rd0WIHnqTz1+tbUndanBi26afL0Odu5Xupvl3HkkDrWlp9sBDHLLKsSZyrEk8juQKcLSNjGSWBZwpxgcelW9RHkp+6JUY6ficD8MVpvoeTFct5y1K7XTvMtnZliowGOMFyOhPf8666w0t8K+qMqwRjIRWARM8jJ75/z0rK0Kxhg0k3q7mmYnO7kZx1rp9MtIrm3W6u1+0SNhsSfdGc9AMVlUb2R6+DhopS1b+4je5idYxYowKg7rh494Ueq5/mPwqmkyQHbpZfPy+ZORhix4O0d+vX/Gr1lbrrN7JFds4hiIVY4ztAGT/jUbTG11NFhWMfKY8sofjHXByM+9Zeh1Sd3cr3Rt4bFFLSxTt1j+80hz3PucdKrok5eJXikklA+5AcbV9CTjqeK3l0eDYLmSW4lmkeJNzyfdDZJxiobO1jO2NQUDwNOxU8lssOvpTukRbmZmyRCO/A1a0aaxjZi1rBcortgcYYA9Dj64PSuD1pkEzAKAvbHQGvSr63SykvIbfKgsQX/iIAXjPoc8jvgVxHjC1SPUHhVn2LIwAJz0OP6VpT3ODMdKd+4nw7gWXXxOzfvYRviXdt3P8A/qzX0NpV/E9lBKn9nQvtKBpZPMkVTgcR5wcHJzz1NeQ/CfR7SaK9upVZpUdUHPGME17p4Z0m3dbR1HltuIBREGNvQ/d6+tcuKnedjvy2nGOFTfU0bF4pYDNc6le3KM2AYYHVUx2wi+uSMnmuWv7De7tDpE87HLGS8BUMQeuMnJwRzgd69Gnh36Wpea4I8pmwJWAyMAHAPvXJXOmWssU0zoxZDgDecfNyeM/X8654vqdmGk7s427a4Ia1j/syKIsUKCMOM56c9Bk96ejXUtsIzrczpt2ldPjjhATkDd8pJ78enfpV2z0qymuIAbdFWR03Ko7ZxisS9vZJdWlsgsUcTkwEogyFBCjGehwetbx20NsRylDUY76G5kRgt3E/7wzTXHmMOc9cDHXNe6fBfzTp3mzuzmSIYLAYUAngYry3xHplro/i99Os0Y2seDGsrlzH0OAT25Nej/COeQ6jc24IWBFBSNVAC564+p5rSEveifOZv71C6PVycnBxT8j2pjdfrUnlr716p8inY//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus of the dorsum of the hand and wrist. Notice the violaceous color of the papules and the linear K&ouml;ebner's phenomenon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sauer, GC, Hall, JC. Manual of skin diseases, 7th ed, Lippincott-Raven, Philadelphia 1996. Copyright &copy; 1996 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22709=[""].join("\n");
var outline_f22_11_22709=null;
var title_f22_11_22710="L-carnitine: Pediatric drug information";
var content_f22_11_22710=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   L-carnitine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"    see \"L-carnitine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/10/28836?source=see_link\">",
"    see \"L-carnitine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F187916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carnitine-300 [OTC];",
"     </li>",
"     <li>",
"      Carnitor&reg;;",
"     </li>",
"     <li>",
"      Carnitor&reg; SF;",
"     </li>",
"     <li>",
"      L-Carnitine [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F187917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Carnitor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Carnitine deficiency, treatment:",
"     </b>",
"     Limited data available:",
"     <b>",
"      Note:",
"     </b>",
"     Dosage should be individualized based upon patient response and serum carnitine concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary deficiency: Oral: Initial: 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses every 3-4 hours; titrate slowly as needed to 50-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Secondary deficiency (other inborn errors of metabolism):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: Initial: 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses every 3-4 hours; titrate slowly as needed to 50-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses; some conditions may require higher daily doses (eg, 300 mg/kg/day) (K&ouml;lker, 2011; Sutton, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 50 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an equivalent dose given over the next 24 hours divided every 3-6 hours may be required; some conditions may require higher daily doses (eg, 300 mg/kg/day) (Sutton, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Supplement to parenteral nutrition:",
"     </b>",
"     Limited data available:  Premature neonates GA &lt;34 weeks: I.V.: Initial: 8-10 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in parenteral nutrition solution; may increase up to 20 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     based on free and total plasma carnitine concentrations (ASPEN Pediatric Nutrition Support Core Curriculum, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=see_link\">",
"      see \"L-carnitine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Carnitine deficiency, treatment: Note:",
"     </b>",
"     Dosage should be individualized based upon patient response and serum carnitine concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Primary deficiency: Oral: Initial: 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses; may titrate slowly as needed to 100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses; maximum daily dose: 3000 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dosing interval (product specific):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Oral solution: Divided doses at evenly spaced intervals with or during meals (every 3-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Tablets: Divide daily dose into 2-3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Secondary deficiency:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Oral: Initial: 50 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses; may titrate slowly as needed to 100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses; some conditions may require higher daily doses (eg, 300 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     ); maximum daily dose: 3000 mg/",
"     <b>",
"      day",
"     </b>",
"     (K&ouml;lker, 2011; Sutton, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Dosing interval (product specific):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Oral solution: Divided doses at evenly spaced intervals with or during meals (every 3-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;text-align:justify;\">",
"     Tablets: Divide daily dose into 2-3 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-right:2em;text-align:justify;\">",
"     I.V.: 50 mg/kg as a single dose; titrate based on patient response. In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an equivalent dose given over the next 24 hours divided every 3-6 hours, may be required; maximum daily dose: 300 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      ESRD patients on hemodialysis:",
"     </b>",
"     Limited data available: Children and Adolescents: I.V.: 10-20 mg/kg dry body weight after each dialysis session; evaluate clinical response at 3-month intervals and titrate to the lowest effective dose. Therapy should be discontinued if no improvement after 9-12 months of therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines do not support the routine use of levocarnitine in dialysis patients (KDOQI Guidelines, 2006; KDOQI Work Group, 2009); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Valproic acid toxicity, acute:",
"     </b>",
"     Children and Adolescents: Limited data available; dosing based on level of hepatic involvement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     No hepatotoxicity: I.V.: 100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 6 hours until serum ammonia and valproic acid concentrations begin to decrease and clinical improvement is evident; maximum dose: 3000 mg  (Russell, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Symptomatic hyperammonemia or hepatotoxicity: Reported dosing regimens variable: I.V.: Loading dose: 100 mg/kg, maximum loading dose: 6",
"     <b>",
"      g",
"     </b>",
"     ;  followed by 50 mg/kg/dose every 8 hours or 15 mg/kg/dose every 4 hours, maximum dose: 3000 mg; continue treatment until serum ammonia concentrations begin to decrease and clinical improvement is evident; patients may require several days of therapy (Perrott, 2010; Russell, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Cyclic vomiting syndrome, prevention:",
"     </b>",
"     Limited data available: Children and Adolescents: Oral: 50-100 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses 2-3 times daily; maximum dose: 1000 mg (Li, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Primary carnitine deficiency:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral solution: Initial: 1000 mg daily in divided doses (spaced every 3-4 hours throughout the day); titrate slowly as needed to 1000-3000 mg per day in divided doses; higher doses may be needed in some patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablets: Oral: 990 mg 2-3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: 50 mg/kg; titrate based on patient response. In patients with severe metabolic crisis, a 50 mg/kg loading dose followed by an equivalent dose given over the next 24 hours (divided every 3 or 4 hours, never less than every 6 hours) may be required. Maximum daily dose: 300 mg/kg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      ESRD patients on hemodialysis:",
"     </b>",
"     I.V.: 20 mg/kg after each dialysis session; evaluate clinical response at 3-month intervals and titrate to the lowest effective dose. Therapy should be discontinued if no improvement after 9-12 months of therapy.",
"     <b>",
"      Note:",
"     </b>",
"     Current guidelines do not support the routine use of levocarnitine in dialysis patients (KDOQI guidelines, 2000); however, the National Kidney Foundation indicates levocarnitine therapy in patients with hyporesponsiveness to erythropoietin-based products, symptomatic intradialytic hypotension, NYHA functional class III-IV or ACC/AHA stage C-D heart failure or symptomatic cardiomyopathy, or muscle weakness and fatigability affecting quality of life which are unresponsive to standard medical therapy (Eknoyan, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of oral carnitine have not been established in ESRD. Chronic administration of high",
"     <b>",
"      oral",
"     </b>",
"     doses to patients with severely compromised renal function or ESRD patients on dialysis may result in accumulation of",
"     <b>",
"      potentially toxic",
"     </b>",
"     metabolites.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F187896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carnitine-300: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-Carnitine: 250 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 200 mg/mL (5 mL, 12.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carnitor&reg;: 200 mg/mL (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 100 mg/mL (118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carnitor&reg;: 100 mg/mL (118 mL) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carnitor&reg; SF: 100 mg/mL (118 mL) [sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 330 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carnitor&reg;: 330 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     L-Carnitine: 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F187881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral solution: May be taken directly or diluted in either beverages or liquid food; consume slowly; doses should be spaced evenly throughout the day, preferably during or following meals (every 3-4 hours) to improve tolerance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:  Dependent upon use:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carnitine deficiency: May be administered undiluted (200 mg/mL) as I.V. push over 2-3 minutes",
"     <b>",
"      or",
"     </b>",
"     further diluted in LR or NS to a final concentration of  0.5-8 mg/mL and administered as an intermittent I.V. infusion typically over 30 minutes",
"     <b>",
"      or",
"     </b>",
"     as a continuous infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ESRD on hemodialysis: May be administered undiluted (200 mg/mL) I.V. push  over 2-3 minutes into the venous return line",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Valproic acid toxicity: May be administered undiluted (200 mg/mL)  I.V. push over 2-3 minutes or further diluted in LR or NS to a final concentration of 0.5-8 mg/mL and administered by intermittent  infusion over 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F14725395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible with NS and LR at concentrations of 0.5-8 mg/mL.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1059751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 25&deg;C (77&deg;F). Solution for I.V. infusion is stable for 24 hours when mixed in NS or LR at a concentration of 0.5-8 mg/mL and stored at 25&deg;C (77&deg;F) in PVC bags; stable in parenteral nutrition solutions for up to 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Solution, tablets: Treatment of primary or secondary carnitine deficiency (FDA approved infants, children, and adults); has also been used in cyclic vomiting syndrome for the prevention of episodes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Treatment of secondary carnitine deficiency and  prevention and treatment of carnitine deficiency in patients undergoing dialysis for end-stage renal disease (ESRD) [FDA approved in pediatric patients (age not specified) and adults]; has also been used for treatment of valproic acid toxicity",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F187954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       LevOCARNitine may be confused with levETIRAcetam, levocabastine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F187952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Intravenous:",
"     </b>",
"     Noted with hemodialysis patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Atrial fibrillation, chest pain, ECG abnormality, hypertension, palpitation, peripheral edema, tachycardia, vascular disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, fever, headache, seizures, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, parathyroid disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, diarrhea, gastritis, gastrointestinal disorder, melena, nausea, taste perversion, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia, eye disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Accidental injury, allergic reaction, body odor, drug dependence, infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Body odor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Myasthenic syndrome (uremic patients)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to carnitine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorders or in those at risk of seizures (eg, CNS mass or medications which may lower seizure threshold); both new onset seizure activity and increased frequency of seizures have been reported. Safety and efficacy of oral carnitine has not been established in ESRD; chronic administration of high doses of oral carnitine in patients with severely compromised renal function or ESRD on dialysis may result in accumulation of potentially toxic metabolites, trimethylamine and trimethylamine-N-oxide. Routine prophylactic use of carnitine in children receiving valproic acid to avoid carnitine deficiency and hepatotoxicity is probably not indicated (Freeman, 1994). Myasthenia has been reported in uremic patients on D,L-carnitine not L-carnitine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F187892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F187904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. There are no adequate and well-controlled studies in pregnant women. However, carnitine is a naturally occurring substance in mammalian metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carnitine serum concentrations should be obtained at baseline and  subsequently monitored weekly to monthly. In metabolic disorders: Blood chemistry, vital signs, and plasma carnitine concentration. In ESRD patients on dialysis: National Kidney Foundation guidelines recommend basing treatment on clinical signs and symptoms; evaluate response at 3-month intervals and discontinue if no clinical improvement noted within 9-12 months (Eknoyan, 2003).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic acid toxicity: Serum valproic acid concentrations (every 4-6 hours until a downward trend is observed), electrolytes, blood gases, mental status, hepatic function, serum ammonia concentration, serum lactate, and platelets",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Plasma free carnitine level: &gt;20 micromoles/L; plasma total carnitine level 30-60 micromoles/L; to evaluate for carnitine deficiency determine the plasma acylcarnitine/free carnitine ratio (A/F ratio)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     A/F ratio = [plasma total carnitine - free carnitine] divided by free carnitine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Normal plasma A/F ratio = 0.25; in carnitine deficiency A/F ratio &gt;0.4",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Endogenous substance required in energy metabolism; facilitates long chain fatty acid entry into the mitochondria; modulates intracellular coenzyme A homeostasis; carnitine deficiency exists when there is insufficient carnitine to buffer toxic acyl-Co A compounds; secondary carnitine deficiency may be a consequence of inborn errors of metabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Does not bind",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to trimethylamine and trimethylamine-N-oxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: 15.1% &plusmn; 5.3%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Solution: 15.9% &plusmn; 4.9%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 17.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 3.3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (76%, 4% to 9% as unchanged drug); feces (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F16032217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/10/28836?source=see_link\">",
"      see \"L-carnitine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     With parenteral therapy, report immediately any dizziness, loss of feeling, acute headache, tremors, or nausea. With oral therapy, abdominal pain, nausea, vomiting, diarrhea, or dizziness may occur. Report acute headache, chest pain, tremors, visual changes, muscle or skeletal weakness, skin rash, or swelling of extremities. The oral solution may be taken alone or dissolved in any liquid and drink with or following meals; the oral solution should be consumed slowly and spaced evenly throughout the day to improve tolerance.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bonner CM, De Brie KL, Hug G, et al, &ldquo;Effects of Parenteral L-Carnitine Supplementation on Fat Metabolism and Nutrition in Premature Neonates,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1995, 126(2):287-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/7844680 /pubmed\" id=\"7844680 \" target=\"_blank\">",
"        7844680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borum PR, &ldquo;Carnitine in Neonatal Nutrition,&rdquo;",
"      <i>",
"       J Child Neurol",
"      </i>",
"      , 1995, 10(Suppl 2):S25-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/8576565 /pubmed\" id=\"8576565 \" target=\"_blank\">",
"        8576565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eknoyan G, Latos DL, and Lindberg J, \"Practice Recommendations for the Use of L-carnitine in Dialysis-Related Carnitine Disorder. National Kidney Foundation Carnitine Consensus Conference,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2003, 41(4):868-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/12666074/pubmed\" id=\"12666074\" target=\"_blank\">",
"        12666074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eyer F, Felgenhauer N, Gempel K, et al, \"Acute Valproate Poisoning: Pharmacokinetics, Alteration in Fatty Acid Metabolism, and Changes During Therapy,\"",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2005, 25(4):376-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/16012283/pubmed\" id=\"16012283\" target=\"_blank\">",
"        16012283",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freeman JM, Vining EP, Cost S, et al, \"Does Carnitine Administration Improve the Symptoms Attributed to Anticonvulsant Medications?: A Double-Blinded, Crossover Study,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1994, 93(6 Pt 1):893-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/8190572/pubmed\" id=\"8190572\" target=\"_blank\">",
"        8190572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Helms RA, Mauer EC, and Hay WW Jr, &ldquo;Effect of Intravenous L-Carnitine on Growth Parameters and Fat Metabolism During Parenteral Nutrition in Neonates,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 1990, 14(5):448-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/2122016 /pubmed\" id=\"2122016 \" target=\"_blank\">",
"        2122016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Katiyar A and Aaron C, \"Case Files of the Children's Hospital of Michigan Regional Poison Control Center: The Use of Carnitine for the Management of Acute Valproic Acid Toxicity,\"",
"      <i>",
"       J Med Toxicol",
"      </i>",
"      , 2007, 3(3):129-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/18072149/pubmed\" id=\"18072149\" target=\"_blank\">",
"        18072149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      KDOQI Work Group, \"KDOQI Clinical Practice Guideline for Nutrition in Children With CKD: 2008 Update. Executive Summary,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2009, 53(3 Suppl 2):S11-104.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/19231749/pubmed\" id=\"19231749\" target=\"_blank\">",
"        19231749",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li BU, Lefevre F, Chelimsky GG, et al, \"North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome,\"",
"      <i>",
"       J Pediatr Gastroenterol Nutr",
"      </i>",
"      , 2008, 47(3):379-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/18728540/pubmed\" id=\"18728540\" target=\"_blank\">",
"        18728540",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mock CM and Schwetschenau KH, \"Levocarnitine for Valproic Acid-Induced Hyperammonemic Encephalopathy,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2012, 69(1):35-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/22180549/pubmed\" id=\"22180549\" target=\"_blank\">",
"        22180549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Kidney Foundation, \"KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease,\"",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2006, 47(5 Suppl 3):S11-145.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/16678659/pubmed\" id=\"16678659\" target=\"_blank\">",
"        16678659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perrott J, Murphy NG, and Zed PJ, \"L-Carnitine for Acute Valproic Acid Overdose: A Systematic Review of Published Cases,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2010, 44(7-8):1287-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/20587742/pubmed\" id=\"20587742\" target=\"_blank\">",
"        20587742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell S, \"Carnitine as an Antidote for Acute Valproate Toxicity in Children,\"",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 2007, 19(2):206-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/11/22710/abstract-text/17496767/pubmed\" id=\"17496767\" target=\"_blank\">",
"        17496767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13119 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-C070ECA3F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22710=[""].join("\n");
var outline_f22_11_22710=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187916\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187917\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059754\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442198\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059748\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187896\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187881\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059758\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14725395\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059751\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059757\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187954\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187952\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059761\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059747\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299590\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221274\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187892\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F187904\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059753\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059756\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059746\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059760\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16032217\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13119|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/16/21766?source=related_link\">",
"      L-carnitine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/10/28836?source=related_link\">",
"      L-carnitine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22711="Intrauterine balloon tamponade for control of postpartum hemorrhage";
var content_f22_11_22711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intrauterine balloon tamponade for control of postpartum hemorrhage",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22711/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22711/contributors\">",
"     Younes N Bakri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22711/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22711/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22711/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22711/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/11/22711/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpartum hemorrhage is an obstetrical emergency that can follow vaginal or cesarean delivery. It is one of the leading causes of maternal mortality, especially in the developing world [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/1\">",
"     1",
"    </a>",
"    ]. A step-wise approach to management of postpartum hemorrhage is recommended. After exclusion of retained products of conception and genital tract trauma, treatment of uterine atony is initiated, progressing from less invasive therapies (uterine massage, uterotonic drugs) to more invasive therapies (arterial embolization, uterine compression sutures, uterine artery ligation) and ultimately hysterectomy.",
"   </p>",
"   <p>",
"    Intrauterine balloon tamponade is an effective intermediate treatment option that can be readily implemented by providers with minimal training. It can be a life-saving intervention, especially in low resource settings where blood transfusion and surgical facilities may not be available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple types of balloons have been proposed for uterine tamponade, including obstetrical silicone balloons (Bakri balloon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/3\">",
"     3",
"    </a>",
"    ], BT-cath [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/4\">",
"     4",
"    </a>",
"    ]), foley catheter balloons, the Sengstaken-Blakemore tube, the Rusch catheter, and condom catheters. It is prudent to include one of these devices in postpartum hemorrhage kits.",
"   </p>",
"   <p>",
"    This topic will discuss the use of intrauterine balloon catheters for control of postpartum uterine hemorrhage. An overview of medical and surgical treatments for postpartum hemorrhage, as well as the causes, can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Use of balloon tamponade and other interventions for management of acute severe menorrhagia are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=see_link\">",
"     \"Managing an episode of severe or prolonged uterine bleeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF BALLOON CATHETERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bakri SOS (Surgical Obstetric Silicone) balloon was specifically designed for placement in the uterus for control of postpartum hemorrhage and is one of two such devices approved by the United States Food and Drug Administration (FDA) for this application. It consists of a silicone balloon connected to a 24 French, 54 cm long silicone catheter (",
"    <a class=\"graphic graphic_figure graphicRef52635 \" href=\"UTD.htm?43/8/44164\">",
"     figure 1",
"    </a>",
"    ). The collapsed balloon is inserted into the uterus; when filled with fluid, the balloon adapts to the configuration of the uterine cavity to tamponade endometrial bleeding. The central lumen of the catheter allows drainage and is designed to monitor ongoing bleeding above the level of the balloon. The device is intended for one-time use.",
"   </p>",
"   <p>",
"    The BT-cath was also designed for tamponade of postpartum uterine hemorrhage. It is a silicone balloon with an inverted pear shape to conform to the shape of the uterine cavity. In contrast to the Bakri balloon, the balloon end of the catheter is flush with the end of the balloon. One lumen of the dual lumen catheter is used to infuse saline and expand the balloon, while the other lumen allows drainage of blood from the fundus. It is intended for one-time use. Little has been published regarding the efficacy of this relatively new product.",
"   </p>",
"   <p>",
"    Other devices that have been tried, but are not intended for this purpose, include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sengstaken-Blakemore tube, which was designed for treatment of bleeding esophageal varices",
"     </li>",
"     <li>",
"      Single or multiple Foley urinary catheters",
"     </li>",
"     <li>",
"      Rusch balloon, which has a large capacity and was used by urologists for bladder stretching",
"     </li>",
"     <li>",
"      Condom catheters, which consist of a condom placed over the end of a Foley-type catheter, the base of the condom is ligated to the catheter to prevent leakage, and then the condom is filled with up to 500 mL fluid via the catheter [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/2,5-8\">",
"       2,5-8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both Rusch balloons and condom catheters are made of latex rubber; the other devices are made of silicone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presumed mechanism of action of uterine balloon catheters is exertion of inward to outward hydrostatic pressure against the uterine wall; this pressure may or may not be in excess of systemic arterial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The net result is reduction in persistent capillary and venous bleeding from the endometrium, placental remnants, and myometrium.",
"   </p>",
"   <p>",
"    In addition, an intrauterine balloon can be used in combination with a B-Lynch uterine compression suture to create a \"uterine sandwich,\" whereby the uterus is compressed between the balloon internally and the compression suture externally [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/11\">",
"     11",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H15\">",
"     'External compression plus internal tamponade'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Other mechanisms may also be involved, and may vary according to the type of balloon catheter. As an example, decreased uterine artery blood flow has been observed on ultrasound examination in patients with an intrauterine Sengstaken-Blakemore tube [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon tamponade is used for management of acute postpartum hemorrhage refractory to medical and other conservative interventions, after bleeding from vaginal and cervical lacerations and retained products of conception has been excluded. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is also used as a temporizing measure for obstetrical and gynecological bleeding emergencies while waiting for other definitive treatment, such as embolization or open surgical procedures, or while the patient is being transferred to another facility for such treatment. Balloon tamponade is often successful, thereby obviating the need for operative intervention.",
"   </p>",
"   <p>",
"    A small number of cases of delayed postpartum hemorrhage have been successfully managed with balloon catheters [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/13\">",
"     13",
"    </a>",
"    ]. Use of these devices should not replace evacuation of retained products of conception or antibiotic treatment of infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of postpartum hemorrhage\", section on 'Secondary postpartum hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Balloon catheters have been used with variable success to control bleeding after cesarean delivery with placenta previa, low lying placenta, or invasive or adherent placenta, and as an adjunctive treatment of cervical ectopic pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/3,14,15\">",
"     3,14,15",
"    </a>",
"    ]. As with any emergent clinical situation, one must assess the risks and benefits to placement of the balloon in these conditions and proceed accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ongoing pregnancy",
"     </li>",
"     <li>",
"      Suspected arterial bleeding",
"     </li>",
"     <li>",
"      Cervical cancer",
"     </li>",
"     <li>",
"      Some uterine anomalies (congenital, large distorting leiomyoma)",
"     </li>",
"     <li>",
"      Purulent infection of the vagina, cervix or uterus",
"     </li>",
"     <li>",
"      Suspected uterine rupture",
"     </li>",
"     <li>",
"      Allergy to balloon material (eg, rubber, latex)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intrauterine tamponade would not be expected to control bleeding from the uterine artery or one of its branches. Cervical cancer is a contraindication because transcervical insertion of the device may increase the risk of dissemination of tumor cells or provoke hemorrhage from bulky or friable gross tumor. Uterine anomalies may not allow placement of the catheter in an appropriate position to drain ongoing arterial blood loss, while a ruptured uterus could allow the balloon to pass into the peritoneal cavity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparation for balloon placement should begin when postpartum hemorrhage is anticipated or encountered. Once the decision has been made to insert the balloon, the procedure involves the following steps.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     After vaginal delivery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ensure that the bladder is empty by placing a Foley catheter.",
"     </li>",
"     <li>",
"      Fill a sterile basin with the maximum volume of sterile saline that may be instilled, but at least 500 mL.",
"     </li>",
"     <li>",
"      Cleanse the cervix and vagina with an antiseptic solution, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Perform a second visual inspection of the vagina and cervix to ensure the absence of bleeding lacerations as the source of the hemorrhage.",
"     </li>",
"     <li>",
"      Grasp the cervix with ring forceps. Use long dressing forceps to insert the balloon catheter into the uterine cavity, ideally above the level of the internal cervical os, if identifiable. Alternatively, the catheter can be inserted manually, similar to insertion of an intrauterine pressure catheter (",
"      <a class=\"graphic graphic_figure graphicRef60864 \" href=\"UTD.htm?18/55/19312\">",
"       figure 2",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Ultrasound, if available, is useful to confirm correct placement in the uterine cavity (ie, exclude extrauterine placement as might occur with uterine rupture). It is also useful to evaluate for significant residual placental tissue, which should be removed if present.",
"      <br/>",
"      <br/>",
"      Avoid excessive force when placing the device, as perforation of the uterus is theoretically possible. If resistance is encountered, catheter placement should be readjusted or the procedure abandoned.",
"      <br/>",
"      <br/>",
"      If an assistant is available, the assistant can perform real-time imaging to guide balloon placement.",
"      <br/>",
"     </li>",
"     <li>",
"      Once the correct position is confirmed, inflate the balloon with sterile saline until slight resistance is encountered to further instillation (this usually occurs between 250 and 300 mL) and bleeding slows down or stops. The maximum volume of the Bakri balloon catheter is 500 mL.",
"      <br/>",
"      <br/>",
"      If an assistant is available,",
"      <span class=\"nowrap\">",
"       he/she",
"      </span>",
"      can inflate the balloon while the operator holds the vaginal portion in position, which helps to keep the intrauterine portion from popping out. Alternatively, if the patient has adequate anesthesia, a stitch can be placed to reduce the size of the cervical os.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     After cesarean delivery",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the end of the catheter through the open uterine incision to the cervix and then into the vagina. Ask an assistant to pull the end of the catheter out of the introitus.",
"     </li>",
"     <li>",
"      Close the uterine incision, taking care not to puncture the balloon.",
"     </li>",
"     <li>",
"      Ask the assistant to inflate the balloon with sterile saline while the surgeon inspects the uterus from above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, the uterus can be closed and an assistant can then insert the balloon catheter from below and inflate it while the surgeon watches from above. This eliminates the risk of accidental needle perforation during uterine closure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PERIPROCEDURE MONITORING AND CARE",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of this intervention is assessed by the \"tamponade test,\" which rapidly identifies patients who will require a laparotomy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/9,16\">",
"       9,16",
"      </a>",
"      ]. Patients with a negative test (ie, bleeding is not controlled with inflation of the balloon) should proceed to laparotomy and, possibly, hysterectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/16\">",
"       16",
"      </a>",
"      ]. Arterial embolization by an interventional radiologist is an option in patients who are hemodynamically stable and when personnel and facilities are readily available. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H16#H16\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Arterial embolization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest administering broad spectrum antibiotic prophylaxis while the balloon is in place. Although the effectiveness of antibiotics in this setting has not been studied, cervicovaginal bacteria can enter the uterus with introduction of the balloon catheter, the surface of the catheter is a potential site for microbial adherence and retention, and the endometrium is a good target for infection.",
"     </li>",
"     <li>",
"      Most clinicians continue use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      to prevent atony [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/3\">",
"       3",
"      </a>",
"      ]. Other uterotonics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32549?source=see_link\">",
"       methylergonovine",
"      </a>",
"      , prostaglandins) may be used instead of, or in addition to, oxytocin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=see_link&amp;anchor=H6#H6\">",
"       \"Management of postpartum hemorrhage at vaginal delivery\", section on 'Uterotonic drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In initial trials, a weight was placed at the end of the catheter and a sterile gauze pack soaked in iodine was placed in the vagina to provide additional compression of the lower uterine segment, although these approaches have been abandoned by some clinicians without loss of efficacy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/15\">",
"       15",
"      </a>",
"      ]. Alternatively, the end of the catheter can be taped to the patient's thigh with or without slight tension, which is our practice. The relatively small number of cases in the literature precludes making any strong recommendations for or against any of these measures [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Periodically flush the drainage port with sterile saline to ensure that it has not become occluded by blood and to remove clots.",
"     </li>",
"     <li>",
"      If the balloon becomes partially or completely dislodged, it can be deflated, repositioned, and reinflated. In patients with a positive tamponade test (ie, no bleeding), a vaginal pack can be used to keep the balloon from sliding out of the dilated postpartum cervix.",
"     </li>",
"     <li>",
"      Monitor for signs and symptoms of ongoing blood loss, such as pallor, dizziness, hypotension, tachycardia, confusion, uterine enlargement, abdominal pain, abdominal distension, and oliguria. Blood transfusion(s)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      blood products should be given, as needed, to correct prior deficits. Obstetrical providers should be prepared to intervene surgically if the patient's hemodynamic status worsens or does not immediately improve.",
"     </li>",
"     <li>",
"      We leave the balloon in the uterus for 8 to 24 hours, but balloons have been left in place for as long as 82 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/3\">",
"       3",
"      </a>",
"      ]. Manufacturers' package inserts state that the in-dwelling time should be 24 hours or less due to concerns about infection and tissue necrosis, but this time interval was not based on any data. The balloon is then deflated, either all at once (our usual practice) or gradually over several hours, while monitoring the patient for recurrent bleeding. Emergency surgical services and experienced staff should be readily available when the balloon is deflated in case of recurrent hemorrhage.",
"      <br/>",
"      <br/>",
"      We do not reinflate or reinsert a balloon if bleeding recurs during deflation or after removal. We consider persistent or recurrent bleeding an indication to proceed with other treatment options.",
"     </li>",
"     <li>",
"      Intrauterine balloon tamponade is painful; it is important to provide adequate analgesia. Although partially deflating the balloon might alleviate pain, it would also reduce tamponade, possibly resulting in hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUCCESS RATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In case series, success rates of uterine balloon catheters for controlling hemorrhage range from 57 percent after cesarean delivery to 100 percent after vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/13-15,17-19\">",
"     13-15,17-19",
"    </a>",
"    ]. Even if balloon tamponade fails, it may reduce bleeding and provide time to prepare for other interventions or transportation from a local hospital to a tertiary center [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the high success rate has resulted in less need for more invasive procedures. As an example, a study that compared rates of arterial embolization in the authors&rsquo; hospital in the periods before and after introduction of a balloon tamponade protocol observed a 75 percent reduction in use of embolization after initiating this protocol as the second-line approach to treatment for severe postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Comparison of methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have not been performed. A comparison of observational studies of uterine balloon tamponade, uterine compression sutures, pelvic devascularization, and arterial embolization concluded there was no high quality evidence that any one method of management of severe postpartum hemorrhage was better than another [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/18\">",
"     18",
"    </a>",
"    ]. As balloon tamponade is the most rapid, least invasive, and least costly of these approaches, we suggest performing this procedure if uterotonic therapy fails and before resorting to more invasive approaches. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among methods for uterine tamponade, packing the uterus with gauze or other material has been employed for centuries to control postpartum hemorrhage and has met with variable levels of success. Compared with balloon tamponade, classic fabric gauze packing has several pitfalls, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It can take a lot of time",
"     </li>",
"     <li>",
"      It is easily soaked with blood, which weakens the desired pressure effect",
"     </li>",
"     <li>",
"      Continued bleeding may be missed because of lack of a drainage port",
"     </li>",
"     <li>",
"      The gauze might be sutured to the uterus inadvertently",
"     </li>",
"     <li>",
"      Fabric inside the uterus may increase the risk of infection",
"     </li>",
"     <li>",
"      The patient may need to return to an operating theater for removal of the pack",
"     </li>",
"     <li>",
"      It does not rapidly identify patients who will require a laparotomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one series of postpartum hemorrhage control with a uterine balloon device, 23 patients underwent placement of either a Bakri balloon or the Sengstaken-Blakemore tube [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/13\">",
"     13",
"    </a>",
"    ]. The overall success rate was 90 percent, and was 100 percent in patients with atony. There was no difference in success rates between the two devices, but use of an obstetrical balloon catheter is still preferable to the Sengstaken-Blakemore tube because:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obstetrical balloon catheters are made of silicone, which is advantageous in patients with latex allergy",
"     </li>",
"     <li>",
"      Their shape more naturally conforms to the uterine cavity",
"     </li>",
"     <li>",
"      The risk of uterine perforation may be less",
"     </li>",
"     <li>",
"      They come presterilized and ready to use, whereas the tip of the Sengstaken-Blakemore tube needs to be cut",
"     </li>",
"     <li>",
"      The Sengstaken-Blakemore tube has extra ports and is more complicated to use",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Foley balloon catheters are typically too small to significantly compress the inner uterus after delivery of a term or near term baby so multiple balloon catheters may need to be used.",
"   </p>",
"   <p>",
"    The Rusch balloon catheter has sufficient volume to adequately compress the inner uterus, but does not have a drainage channel to monitor ongoing bleeding after placement. A study including 22 patients with ongoing severe postpartum hemorrhage despite medical management reported placement of the Rusch balloon catheter controlled bleeding in 13 patients (59 percent), but was unsuccessful and hysterectomy was required in 7 patients (32 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The condom catheter is similarly limited by the absence of a channel for drainage and the need for some preparation (tying the condom around the catheter) prior to insertion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential complications include perforation of uterus during placement or inflation and cervical trauma due to inflation at an incorrect location; however, these complications have not been reported in the postpartum uterus. Infection has been reported, but causality is difficult to prove, as these patients have had multiple risk factors for postpartum fever. Uterine rupture of the nonpuerperal uterus has been reported after inflation of various types of intrauterine balloons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The balloon should NOT be insufflated with air or carbon dioxide due to the risk of air embolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     OTHER APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combinations of techniques can be employed when use of a single approach alone fails.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     External compression plus internal tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"uterine sandwich\" technique refers to use of an obstetrical balloon catheter in combination with the B-Lynch suture (",
"    <a class=\"graphic graphic_figure graphicRef71907 \" href=\"UTD.htm?0/22/356\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/11,24,25\">",
"     11,24,25",
"    </a>",
"    ]. It has been successfully employed post cesarean delivery in patients with persistent bleeding from uterine atony refractory to both medical therapy and a B-lynch suture. In one series of 24 cases of severe postpartum hemorrhage, 12 patients were successfully treated with the balloon catheter alone and 6 were successfully treated with the balloon catheter and the B-lynch suture [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After placement of the balloon catheter and careful closure of the hysterotomy, the balloon is inflated with median volume of 100 mL of fluid (range 60 to 250 mL) to avoid \"undue blanching at the compression suture sites,\" which might lead to uterine laceration or necrosis. Procedure-related complications of uterine compression sutures, such as uterine ischemic necrosis, erosion, pyometra, adhesions, and peritonitis, have been reported, but are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22711/abstract/26-33\">",
"     26-33",
"    </a>",
"    ]. Blood loss was reduced in all of the patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Uterine vessel ligation plus internal tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;We have developed a technique of bilateral looped uterine vessel sutures (B-LUVS) for managing selected cases of postpartum hemorrhage, such as bleeding from uterine atony or placenta accreta. These sutures have been used in combination with the Bakri balloon catheter in several patients with 100 percent success (ie, complete control of obstetric hemorrhage immediately after the procedure) and without known short- or long-term complications. Further evaluation of safety and efficacy of this technique is ongoing.",
"   </p>",
"   <p>",
"    We use a curved, blunt edge 65 mm needle and a looped #1 monofilament absorbable or chromic gut suture to perform a continuous whip stitch through the full thickness of the lateral uterine wall (ie, serosa, myometrium, endometrium) on each side of the uterus (",
"    <a class=\"graphic graphic_figure graphicRef64192 \" href=\"UTD.htm?0/11/178\">",
"     figure 4",
"    </a>",
"    ). Use of a looped suture adds strength and avoids the need for a knot where the stitch is begun. The stepwise stitches begin at the lowest possible location of the lower uterine segment and continue up to the cornual end if needed, while avoiding important adjacent structures: bladder, ureter, and fallopian tube. At the cornua, the loop is cut at one end, another stitch is taken, and the two ends of the suture are used to tie a knot.",
"   </p>",
"   <p>",
"    After completing these sutures, the balloon catheter is inserted into the uterine cavity either transcervically or through the hysterotomy incision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postpartum hemorrhage is an obstetrical emergency that is managed in a step-wise approach. After exclusion of retained products of conception and genital tract trauma, treatment of uterine atony is initiated, progressing from less invasive therapies (uterine massage, uterotonic drugs) to more invasive therapies (balloon tamponade, arterial embolization, uterine compression sutures, uterine artery ligation) and ultimately hysterectomy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After bleeding from vaginal and cervical lacerations and retained products of conception has been excluded, we suggest balloon tamponade for management of acute postpartum hemorrhage refractory to medical and other conservative interventions (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Balloon tamponade is as effective, but more rapid, less invasive, and less costly than arterial embolization and open surgical approaches for control of hemorrhage. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Success rate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest balloon tamponade as a temporizing measure while the patient is waiting for arterial embolization or open surgical treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In many such patients, use of balloon tamponade obviates the need for operative intervention. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The effectiveness of balloon tamponade is assessed by the \"tamponade test,\" which rapidly identifies patients who will require a laparotomy. Patients with a negative test (ie, bleeding is not controlled with inflation of the balloon) should proceed to laparotomy and, possibly, hysterectomy. Arterial embolization by an interventional radiologist is an option for patients who are hemodynamically stable and when personnel and facilities are readily available. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Periprocedure monitoring and care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We leave the balloon in the uterus for 8 to 24 hours. The balloon is then deflated, either all at once or gradually over several hours, while monitoring the patient for recurrent bleeding. Emergency surgical services and experienced staff should be readily available when the balloon is deflated in case of recurrent hemorrhage. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Periprocedure monitoring and care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Balloon tamponade can be combined with other measures, such as the B-Lynch suture or B-LUVS suture technique. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Other approaches'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/1\">",
"      Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet 2006; 367:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/2\">",
"      Tindell K, Garfinkel R, Abu-Haydar E, et al. Uterine balloon tamponade for the treatment of postpartum haemorrhage in resource-poor settings: a systematic review. BJOG 2013; 120:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/3\">",
"      Georgiou C. Balloon tamponade in the management of postpartum haemorrhage: a review. BJOG 2009; 116:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/4\">",
"      Barbieri, R. Planning reduces the risk of maternal death. This tool helps. OBG Management 2009; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/5\">",
"      Rathore AM, Gupta S, Manaktala U, et al. Uterine tamponade using condom catheter balloon in the management of non-traumatic postpartum hemorrhage. J Obstet Gynaecol Res 2012; 38:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/6\">",
"      Thapa K, Malla B, Pandey S, Amatya S. Intrauterine condom tamponade in management of post partum haemorrhage. J Nepal Health Res Counc 2010; 8:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/7\">",
"      Airede LR, Nnadi DC. The use of the condom-catheter for the treatment of postpartum haemorrhage - the Sokoto experience. Trop Doct 2008; 38:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/8\">",
"      Akhter S, Begum MR, Kabir Z, et al. Use of a condom to control massive postpartum hemorrhage. MedGenMed 2003; 5:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/9\">",
"      Sinha SM. The \"tamponade test\" in the management of massive postpartum hemorrhage. Obstet Gynecol 2003; 102:641; author reply 641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/10\">",
"      Georgiou C. Intraluminal pressure readings during the establishment of a positive 'tamponade test' in the management of postpartum haemorrhage. BJOG 2010; 117:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/11\">",
"      Nelson WL, O'Brien JM. The uterine sandwich for persistent uterine atony: combining the B-Lynch compression suture and an intrauterine Bakri balloon. Am J Obstet Gynecol 2007; 196:e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/12\">",
"      Cho Y, Rizvi C, Uppal T, Condous G. Ultrasonographic visualization of balloon placement for uterine tamponade in massive primary postpartum hemorrhage. Ultrasound Obstet Gynecol 2008; 32:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/13\">",
"      Dabelea V, Schultze PM, McDuffie RS Jr. Intrauterine balloon tamponade in the management of postpartum hemorrhage. Am J Perinatol 2007; 24:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/14\">",
"      Bakri YN, Amri A, Abdul Jabbar F. Tamponade-balloon for obstetrical bleeding. Int J Gynaecol Obstet 2001; 74:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/15\">",
"      Vitthala S, Tsoumpou I, Anjum ZK, Aziz NA. Use of Bakri balloon in post-partum haemorrhage: a series of 15 cases. Aust N Z J Obstet Gynaecol 2009; 49:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/16\">",
"      Condous GS, Arulkumaran S, Symonds I, et al. The \"tamponade test\" in the management of massive postpartum hemorrhage. Obstet Gynecol 2003; 101:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/17\">",
"      Gr&ouml;nvall M, Tikkanen M, Tallberg E, et al. Use of Bakri balloon tamponade in the treatment of postpartum hemorrhage: a series of 50 cases from a tertiary teaching hospital. Acta Obstet Gynecol Scand 2013; 92:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/18\">",
"      Doumouchtsis SK, Papageorghiou AT, Arulkumaran S. Systematic review of conservative management of postpartum hemorrhage: what to do when medical treatment fails. Obstet Gynecol Surv 2007; 62:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/19\">",
"      Laas E, Bui C, Popowski T, et al. Trends in the rate of invasive procedures after the addition of the intrauterine tamponade test to a protocol for management of severe postpartum hemorrhage. Am J Obstet Gynecol 2012; 207:281.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/20\">",
"      Majumdar A, Saleh S, Davis M, et al. Use of balloon catheter tamponade for massive postpartum haemorrhage. J Obstet Gynaecol 2010; 30:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/21\">",
"      Goorah B, Tulandi T. Uterine rupture resulting from the pressure of an intrauterine balloon. J Obstet Gynaecol Can 2009; 31:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/22\">",
"      Wu HH, Yeh GP, Hsieh TC. Iatrogenic uterine rupture caused by overinflation of RUMI manipulator balloon. J Minim Invasive Gynecol 2005; 12:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/23\">",
"      Vlahos NP, Bankowski BJ, Makrakis E. Non-puerperal uterine rupture after use of misoprostol and a Foley catheter for management of uterine bleeding. Int J Gynaecol Obstet 2005; 88:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/24\">",
"      Price N, Whitelaw N, B-Lynch C. Application of the B-Lynch brace suture with associated intrauterine balloon catheter for massive haemorrhage due to placenta accreta following a second-trimester miscarriage. J Obstet Gynaecol 2006; 26:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/25\">",
"      Diemert A, Ortmeyer G, Hollwitz B, et al. The combination of intrauterine balloon tamponade and the B-Lynch procedure for the treatment of severe postpartum hemorrhage. Am J Obstet Gynecol 2012; 206:65.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/26\">",
"      Gottlieb AG, Pandipati S, Davis KM, Gibbs RS. Uterine necrosis: a complication of uterine compression sutures. Obstet Gynecol 2008; 112:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/27\">",
"      B-Lynch C. Partial ischemic necrosis of the uterus following a uterine brace compression suture. BJOG 2005; 112:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/28\">",
"      Joshi VM, Shrivastava M. Partial ischemic necrosis of the uterus following a uterine brace compression suture. BJOG 2004; 111:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/29\">",
"      Reyftmann L, Nguyen A, Ristic V, et al. [Partial uterine wall necrosis following Cho hemostatic sutures for the treatment of postpartum hemorrhage]. Gynecol Obstet Fertil 2009; 37:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/30\">",
"      El-Hamamy E. Partial ischemic necrosis of the uterus following a uterine brace compression suture. BJOG 2005; 112:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/31\">",
"      Pechtor K, Richards B, Paterson H. Antenatal catastrophic uterine rupture at 32 weeks of gestation after previous B-Lynch suture. BJOG 2010; 117:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/32\">",
"      Fotopoulou C, Dudenhausen JW. Uterine compression sutures for preserving fertility in severe postpartum haemorrhage: an overview 13 years after the first description. J Obstet Gynaecol 2010; 30:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22711/abstract/33\">",
"      Mallappa Saroja CS, Nankani A, El-Hamamy E. Uterine compression sutures, an update: review of efficacy, safety and complications of B-Lynch suture and other uterine compression techniques for postpartum haemorrhage. Arch Gynecol Obstet 2010; 281:581.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4440 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-41B8DEA544-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22711=[""].join("\n");
var outline_f22_11_22711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF BALLOON CATHETERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      After vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      After cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PERIPROCEDURE MONITORING AND CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUCCESS RATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Comparison of methods",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      OTHER APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      External compression plus internal tamponade",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Uterine vessel ligation plus internal tamponade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4440\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4440|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/8/44164\" title=\"figure 1\">",
"      Bakri balloon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/55/19312\" title=\"figure 2\">",
"      Intrauterine balloon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/22/356\" title=\"figure 3\">",
"      B-Lynch suture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/11/178\" title=\"figure 4\">",
"      B-LUVS and balloon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11305?source=related_link\">",
"      Managing an episode of severe or prolonged uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22712="Clinical features and diagnosis of thoracic aortic aneurysm";
var content_f22_11_22712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of thoracic aortic aneurysm",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Y Joseph Woo, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22712/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/11/22712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic aortic aneurysms are less common than aneurysms of the abdominal aorta. An aneurysm is defined as a permanent localized dilation of an artery, having at least a 50 percent increase in diameter compared with the expected normal diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/1\">",
"     1",
"    </a>",
"    ]. True aneurysm involves all three layers of the vessel wall, whereas pseudoaneurysm, or false aneurysm, represents a collection of blood and connective tissue outside the aortic wall, often a result of rupture. &nbsp;",
"   </p>",
"   <p>",
"    This topic will review the classification, etiology, clinical features, and diagnosis of true thoracic aortic aneurysms. The management and outcome of this disorder are discussed separately. Abdominal aortic aneurysm is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10361?source=see_link\">",
"     \"Management and outcome of thoracic aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=see_link\">",
"     \"Thoracic endovascular aneurysm repair\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=see_link\">",
"     \"Management of asymptomatic abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=see_link\">",
"     \"Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058417799\">",
"    <span class=\"h1\">",
"     ANATOMIC ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058417791\">",
"    <span class=\"h2\">",
"     Anatomy of the thoracic aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aorta is the major arterial conduit conveying blood from the heart to the systemic circulation. It originates immediately beyond the aortic valve and ascends initially, then it curves forming the aortic arch, and descends caudally adjacent the spine. The ascending thoracic aorta gives off the coronary arteries, and the aortic arch branches are typically the brachiocephalic trunk (branches to the right carotid and right subclavian arteries), left carotid and left subclavian arteries. Aortic arch anatomy is variable (",
"    <a class=\"graphic graphic_figure graphicRef54048 \" href=\"UTD.htm?5/47/5878\">",
"     figure 1",
"    </a>",
"    ). The descending thoracic aorta provides paired thoracic arteries (T1-T12) and continues through the hiatus of the diaphragm to become the abdominal aorta which extends retroperitoneally to its bifurcation into the common iliac arteries at the level of the fourth lumbar vertebra (",
"    <a class=\"graphic graphic_figure graphicRef51087 \" href=\"UTD.htm?42/14/43234\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1058418009\">",
"    <span class=\"h2\">",
"     Definition of TAA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A true aneurysm is defined as a permanent localized dilation of an artery, having at least a 50 percent increase in diameter compared with the expected normal diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Although &ldquo;normal&rdquo; diameter varies with age, gender, and body habitus, average diameters of the thoracic aorta on imaging (computed tomography, magnetic resonance) are given below for adult males and females and normal dimensions obtained using echocardiography are given in the table (",
"    <a class=\"graphic graphic_table graphicRef52100 \" href=\"UTD.htm?7/7/7292\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Male",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aortic sinus: 3.63 to 3.91 cm",
"     </li>",
"     <li>",
"      Ascending aorta: 2.86 cm",
"     </li>",
"     <li>",
"      Mid-descending aorta: 2.39 to 2.98 cm",
"     </li>",
"     <li>",
"      At diaphragm: 2.43 to 2.69 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Female",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Aortic root: 3.5 to 3.72 cm",
"     </li>",
"     <li>",
"      Ascending aorta: 2.86 cm",
"     </li>",
"     <li>",
"      Mid-descending aorta: 2.45 to 2.64 cm",
"     </li>",
"     <li>",
"      At diaphragm: 2.40 to 2.44 cm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;True aneurysms include all three layers of the vessel including the intima, media, and adventitia. In the thoracic aorta, the intima and media in large aneurysms may be so attenuated that in some areas these layers may be undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/1\">",
"     1",
"    </a>",
"    ]. A pseudoaneurysm or false aneurysm is a collection of blood and connective tissue outside the aortic wall, usually the result of a rupture.",
"   </p>",
"   <p>",
"    There are two major types of aneurysm morphology: fusiform, which is uniform in shape with symmetrical dilatation that involves the entire circumference of the aortic wall; and saccular, which is more localized and appears as an outpouching of only a portion of the aortic wall.",
"   </p>",
"   <p>",
"    Aneurysms of the thoracic aorta can be classified into four general anatomic categories, although some aneurysms involve more than one segment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ascending aortic aneurysms arise anywhere from the aortic valve to the innominate artery &ndash; 60 percent",
"     </li>",
"     <li>",
"      Aortic arch aneurysms include any thoracic aneurysm that involves the brachiocephalic vessels &ndash; 10 percent",
"     </li>",
"     <li>",
"      Descending aortic aneurysms are those distal to the left subclavian artery (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87419 \" href=\"UTD.htm?20/15/20728\">",
"       image 1",
"      </a>",
"      ) &ndash; 40 percent",
"     </li>",
"     <li>",
"      Thoracoabdominal aneurysms &ndash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thoracoabdominal aneurysms are further divided according to the Crawford classification (",
"    <a class=\"graphic graphic_figure graphicRef66037 \" href=\"UTD.htm?4/39/4726\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type &nbsp; I: Proximal descending thoracic to proximal abdominal aorta",
"     </li>",
"     <li>",
"      Type &nbsp;II: Proximal descending to infrarenal aorta",
"     </li>",
"     <li>",
"      Type III: Distal descending with abdominal aorta",
"     </li>",
"     <li>",
"      Type IV: Primarily abdominal aorta",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Beyond distinguishing thoracic aneurysms by anatomic position, the three broad categories further provide guidance for the operative approach to repair the aneurysm, intraoperative circulatory management, and end-organ injury risk stratification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of thoracic aortic aneurysm is estimated to be six to ten cases per 100,000 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic aneurysms occur most commonly in the sixth and seventh decade of life.",
"     </li>",
"     <li>",
"      Males are affected approximately two to four times more commonly than females.",
"     </li>",
"     <li>",
"      Hypertension is an important risk factor, being present in over 60 percent of patients",
"     </li>",
"     <li>",
"      Up to 13 percent of patients diagnosed with an aortic aneurysm are found to have multiple aneurysms; approximately 20 to 25 percent of patients with a large thoracic aortic aneurysm also have an abdominal aortic aneurysm [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic aortic aneurysms most often result from cystic medial degeneration that leads to weakening of the aortic wall [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/4\">",
"     4",
"    </a>",
"    ]. Cystic medial degeneration occurs normally with aging and is increased with hypertension. When it occurs in young patients, it is most often due to Marfan syndrome or other less common connective tissue disorders such as Ehlers-Danlos syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Association with atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of descending thoracic aneurysms are associated with atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/4\">",
"     4",
"    </a>",
"    ] and the risk factors for aneurysm formation are the same as those for atherosclerosis (eg, hypertension, hypercholesterolemia, smoking) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/10\">",
"     10",
"    </a>",
"    ]. However, it remains unclear whether atherosclerosis is actually responsible for aneurysm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/10\">",
"     10",
"    </a>",
"    ]. It seems likely that there is a multifactorial, systemic, nonatherosclerotic causal process, such as a defect in vascular structural proteins, with atherosclerosis occurring secondarily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most theories emphasize the primary role of breakdown of the extracellular matrix proteins elastin and collagen by proteases such as collagenase, elastase, various matrix metalloproteinases, and plasmin (formed from plasminogen by urokinase plasminogen activator and tissue type plasminogen activator) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/12\">",
"     12",
"    </a>",
"    ]. These proteolytic factors are derived from endothelial and smooth muscle cells and from inflammatory cells infiltrating the media and adventitia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of protein degradation and mechanical factors are thought to cause cystic medial necrosis, which has the appearance of smooth muscle cell necrosis and elastic fiber degeneration with cystic spaces in the media filled with mucoid material. These changes result in vessel dilatation and subsequent aneurysm formation and possible rupture.",
"   </p>",
"   <p>",
"    The following observations in animal models are consistent with the importance of plasmin and metalloproteinases in aortic aneurysm formation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blockade of plasmin formation by overexpression of plasminogen activator inhibitor-1 prevents the formation of aneurysms and rupture by inhibiting metalloproteinase activation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Aneurysm rupture correlates with an increase in metalloproteinase (gelatinase A and B) levels; local overexpression of tissue inhibitor of matrix metalloproteinases, produced by retrovirally infected smooth muscle cells, can prevent aneurysmal degeneration and rupture [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic dissections often involve the ascending and thoracic aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are specific etiologic genetic defects when thoracic aneurysms occur in association with connective tissue disorders such as the Marfan or Ehlers-Danlos syndromes. There are also familial associations with thoracic aneurysms in a small number of patients without these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Marfan syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Marfan syndrome is associated with aortic root dilatation (normal &le;35 mm) due to cystic medial degeneration prior to aneurysm formation. This disorder is due to mutations in the fibrillin-1 (FBN1) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/15\">",
"     15",
"    </a>",
"    ]. Aortic root disease, which leads to the formation of aneurysmal dilatation, aortic regurgitation, and dissection, is the main cause of morbidity and mortality in the Marfan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/16\">",
"     16",
"    </a>",
"    ]. Marfan syndrome is also frequently associated with aortic dissection. Marfan syndrome is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Ehlers-Danlos syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ehlers-Danlos syndrome is a group of conditions due to defects in type III collagen that cause hyperelasticity and fragility of the skin and hypermobility of the joints. Mitral valve prolapse is often present. Although aortic root dilatation is uncommon, spontaneous rupture of large and medium-sized arteries, usually without dissection, is the most serious cardiovascular complication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and treatment of the hypermobility syndrome\", section on 'Ehlers-Danlos syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that as many as 19 percent of patients with a thoracic aortic",
"    <span class=\"nowrap\">",
"     aneurysm/dissection",
"    </span>",
"    have a family history of aortic aneurysm independent of Marfan or Ehlers-Danlos syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/17\">",
"     17",
"    </a>",
"    ]. A number of mutations associated with the presence of thoracic aneurysm have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. It has been estimated that mutations in the transforming growth factor beta receptor 2 gene (TGFBR2) are responsible for about 5 percent of familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/20\">",
"     20",
"    </a>",
"    ]. Mutations in this gene and in fibrillin-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/18\">",
"     18",
"    </a>",
"    ] can also cause Marfan syndrome. Loeys-Dietz syndrome, which is characterized by hypertelorism, split uvula or cleft palate, tortuous arteries and aortic aneurysms, is an autosomal dominant condition due to mutations in genes for TGF Beta (TGFBR1 and TGFBR2) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=see_link&amp;anchor=H16#H16\">",
"     \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\", section on 'Spectrum of phenotypes and differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Bicuspid aortic valve and aortic coarctation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an association between bicuspid aortic valve and thoracic aortic aneurysm. In a study of young men with normally functioning bicuspid aortic valves, enlargement of the aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending aorta was noted in 52 percent; this finding was independent of hemodynamic abnormalities, age, or body size [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, a bicuspid aortic valve is an independent predictor of ascending aortic aneurysm formation after surgical correction of aortic coarctation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/26\">",
"     26",
"    </a>",
"    ] and is associated with aortic root dilatation in patients with Turner syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\", section on 'Cardiovascular disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inflammatory/infectious disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad grouping of inflammatory and infectious disorders, classified under aortitis, can occasionally cause aortic aneurysm. These diseases include giant cell arteritis, syphilitic aortitis, mycotic aneurysm often due to bacterial endocarditis, Takayasu arteritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, Wegener's granulomatosis, and reactive arthritis. (See appropriate topic reviews)",
"   </p>",
"   <p>",
"    The pathophysiologic process leading to aortic dilatation and aneurysm formation is thought to be due to intramural inflammation and degeneration either in response to spirochete infection as in syphilitic aortitis or as a manifestation of a systemic autoimmune process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Giant cell arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic aneurysm formation is a particular problem in patients with giant cell arteritis that occurs in as many as 11 percent of patients and may be associated with aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/28\">",
"     28",
"    </a>",
"    ]. It is a usually late manifestation of the disease that can occur in otherwise asymptomatic patients who had been treated for a number of years prior to aortic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/29\">",
"     29",
"    </a>",
"    ]. As a result, it is recommended that yearly chest x-rays be performed for up to 10 years to identify patients with thoracic aortic aneurysms prior to rupture or dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations of giant cell (temporal) arteritis\", section on 'Aneurysms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thoracic aneurysms are often asymptomatic at the time of presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/9\">",
"     9",
"    </a>",
"    ]. However, depending upon aneurysm location, chest, back, flank, or abdominal pain can be a presenting symptom. Symptoms are usually attributed to compression or distortion of adjacent structures or vessels, a vascular consequence such as aortic regurgitation, or thromboembolic sequelae.",
"   </p>",
"   <p>",
"    Ascending aneurysms can present with heart failure due to aortic regurgitation from aortic root dilatation and annular distortion. In addition, compression of a coronary artery can result in myocardial ischemia or infarction, while a sinus of Valsalva aneurysm can rupture into the right side of the heart, producing a continuous murmur and, in some cases, heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ascending and arch aneurysms can erode into the mediastinum. Such patients can present with one or more of the following: hoarseness due to compression of left vagus or left recurrent laryngeal nerve; hemidiaphragmatic paralysis due to compression of the phrenic nerve; wheezing, cough, hemoptysis, dyspnea, or pneumonitis if there is compression of the tracheobronchial tree; dysphagia due to esophageal compression; or the superior vena cava syndrome. Aneurysmal compression of other intrathoracic structures or erosion into adjacent bone may cause chest or back pain.",
"   </p>",
"   <p>",
"    Aneurysmal compression of branch vessels or the occurrence of embolism to various peripheral arteries due to thrombus within the aneurysm can cause coronary, cerebral, renal, mesenteric, lower extremity, and, rarely, spinal cord ischemia and resultant symptoms.",
"   </p>",
"   <p>",
"    The most serious complication of thoracic aortic aneurysm is rupture, most often into the left intrapleural space or intrapericardial space (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef53799 \" href=\"UTD.htm?40/9/41107\">",
"     image 2",
"    </a>",
"    ). A descending thoracic aortic aneurysm can rupture into the adjacent esophagus, producing an aortoesophageal fistula and presenting with hematemesis. Rupture is often catastrophic, being associated with severe pain and hypotension or shock. Aortic dissection can also occur, but is a less common manifestation of aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of noninvasive and invasive methods are useful for the diagnosis and evaluation of a thoracic aortic aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chest x-ray",
"    </span>",
"    &nbsp;&mdash;&nbsp;A common way in which asymptomatic aneurysms are detected is on routine chest radiography. The aneurysm produces a widening of the mediastinal silhouette, enlargement of the aortic knob, or displacement of the trachea from midline (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79278 \" href=\"UTD.htm?43/42/44707\">",
"     image 3",
"    </a>",
"    ). Other reported features include displaced calcification, aortic kinking, and opacification of the aorticopulmonary window [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, chest x-ray cannot distinguish an aneurysm from a tortuous aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/4\">",
"     4",
"    </a>",
"    ] and many aneurysms are not apparent on the chest x-ray. The frequency with which this occurs was illustrated in a series of 36 patients presenting with acute onset of chest or back pain within the prior 14 days who were found to have non-dissecting thoracic aortic aneurysms; radiographic abnormalities were detected in only 22 (61 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/30\">",
"     30",
"    </a>",
"    ]. For this reason as well as better visualization, additional imaging studies are obtained in virtually all patients suspected of having a thoracic aortic aneurysm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519597075\">",
"    <span class=\"h2\">",
"     CT/MR/Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) with intravenous contrast and magnetic resonance (MR) are the preferred imaging tests to detect a thoracic aortic aneurysm, determine its size, and define aortic and branch vessel anatomy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72571 \" href=\"UTD.htm?30/52/31566\">",
"     image 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/4,31,32\">",
"     4,31,32",
"    </a>",
"    ]. MR is preferred for aneurysms involving the aortic root [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/4\">",
"     4",
"    </a>",
"    ]. However, CT is used more often than MR in the acute setting to rule out dissection due to availability, efficiency, and proximity to the emergency department. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with known bicuspid aortic valves, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommend CT or MR imaging when morphology of the aortic root or ascending aorta cannot be accurately assessed by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/33\">",
"     33",
"    </a>",
"    ]. MR or CT is reasonable in patients with bicuspid aortic valves and aortic root dilatation on echocardiography to further quantify severity of dilatation and involvement of the ascending aorta.",
"   </p>",
"   <p>",
"    Contrast arteriography provides sharper resolution of luminal characteristics and may be a better method for evaluating branch vessel pathology (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87418 \" href=\"UTD.htm?29/56/30595\">",
"     image 5",
"    </a>",
"    ); however, multislice CT and MR show sufficient detail under most circumstances. Arteriography is also invasive with potential nephrotoxicity from contrast medium, and is unable to discern extraluminal aneurysmal size, but is necessary for placement of thoracic aortic endografts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An aortic aneurysm is often initially diagnosed on echocardiography indicated for other reasons. The 2003",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    practice guidelines for echocardiography recommended echocardiography for the diagnosis of aortic aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/34\">",
"     34",
"    </a>",
"    ]. Transthoracic echocardiography (TTE) is the preferred procedure (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61910 graphicRef60999 \" href=\"UTD.htm?26/42/27300\">",
"     image 6A-B",
"    </a>",
"    ), with transesophageal echocardiography (TEE) usually being performed only if the examination is incomplete or additional information is needed. There are, however, two settings in which TEE is preferred: for examination of the entire aorta, especially in emergency situations; and for imaging when coexistent dissection is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/44/10952?source=see_link\">",
"     \"Echocardiographic evaluation of the thoracic and proximal abdominal aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=see_link\">",
"     \"Transesophageal echocardiography: Indications, complications, and normal views\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with known bicuspid aortic valves, the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on valvular heart disease recommend an initial TTE to assess the diameters of the aortic root and ascending aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22712/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with aortic root or ascending aorta diameter greater than 4.0 cm (lower threshold compared with patients who do not have bicuspid aortic valve) should undergo serial evaluation of aortic",
"    <span class=\"nowrap\">",
"     root/ascending",
"    </span>",
"    aortic size and morphology by echocardiography, computed tomography or magnetic resonance on a yearly basis. A lower threshold for ascending aorta diameter should be considered in patients of small stature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519591796\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thoracic aortic aneurysm is defined as a permanent localized dilation of the thoracic aorta, having at least a 50 percent increase in diameter compared with the expected normal diameter for that aortic segment. Normal diameters for the thoracic aorta are given in the text above. True aneurysms include all three layers of the vessel including the intima, media, and adventitia. A pseudoaneurysm, or false aneurysm, is a collection of blood and connective tissue outside the aortic wall, usually the result of a focal rupture. Aneurysms of the thoracic aorta are classified by the segment of the aorta that is involved (",
"      <a class=\"graphic graphic_figure graphicRef66037 \" href=\"UTD.htm?4/39/4726\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence of thoracic aortic aneurysm is estimated to be 6 to 10 cases per 100,000 patient-years. Thoracic aortic aneurysm is more common in elderly males. Hypertension and other large artery aneurysms are important risk factors. Other diseases that are associated with thoracic aortic aneurysm include inflammatory",
"      <span class=\"nowrap\">",
"       disorders/vasculitis",
"      </span>",
"      (eg, giant cell arteritis, mycotic aneurysm, Takayasu&rsquo;s aortitis), bicuspid aortic valve disease, and connective tissue disorders such as the Marfan, Loeys-Dietz, or Ehlers-Danlos syndromes. There are also familial associations with thoracic aneurysms, and it has been estimated that as many as 19 percent of patients with a thoracic aortic",
"      <span class=\"nowrap\">",
"       aneurysm/dissection",
"      </span>",
"      have a family history of this disorder independent of those with Marfan or Ehlers-Danlos syndrome. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the majority of thoracic aneurysms are associated with atherosclerosis and the risk factors for aneurysm formation are the same as those for atherosclerosis (eg, hypertension, hypercholesterolemia, smoking), thoracic aortic aneurysms are likely the result of aortic wall degeneration from a multifactorial, systemic, nonatherosclerotic etiology. Most theories emphasize the primary role of breakdown of the extracellular matrix proteins elastin and collagen by proteases such as collagenase, elastase, various matrix metalloproteinases, and plasmin (formed from plasminogen by urokinase plasminogen activator and tissue type plasminogen activator). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with thoracic aneurysms are often asymptomatic at the time of presentation. When present, symptoms are usually due to compression of adjacent structures which may lead to chest, back, flank, or abdominal pain depending upon aneurysm location, pulmonary symptoms, or signs of nerve compression (eg, hoarseness, diaphragm paralysis). Other symptoms may be due to aortic regurgitation, or thromboembolism to nearly any vascular bed (eg, coronary, cerebral, renal, mesenteric, lower extremity, and, rarely, spinal cord). The most serious complications of thoracic aortic aneurysm are aortic dissection and rupture, which is most often into the left intrapleural space or intrapericardial space. Rupture is associated with severe pain and hypotension or shock. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A thoracic aortic aneurysm may be suspected based upon the appearance of a routine chest radiograph. The aneurysm produces a widening of the mediastinal silhouette, enlargement of the aortic knob, or displacement of the trachea from midline. Other radiographic features include displaced calcification, aortic kinking, and opacification of the aorticopulmonary window. Chest radiography cannot distinguish an aneurysm from a tortuous aorta, and many aneurysms are not apparent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chest x-ray'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomographic (CT) angiography with intravenous contrast or magnetic resonance imaging are the tests of choice to detect a thoracic aortic aneurysm, determine its size, define aortic and branch vessel anatomy and rule out an associated dissection. Magnetic resonance imaging is better than CT for aneurysms involving the aortic root or when avoiding intravenous contrast is necessary. Although contrast arteriography provides sharper resolution of luminal characteristics, and is the best method for evaluating branch vessel pathology, this procedure is invasive, is unable to determine the true aneurysm diameter, and has potential for nephrotoxicity from contrast medium. (See",
"      <a class=\"local\" href=\"#H519597075\">",
"       'CT/MR/Arteriography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with known bicuspid aortic valves, transthoracic echocardiography should be performed to assess the diameters of the aortic root and the ascending aorta, which, if greater than 4.0 cm (lower threshold for smaller stature), indicates the need for serial evaluation of aortic",
"      <span class=\"nowrap\">",
"       root/ascending",
"      </span>",
"      aortic size and morphology annually by echocardiography, CT, or MR. Transesophageal echocardiography (TEE) is preferred over TTE for examination of the entire aorta, particularly in emergency situations and for imaging when coexistent dissection is suspected. TEE may also augment the examination of TTE if the examination is incomplete or additional information is needed. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/1\">",
"      Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation 2010; 121:e266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/2\">",
"      Johnston KW, Rutherford RB, Tilson MD, et al. Suggested standards for reporting on arterial aneurysms. Subcommittee on Reporting Standards for Arterial Aneurysms, Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery and North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg 1991; 13:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/3\">",
"      Creager MA, Belkin M, Bluth EI, et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS Key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to develop Clinical Data Standards for peripheral atherosclerotic vascular disease). J Am Coll Cardiol 2012; 59:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/4\">",
"      Isselbacher EM. Thoracic and abdominal aortic aneurysms. Circulation 2005; 111:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/5\">",
"      Svensson LG, Crawford ES, Hess KR, et al. Experience with 1509 patients undergoing thoracoabdominal aortic operations. J Vasc Surg 1993; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/6\">",
"      Bickerstaff LK, Pairolero PC, Hollier LH, et al. Thoracic aortic aneurysms: a population-based study. Surgery 1982; 92:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/7\">",
"      Conrad MF, Cambria RP. Contemporary management of descending thoracic and thoracoabdominal aortic aneurysms: endovascular versus open. Circulation 2008; 117:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/8\">",
"      Crawford ES, Cohen ES. Aortic aneurysm: a multifocal disease. Presidential address. Arch Surg 1982; 117:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/9\">",
"      Pressler V, McNamara JJ. Aneurysm of the thoracic aorta. Review of 260 cases. J Thorac Cardiovasc Surg 1985; 89:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/10\">",
"      Reed D, Reed C, Stemmermann G, Hayashi T. Are aortic aneurysms caused by atherosclerosis? Circulation 1992; 85:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/11\">",
"      Tilson MD. Aortic aneurysms and atherosclerosis. Circulation 1992; 85:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/12\">",
"      MacSweeney ST, Powell JT, Greenhalgh RM. Pathogenesis of abdominal aortic aneurysm. Br J Surg 1994; 81:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/13\">",
"      Allaire E, Hasenstab D, Kenagy RD, et al. Prevention of aneurysm development and rupture by local overexpression of plasminogen activator inhibitor-1. Circulation 1998; 98:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/14\">",
"      Allaire E, Forough R, Clowes M, et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 1998; 102:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/15\">",
"      Lee B, Godfrey M, Vitale E, et al. Linkage of Marfan syndrome and a phenotypically related disorder to two different fibrillin genes. Nature 1991; 352:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/16\">",
"      Adams JN, Trent RJ. Aortic complications of Marfan's syndrome. Lancet 1998; 352:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/17\">",
"      Coady MA, Davies RR, Roberts M, et al. Familial patterns of thoracic aortic aneurysms. Arch Surg 1999; 134:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/18\">",
"      Milewicz DM, Michael K, Fisher N, et al. Fibrillin-1 (FBN1) mutations in patients with thoracic aortic aneurysms. Circulation 1996; 94:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/19\">",
"      Milewicz DM, Chen H, Park ES, et al. Reduced penetrance and variable expressivity of familial thoracic aortic aneurysms/dissections. Am J Cardiol 1998; 82:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/20\">",
"      Pannu H, Fadulu VT, Chang J, et al. Mutations in transforming growth factor-beta receptor type II cause familial thoracic aortic aneurysms and dissections. Circulation 2005; 112:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/21\">",
"      Guo D, Hasham S, Kuang SQ, et al. Familial thoracic aortic aneurysms and dissections: genetic heterogeneity with a major locus mapping to 5q13-14. Circulation 2001; 103:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/22\">",
"      Vaughan CJ, Casey M, He J, et al. Identification of a chromosome 11q23.2-q24 locus for familial aortic aneurysm disease, a genetically heterogeneous disorder. Circulation 2001; 103:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/23\">",
"      Khau Van Kien P, Mathieu F, Zhu L, et al. Mapping of familial thoracic aortic aneurysm/dissection with patent ductus arteriosus to 16p12.2-p13.13. Circulation 2005; 112:200.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.marfan.org/marfan/2290/Loeys-Dietz-Syndrome/  file://www.ncbi.nlm.nih.gov/books/NBK1133/.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/25\">",
"      Nistri S, Sorbo MD, Marin M, et al. Aortic root dilatation in young men with normally functioning bicuspid aortic valves. Heart 1999; 82:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/26\">",
"      von Kodolitsch Y, Aydin MA, Koschyk DH, et al. Predictors of aneurysmal formation after surgical correction of aortic coarctation. J Am Coll Cardiol 2002; 39:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/27\">",
"      Elsheikh M, Casadei B, Conway GS, Wass JA. Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. Clin Endocrinol (Oxf) 2001; 54:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/28\">",
"      Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/29\">",
"      Evans JM, Bowles CA, Bjornsson J, et al. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum 1994; 37:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/30\">",
"      von Kodolitsch Y, Nienaber CA, Dieckmann C, et al. Chest radiography for the diagnosis of acute aortic syndrome. Am J Med 2004; 116:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/31\">",
"      Rubin GD. Helical CT angiography of the thoracic aorta. J Thorac Imaging 1997; 12:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/32\">",
"      Roberts DA. Magnetic resonance imaging of thoracic aortic aneurysm and dissection. Semin Roentgenol 2001; 36:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/33\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22712/abstract/34\">",
"      Cheitlin MD, Armstrong WF, Aurigemma GP, et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). Circulation 2003; 108:1146.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8192 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22712=[""].join("\n");
var outline_f22_11_22712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H519591796\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1058417799\">",
"      ANATOMIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1058417791\">",
"      Anatomy of the thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1058418009\">",
"      Definition of TAA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Association with atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Ehlers-Danlos syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Bicuspid aortic valve and aortic coarctation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inflammatory/infectious disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H519597075\">",
"      CT/MR/Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519591796\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8192\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8192|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/15/20728\" title=\"diagnostic image 1\">",
"      Thoracoabdominal abdominal aortic aneurysm 3D reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?40/9/41107\" title=\"diagnostic image 2\">",
"      Ruptured thoracic aortic aneurysm on chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/42/44707\" title=\"diagnostic image 3\">",
"      Thoracic aortic aneurysm plain chest film",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?30/52/31566\" title=\"diagnostic image 4\">",
"      Thoracic aortic aneurysm in giant cell arteritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/56/30595\" title=\"diagnostic image 5\">",
"      Thoracoabdominal aortic aneurysm on aortogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/5/18512\" title=\"diagnostic image 6A\">",
"      2D TTE 4-chamber descending thoracic aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/22/36207\" title=\"diagnostic image 6B\">",
"      Thoracic aorta dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8192|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/47/5878\" title=\"figure 1\">",
"      Variations of aortic arch branching",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/14/43234\" title=\"figure 2\">",
"      Normal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/39/4726\" title=\"figure 3\">",
"      Crawford classification of thoracoabdominal aortic aneurysms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8192|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/7/7292\" title=\"table 1\">",
"      Normal echo dimensions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/56/2953?source=related_link\">",
"      Clinical manifestations and treatment of the hypermobility syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/33/18969?source=related_link\">",
"      Clinical manifestations of giant cell (temporal) arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/44/10952?source=related_link\">",
"      Echocardiographic evaluation of the thoracic and proximal abdominal aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/7/10361?source=related_link\">",
"      Management and outcome of thoracic aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38746?source=related_link\">",
"      Management of asymptomatic abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11225?source=related_link\">",
"      Management of symptomatic (non-ruptured) and ruptured abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=related_link\">",
"      Pregnancy and Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37240?source=related_link\">",
"      Thoracic endovascular aneurysm repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38280?source=related_link\">",
"      Transesophageal echocardiography: Indications, complications, and normal views",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22713="Late preterm infants";
var content_f22_11_22713=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Late preterm infants",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Wanda D Barfield, MD, MPH, FAAP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Kimberly G Lee, MD, MS, IBCLC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22713/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/11/22713/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late preterm infants are born at a gestational age between 34 weeks, and 36 weeks and 6 days. They have higher morbidity and mortality rates than term infants (gestational age &ge;37 weeks) due to their relative physiologic and metabolic immaturity, even though they are often the size and weight of some term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Late preterm term has replaced near term to describe this group of infants, since near term incorrectly implies that these infants are \"almost term\" and only require routine neonatal care [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, outcome, and management of late preterm infants will be reviewed here.",
"   </p>",
"   <p>",
"    The views reported in this article are those of the author and do not necessarily represent the official position of the Centers for Disease Control and Prevention (CDC).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is well established that gestational age has a major impact upon clinical outcome. Thus, it is necessary to standardize medical terminology related to neonatal maturation by gestational age rather than birthweight so that gestational-age appropriate care can be administered, and data from different studies can be compared.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Premature birth &ndash; The World Health Organization (WHO), the American Academy of Pediatrics (AAP), and the American College of Obstetricians and Gynecologists (ACOG) define premature birth as the delivery of an infant before completion of 37 weeks gestation. This occurs on or before the 259th day after the first day of the last menstrual period (LMP) of the mother.",
"      <br/>",
"      <br/>",
"      The National Center for Health Statistics (NCHS) of the Centers for Disease Control and Prevention (CDC) generally reports data on three categories of preterm birth: overall preterm (&lt;37 weeks gestation), moderately preterm (between 32 and 36 weeks gestation), and very preterm births (&lt;32 weeks gestation). By convention, only completed weeks of gestation are reported. Thus, infants born five days after completing 35 weeks are reported as 35 weeks gestation, and are not rounded up to 36 weeks gestation. If a more precise gestational age is desired, a superscript to specify the number of days after the completed week of gestation is usually used.",
"     </li>",
"     <li>",
"      Late preterm infants &ndash; The AAP, ACOG, and NCHS define late preterm birth as the delivery of an infant between 34 weeks, and 36 weeks and 6 days of gestation (ie, 239 to 259 days after the first day of the LMP).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm deliveries occur as a result of spontaneous preterm labor, including cases when premature rupture of membranes precedes the onset of labor, or medical interventions (ie, labor induction or cesarean delivery) that are initiated to reduce poor outcome associated with specific maternal or fetal conditions (",
"    <a class=\"graphic graphic_table graphicRef74561 \" href=\"UTD.htm?7/40/7819\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In the United States, premature births have increased from 10.6 percent in 1990 to a high of 12.8 percent of all live births in 2006, and have declined over three consecutive years to 11.7 percent of all births in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/6\">",
"     6",
"    </a>",
"    ]. The rise of preterm births during the last three decades was primarily due to a rise in late preterm births from 7.3 to 9.1 percent of all live births in 2006 (",
"    <a class=\"graphic graphic_table graphicRef61972 \" href=\"UTD.htm?2/10/2220\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55128 \" href=\"UTD.htm?36/9/37022\">",
"     figure 1",
"    </a>",
"    ) and accounts for over 250,000 births per year. Declines in preterm birth are reflected in declines in late preterm birth from 2007 to 2011, from 9 percent to now 8.3 percent of all births, reflecting progress in the prevention of late preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Prevention'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Risk factors for premature infants (",
"    <a class=\"graphic graphic_table graphicRef68992 \" href=\"UTD.htm?27/48/28428\">",
"     table 3",
"    </a>",
"    ) are similar for the three different categories of preterm infants (ie, late preterm births, births between 32 and 33 weeks gestation, and very preterm infants), and are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link\">",
"     \"Risk factors for preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study based upon data from the British Columbia Perinatal Database Registry, maternal risk factors that were more common in late preterm (defined as 33 to 36 weeks gestation) compared with term infants included chorioamnionitis, hypertension, diabetes, thrombophilia, premature rupture of membranes, primigravida, and teenage pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Factors associated with increased late preterm birth",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned previously, the overall rise in preterm birth rates over the last three decades is primarily due to an increase in late preterm births (",
"    <a class=\"graphic graphic_figure graphicRef62719 \" href=\"UTD.htm?0/14/224\">",
"     figure 2",
"    </a>",
"    ). This change is attributed to increased obstetrical surveillance that detects maternal, placental, and fetal conditions, which results in medically indicated births (ie, induction of labor or cesarean delivery) as these disorders would result in worse outcomes if pregnancy is allowed to continue (",
"    <a class=\"graphic graphic_figure graphicRef52580 \" href=\"UTD.htm?38/62/39908\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. The rise in assisted reproductive technology births resulting in multiple deliveries (multiple deliveries occur earlier in gestation than singleton births) has contributed to the increase in preterm birth rates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Improved obstetrical surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, obstetrical surveillance has increased as demonstrated by higher rates of fetal assessments, prenatal ultrasonography, and electronic fetal heart monitoring. The increase in surveillance is paralleled by a rise in the rate of medically indicated births.",
"   </p>",
"   <p>",
"    In the United States, medically indicated births increased from 29 percent in 1992 to 41 percent of all births in 2002 with a parallel increase in premature births [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The rise in medically indicated preterm births primarily occurred in late preterm births (6.4 versus 7.4 percent) compared with a small decrease in very premature infants (1.6 versus 1.5 percent) and a much smaller increase in preterm infants born between 32 and 33 weeks (1.2 versus 1.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The issue of timing of indicated late preterm and early term births was addressed at a workshop held by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and the Society for Maternal-Fetal Medicine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/8\">",
"     8",
"    </a>",
"    ]. The workshop developed consensus recommendations regarding the gestational age for delivery to optimize maternal, fetal, and neonatal outcomes (",
"    <a class=\"graphic graphic_table graphicRef64814 \" href=\"UTD.htm?28/36/29262\">",
"     table 4",
"    </a>",
"    ). These recommendations and those of the American College of Obstetricians and Gynecologists (ACOG) are based on the balance between maternal and newborn risks of early delivery with the risk of further continuation of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fetal surveillance and the indication for medically indicated births are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H3#H3\">",
"     \"Principles of labor induction\", section on 'Indications for delivery before onset of labor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=see_link&amp;anchor=H4#H4\">",
"     \"Cesarean delivery: Preoperative issues\", section on 'Indications and contraindications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link&amp;anchor=H10700886#H10700886\">",
"     \"Principles of labor induction\", section on 'Contraindications to induction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Multiple births",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants who are products of multiple births generally deliver at an earlier gestational age than infants of a singleton birth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the United States, about 60 percent of twins were born prematurely with a mean gestational age of 35.2 weeks in 2006 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/17\">",
"     17",
"    </a>",
"    ]. Almost all triplets were born prematurely (93 percent) with a mean gestational age of 32 weeks.",
"   </p>",
"   <p>",
"    Over the last several decades, multiple births rates have increased in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/17\">",
"     17",
"    </a>",
"    ]. For example, twin births increased from 22.3 to 32.1 per 1000 live births from 1990 to 2006. This change was primarily due to the rise of twin births in late preterm infants from 29.1 to 38.3 per 1000 live births (",
"    <a class=\"graphic graphic_figure graphicRef57575 \" href=\"UTD.htm?19/24/19854\">",
"     figure 4",
"    </a>",
"    ). A similar observation was seen in triplet and higher orders multiple births with an increase from 23 to 33.7 per 1000 live births.",
"   </p>",
"   <p>",
"    The rise in multiple births is primarily attributed to the following [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in the number of mothers who are older than 30 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/9,17\">",
"       9,17",
"      </a>",
"      ]. Women in their thirties are more likely than younger women to conceive multiple births spontaneously.",
"     </li>",
"     <li>",
"      Increased use of assisted reproductive technology (ART), which increases the likelihood for multifetal pregnancies and premature delivery. Singleton pregnancies following ART compared with spontaneously conceived pregnancies also are at higher risk for premature delivery. The estimated contribution of ART to the increase in preterm birth rate is about 10 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/18\">",
"       18",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"       \"Pregnancy outcome after assisted reproductive technology\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, other factors that have increased preterm births, particularly late preterm births, include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increasing maternal age &ndash; Higher maternal age (women in their thirties) is associated with an increase risk of premature birth than women who are between 21 and 24 years of age. In the United States, the birth rate of women over 30 years of age has risen to its highest level in more than four decades [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/9,17\">",
"       9,17",
"      </a>",
"      ]. These women, as discussed previously, are more likely to conceive multiple fetuses spontaneously or seek ART, which also results in multiple births [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/9,19\">",
"       9,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inaccurate gestational age &ndash; It appears that some late preterm births are a result of medically assisted deliveries of late preterm fetuses who were incorrectly thought to have reached term [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/20\">",
"       20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Elective induction of labor at term should be avoided if there is no",
"      <span class=\"nowrap\">",
"       medical/obstetrical",
"      </span>",
"      indication for delivery due to increased risk morbidity (eg, respiratory distress). However, if elective induction is undertaken for nonmedical reasons, an accurate gestational age is important to prevent late preterm birth. Elective induction should only take place if the preinduction assessment ensures the gestational age is at least 39 weeks. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Prevention'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"       \"Principles of labor induction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Prenatal gestational age may be determined by several methods. Clinical assessment by either history (ie, using the date of the last menstrual period [LMP] to calculate the estimated date of delivery) or physical examination of the uterus may be imprecise, resulting in an inaccurate gestational age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/20\">",
"       20",
"      </a>",
"      ]. Early fetal ultrasound is superior to either of these two clinical dating methods. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"       \"Prenatal assessment of gestational age\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Increasing maternal obesity &ndash; In the United States, the epidemic of overweight and obesity has led to a higher prevalence of maternal obesity. Women who are overweight or obese are more likely to have a preterm delivery than nonobese women due to obesity-related medical and antenatal complications (eg, maternal diabetes and hypertension, and multifetal pregnancy), which may lead to delivery interventions rather than an intrinsic predisposition to spontaneous preterm birth. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link&amp;anchor=H12#H12\">",
"       \"The impact of obesity on fertility and pregnancy\", section on 'Preterm birth'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared with their term counterparts, late-preterm infants have a higher morbidity rate during birth hospitalization, higher rates of readmission during the neonatal period and first year of life, and may be at increased risk for long-term neurodevelopmental impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Birth hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the birth hospitalization, late preterm infants have a six to sevenfold greater morbidity rate than term infants. This risk significantly rises in infants with other neonatal morbidity risk factors.",
"   </p>",
"   <p>",
"    This was illustrated from a population-based study from Massachusetts that compared the outcome of 26,170 late preterm infants with 377,638 term infants using birth and death certificates, and linking it to infant and maternal hospital discharge records from the Massachusetts Pregnancy to Early Life Longitudinal data system [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/21\">",
"     21",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonatal morbidity was seven times greater in late preterm infants (22 versus 3 percent). Morbidity rate doubled for each gestational week earlier than 38 weeks.",
"     </li>",
"     <li>",
"      Morbidity rates were 10- to 14-fold greater in late preterm infants with other known risk factors for neonatal morbidity when compared with similarly exposed term infants. These factors included maternal hypertension and diabetes, antepartum hemorrhage, infections, and maternal chronic disorders (eg, renal, pulmonary, and cardiac disease). The observed joint morbidity rates for late preterm infants were higher than the expected additive effect for each maternal condition, except for maternal infection. As an example, the observed 12-fold increase in morbidity for antepartum hemorrhage in late preterm infants was greater than the expected risk of sevenfold increase.",
"     </li>",
"     <li>",
"      Morbidity rates increased with the number of additional maternal risk factors, and were 18, 29, and 37 percent in infants with none, one, and two other risk factors, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Late preterm infants compared with those delivered at term have a higher cost of care.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study that analyzed data from a cohort of commercially insured neonates in the United States, late preterm infants had a longer average birth hospital stay (8.8 versus 2.2 days) with a 10-fold higher cost of care ($26,054 versus $2061) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study based on Arkansas Medicaid claims data, late preterm infants had greater costs for the first year of life with increases in both the outpatient ($108, 95% CI $58-158) and inpatient expenditures ($597, 95% CI $528-666) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/23\">",
"       23",
"      </a>",
"      ]. This may be due to their increased risk of respiratory distress syndrome, hypoglycemia, and need for mechanical ventilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the birth hospitalization, the late preterm infants compared with term infants are more likely to have the following complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3,24,25\">",
"     3,24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypothermia",
"     </li>",
"     <li>",
"      Hypoglycemia",
"     </li>",
"     <li>",
"      Respiratory distress",
"     </li>",
"     <li>",
"      Apnea",
"     </li>",
"     <li>",
"      Hyperbilirubinemia",
"     </li>",
"     <li>",
"      Feeding difficulties",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This was illustrated in a retrospective review of all spontaneous, low-risk late preterm deliveries between 1997 and 2006 at a single Israeli tertiary center [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/26\">",
"     26",
"    </a>",
"    ]. Infants of multiple gestations, premature rupture of membranes, or with maternal or fetal complications were excluded. Short-term outcome was compared with a control group of term infants. Late preterm infants compared with term infants had a greater risk of jaundice requiring phototherapy (18 versus 2.5 percent), hypoglycemia (6.8 versus 0.4 percent), respiratory distress (4.2 versus 0.1 percent), sepsis (0.4 versus 0.04 percent), and intraventricular hemorrhage (0.2 versus 0.02 percent).",
"   </p>",
"   <p>",
"    In a systematic review of 22 studies that compared the short- and long-term outcome of late preterm infants with term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/27\">",
"     27",
"    </a>",
"    ], late preterm infants compared with term infants during the neonatal period were more likely to have respiratory distress syndrome (5.3 versus 0.39 percent), intraventricular hemorrhage (0.41 versus 0.09 percent), necrotizing enterocolitis (0.11 versus 0.007 percent), and be mechanically ventilated (2.5 versus 1.2 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late preterm infants are more susceptible to hypothermia compared with term infants, as they have less white adipose tissue for insulation, cannot generate heat as effectively from brown adipose tissue, and lose heat more readily due to their larger ratio of surface area to weight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3,24,28\">",
"     3,24,28",
"    </a>",
"    ]. In one study of 196 infants consecutively admitted to the newborn nursery, 49 percent were hypothermic (core temperature &lt;36.5&ordm;C) of whom half were late preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of hypoglycemia is reported to be three times greater in late preterm infants than in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3\">",
"     3",
"    </a>",
"    ]. Hypoglycemia may occur in newborn infants of all gestational ages as the result of an insufficient metabolic response to the abrupt loss of maternal glucose supply after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/22,24\">",
"     22,24",
"    </a>",
"    ]. The incidence of hypoglycemia increases with decreasing gestational age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=see_link\">",
"     \"Neonatal hypoglycemia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H12\">",
"     'Respiratory morbidity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Respiratory morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of and risk for respiratory morbidity, including respiratory distress syndrome, transient tachypnea of the newborn, pneumonia, respiratory failure, and the need for ventilator support, are greater in late preterm infants compared with term infants. Respiratory morbidity increases with decreasing gestational age as illustrated by a retrospective report from the Consortium on Safe Labor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/30\">",
"     30",
"    </a>",
"    ]. Data from 12 participating clinical centers across the United States were collected from medical records of 233,844 deliveries from 2002 and 2008 including 19,334 late preterm births. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The admission rate to the neonatal intensive care unit (NICU) was greater in late preterm infants compared with term infants (36.5 versus 7.2 percent). Admission with respiratory compromise was also greater in late preterm infants (10.5 versus 1.1 percent).",
"     </li>",
"     <li>",
"      Respiratory diagnoses included respiratory distress syndrome (RDS), transient tachypnea of the newborn, pneumonia, and respiratory failure. For each of these diagnoses, the incidence decreased with each advancing week of gestation until 38 weeks. As an example, the incidence of respiratory distress syndrome decreased from 10.5, 6, 2.8, 1, and 0.3 percent for infants born at 34, 35, 36, 37, and &ge;38 weeks gestation.",
"     </li>",
"     <li>",
"      The need for respiratory intervention including oxygen supplementation, intubation, administration of surfactant, and ventilator support was greater in late preterm infants and also decreased with each advancing week of gestation until 39 weeks.",
"     </li>",
"     <li>",
"      Late preterm infants required greater level of resuscitation (ie, oxygen supplementation, positive-pressure ventilation, intubation, and chest compressions) than term infants. With the exception of intubation for meconium, the level of resuscitation required decreased with each advancing gestational week until 39 weeks gestation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=see_link\">",
"       \"Neonatal resuscitation in the delivery room\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased risk of respiratory morbidity in late preterm infants is caused by immature lung structure, since lung development of the terminal respiratory sacs and alveoli maturation continues through gestational weeks 34 and 36. In addition, some late preterm infants may miss the surfactant surge, which generally occurs at 34 weeks. This delays pulmonary maturation and results in an increased risk of RDS, especially for infants of mothers who did not receive antenatal steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3,24,31\">",
"     3,24,31",
"    </a>",
"    ]. Since biochemical changes during labor enhance fetal lung maturation and clearance of pulmonary fluids, both infants of diabetic mothers and those born via cesarean delivery without labor also are more likely to have RDS [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=see_link\">",
"     \"Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transient tachypnea and persistent pulmonary hypertension are other causes of respiratory distress seen in late preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/20,24,33\">",
"     20,24,33",
"    </a>",
"    ]. Late preterm infants are at increased risk for respiratory failure and are more likely then term infants to require extracorporeal membrane oxygenation (ECMO) support with a greater risk of subsequent mortality and morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=see_link\">",
"     \"Overview of neonatal respiratory distress: Disorders of transition\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Apnea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of apnea in late preterm infants (4 to 7 percent) is greater than in term infants (1 to 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3,28,36-38\">",
"     3,28,36-38",
"    </a>",
"    ]. In the Collaborative Home Infant Monitoring study (CHIME), the recorded rate of apnea (obstructive and central apnea) and bradycardia events was greater in late preterm infants versus term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Late preterm infants are also at increased risk for sudden infant death syndrome compared with term infants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12360?source=see_link\">",
"     \"Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=see_link&amp;anchor=H5#H5\">",
"     \"Sudden infant death syndrome: Risk factors and risk reduction strategies\", section on 'Prematurity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hyperbilirubinemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of immaturity and delay in the development of hepatic bilirubin conjugation pathways, late preterm infants are twice as likely as term infants to have prolonged jaundice with significantly elevated unconjugated serum bilirubin at 5 days of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/2,24,39\">",
"     2,24,39",
"    </a>",
"    ]. Feeding difficulties also can lead to a delay in the resolution of enterohepatic recirculation of bilirubin thereby, causing an increase in serum bilirubin.",
"   </p>",
"   <p>",
"    At a given serum bilirubin concentration, the risks for bilirubin-induced brain injury and kernicterus are greater in the late preterm infant compared with term infants due to the relative immaturity of the blood-brain barrier, lower circulating bilirubin-binding albumin concentrations, and higher risk of concurrent illness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Hyperbilirubinemia is the most common reason for readmission for the late preterm infant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Post-birth discharge'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=see_link\">",
"     \"Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=see_link\">",
"     \"Treatment of unconjugated hyperbilirubinemia in term and late preterm infants\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Feeding difficulties",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breastfeeding remains the optimal feeding choice for late preterm infants because of the benefits to both mother and infant. However, late preterm infants often require additional monitoring and support compared with term infants because their oro-buccal coordination and swallowing mechanisms are not fully matured [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. As a result, mothers of late preterm infants may need to express milk to fully establish their milk supply.",
"   </p>",
"   <p>",
"    Difficulty in establishing successful feeding appears to be the greatest contributing factor in this population's increased risk of readmission due to increased risk of dehydration that may require intervention with intravenous fluids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/3,42,43\">",
"     3,42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=see_link&amp;anchor=H16#H16\">",
"     \"Breastfeeding the preterm infant\", section on 'Late preterm infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Post-birth discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late preterm infants are more likely than term infants to have significant morbidities that require medical attention. In particular, readmission rates are two to three times greater for late preterm compared with term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/2,22,44-46\">",
"     2,22,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in the previously discussed cohort study of commercially insured infants, readmission rates over the first year of life for late preterm infants were 15 compared with 8 percent in term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/22\">",
"     22",
"    </a>",
"    ]. Late preterm infants are also three times more likely to be admitted within the first 15 days after discharge from the birth hospitalization (3.8 versus 1.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/22\">",
"     22",
"    </a>",
"    ]. The most common reasons for early readmission are jaundice, feeding difficulties, poor weight gain, dehydration, and apnea. Respiratory (including bronchiolitis) and gastrointestinal disorders are the most common diagnoses for late readmission (&ge;15 days after the date of discharge) during the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/22\">",
"     22",
"    </a>",
"    ]. One study from California noted the largest cohort of infants readmitted to the hospital at least once during the first month of life were infants born at 35 weeks gestation, most commonly due to a respiratory illness [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/47\">",
"     47",
"    </a>",
"    ]. The cost of hospital readmission for this cohort of infants was 92.9 million dollars.",
"   </p>",
"   <p>",
"    A retrospective study linking health records of live born infants from the Quebec Registry Pregnancy with health care administrative databases demonstrated higher rates of hospitalization and physician visits during the first two years of life for late preterm survivors compared with those born at term [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/48\">",
"     48",
"    </a>",
"    ]. For both groups, acute bronchitis, otitis media, and pneumonia were the three most common diagnoses for hospitalization, and for physician visits, the three most common reasons were acute upper respiratory infection, otitis media, and bronchiolitis. The mean health cost for late preterm infants was double that of those born at term ($2568 versus $1285 Canadian dollars).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Neurodevelopmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that late preterm compared with term infants are at increased risk for long-term neurodevelopmental morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/27,49-54\">",
"     27,49-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the previously mentioned systematic review of 22 studies, 11 reported on long-term outcomes of late preterm infants compared with term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late term infants were more likely to have neurodevelopmental impairment with increased risk of cerebral palsy (0.43 versus 0.14 percent) and mental retardation (0.81 versus 0.49 percent).",
"     </li>",
"     <li>",
"      In one of the included studies (a population-based study of all infants who were born alive and without congenital anomalies in Norway between 1967 and 1983), late preterm infants appeared to be at risk for developing schizophrenia (RR 1.3, 95% CI 1.0-1.7), disorders of psychological development, behavior, and emotion (RR 1.5, 95% CI 1.2-1.8), but not autism [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/53\">",
"       53",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, another study from the National Institute of Child Health and Development Study of Early Child Care and Youth Development demonstrated no significant consistent differences between healthy late preterm and term infants based upon standard measures of cognition, achievement, social skills, and",
"      <span class=\"nowrap\">",
"       behavioral/emotional",
"      </span>",
"      problems from 4 to 15 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children who were late preterm infants were more likely to have school-related problems than those born at term.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In one study children who were born late preterm compared with those born at term had an increased risk for developmental delay or disability, and school-related problems such as retention in kindergarten and suspension in kindergarten [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study based upon the Early Childhood Longitudinal Study-Kindergarten Cohort dataset, children who were born late preterm had lower reading scores and poorer teacher evaluations for math skills in kindergarten and first grade, and reading skills from kindergarten through 5th grade than term infants [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/51\">",
"       51",
"      </a>",
"      ]. Late preterm survivors also had a higher rate of special education participation in early grades.",
"     </li>",
"     <li>",
"      Individuals who were late preterm infants compared with controls who were born full term were less likely to finish high school (72 versus 75 percent) and college (32 versus 35 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late preterm children were at increased risk for failure to thrive at two years of age compared with children born at term. Supportive evidence was provided by a study of 7624 infants with gestational age ranging from 34 to 42 weeks that showed infants who were born between 34 and 36 weeks of gestation were more likely to be underweight (defined as a weight-for-age score less than -2) at 6 months and 12 months of age than infants with a gestational age between 39 and 42 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/56\">",
"       56",
"      </a>",
"      ]. However, there was no difference between the two groups at 18 months of age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent case-controlled study, after adjusting for confounding factors (eg, maternal education and socioeconomic status), children who were born late preterm were still more likely to have scores below 85 on full-scale (OR 2.35, 95% CI 1.2-4.6) and performance (OR 2.04, 95% CI 1.09-3.82) intelligence testing compared with controls born at term and matched for birth weight Z-score at six years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/52\">",
"     52",
"    </a>",
"    ]. In addition, late preterm birth was associated with higher levels of internalizing and attention problems.",
"   </p>",
"   <p>",
"    Brain immaturity may play a role in the observed long-term neurodevelopmental disabilities in some individuals who were born late preterm. Although data are limited upon the brain maturation of late-preterm infants, autopsy and magnetic resonance imaging demonstrate that at 35 weeks gestation, the brain weighs 65 percent of a full term infant's brain, and the external surface has fewer sulci [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. This immaturity may increase the brain's vulnerability to long-term injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the relative risk of mortality for late preterm infants versus term infants is modest compared with infants born at &lt;32 weeks versus term infants, about 10 percent of all neonatal deaths in the United States occurred in late preterm infants in 2007 (",
"    <a class=\"graphic graphic_figure graphicRef73407 \" href=\"UTD.htm?38/31/39422\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late preterm infants have a greater risk of mortality than term infants, as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the United States, although there have been significant declines in mortality rates for both late preterm and term infants (",
"      <a class=\"graphic graphic_figure graphicRef73407 \" href=\"UTD.htm?38/31/39422\">",
"       figure 5",
"      </a>",
"      ), the mortality rate remains more than three times higher in late preterm versus term infants [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based study from British Columbia between 1999 to 2002, infants with a gestational age between 33 and 36 weeks compared with term infants had an eightfold greater perinatal, 5.5-fold greater neonatal, and a 3.5-fold greater infant mortality rates [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the previously mentioned systematic review of 22 studies, which did not include data from the above reports, late preterm infants compared with term infants had a sixfold increase in neonatal death and a fourfold increase in infant death in the first year after delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of neonatal death increases with decreasing gestational age, as illustrated by a population-based study of late preterm and term infants from Utah that reported a mortality rate that was highest at 34 weeks gestation (8.2 per 1000 live births) compared with the lowest rate of infants born at 40 weeks gestation (0.5 per 1000 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other co-morbid factors increase neonatal mortality such as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Birth defects &ndash; In the above study from Utah, 63 percent of late preterm infant deaths were due to a birth defect.",
"     </li>",
"     <li>",
"      Fetal growth restriction &ndash; Another study from Utah, which used linked birth and death certificate data for all infants born between 1999 and 2005, found that late preterm infants who were small for gestational age (SGA) had an even greater mortality rate compared with infants born at term with an appropriate birth weight for gestational age (AGA) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/62\">",
"       62",
"      </a>",
"      ]. SGA late preterm infants were 44 times more likely than term AGA infants to die within the first month of life, and 22 times more likely to die in their first year of life. These differences persisted even when infants with congenital conditions were excluded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;To decrease the mortality and morbidity associated with late preterm births, prevention is one of the key components. One major step towards lowering late preterm birth is to ensure no elective delivery is done prior to 39 weeks gestation. The American College of Obstetricians and Gynecologists (ACOG) does not recommend induced vaginal or planned cesarean delivery prior to 39 weeks gestation unless medically indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/63\">",
"     63",
"    </a>",
"    ]. If elective induction is undertaken for nonmedical reasons, it should only take place if the preinduction assessment ensures the gestational age is at least 39 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=see_link\">",
"     \"Principles of labor induction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, further research is needed to refine the management of the fetus and mother at late preterm gestation, such as better identification of pregnancies that require early delivery for medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/8\">",
"     8",
"    </a>",
"    ]. Areas of research include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the",
"      <span class=\"nowrap\">",
"       risk/benefit",
"      </span>",
"      ratio for diagnosis-specific indications for late preterm delivery, such as more accurate estimation of fetal well-being and outcome in the presence of maternal diseases (eg, hypertension and diabetes).",
"     </li>",
"     <li>",
"      Identify management strategies to improve specific outcomes in late preterm infants. One proposed strategy is the use of antenatal steroids in late preterm multiple-fetal pregnancies.",
"     </li>",
"     <li>",
"      Improve the precision of determining gestational age.",
"     </li>",
"     <li>",
"      Improve the ability to identify the fetus at risk for late pregnancy intrauterine death (ie, stillbirth). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=see_link&amp;anchor=H30#H30\">",
"       \"Incidence, etiology, and prevention of stillbirth\", section on 'Prevention strategies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neonatal management and discharge criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians who care for late preterm infants need to be aware that these infants are at increased risk for neonatal morbidity and mortality. They need to be familiar with the associated complications of late preterm birth and provide appropriate intervention. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Birth hospitalization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Prior to hospital discharge, parents need to be educated that their infant is at increased risk for hyperbilirubinemia, feeding difficulties, and dehydration. Teaching should focus on developing the parents' skills to recognize these conditions and seek appropriate care after hospital discharge.",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics has established the following guidelines for discharge criteria for late preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/24\">",
"     24",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Determine the accurate gestational age, and ensure that there are no abnormalities or medical condition (ie, hyperbilirubinemia) that requires further hospitalization.",
"     </li>",
"     <li>",
"      The infant demonstrates physiologic stability by demonstrating competency in the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Thermoregulation defined as an axillary temperature of 36.5 to 37.4&ordm;C in an open crib.",
"     </li>",
"     <li>",
"      Feeding defined as coordinated sucking, swallowing, and breathing while feeding, and weight loss not to exceed 7 percent of birth weight during birth hospitalization. If the infant is breastfed, twice daily documented observation by trained caregivers of successful position, latch, and milk transfer after birth also should be performed [",
"      <a class=\"abstract\" href=\"UTD.htm?22/11/22713/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=see_link&amp;anchor=H16#H16\">",
"       \"Breastfeeding the preterm infant\", section on 'Late preterm infants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiorespiratory control with stable vital signs of a respiratory rate less than 60 breaths per minute and a heart rate between 100 and 160 beats per minute, and absence of medical illness.",
"     </li>",
"     <li>",
"      At least one stool has passed spontaneously.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other routine newborn care has been completed. This includes screening tests (ie, hearing and disorders that are threatening to life or long-term health), vaccinations (ie,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/17/15639?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      ), and prophylactic treatment (ie, vitamin K prophylaxis). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=see_link\">",
"       \"Overview of the routine management of the healthy newborn infant\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Assessment of the family and home environment to identify any risk factors that may impact on the health of the infant.",
"     </li>",
"     <li>",
"      Successful training of the parents who have demonstrated competency in the care of their infant and the ability to assess for hyperbilirubinemia, feeding difficulties, and dehydration.",
"     </li>",
"     <li>",
"      A follow-up visit for 24 to 48 hours after discharge is scheduled with an identified primary care provider.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6764455\">",
"    <span class=\"h1\">",
"     DISCLAIMER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The opinions expressed herein are those of the authors and do not represent the official position or policy of the Centers for Disease Control and Prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Late preterm infants are infants with a gestational age between 34 to 36 weeks and 6 days. They have higher morbidity and mortality rates than term infants even though they are often the size and weight of some term infants. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Morbidity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, the birth rate of late preterm infants is about 8.3. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late preterm infants have a reported sevenfold increased risk of morbidity compared with term infants during birth hospitalization leading to a longer hospital stay and higher medical costs. The most common causes of morbidity include hypothermia, hypoglycemia, respiratory distress, apnea, hyperbilirubinemia, and feeding difficulties. However, late preterm infants are also at increased, although very low, risk of necrotizing enterocolitis and intraventricular hemorrhage, and receiving mechanical ventilation when compared with term infants. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Birth hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Readmission rates are two to three times greater for late preterm compared with term infants. Early readmission (within 15 days of discharge from birth hospitalization) includes hyperbilirubinemia, feeding difficulties, poor weight gain, dehydration, and apnea. Many of these readmissions can be prevented by careful monitoring and support of breastfeeding during the birth admission. During the first year of life, respiratory and gastrointestinal disorders are the most common diagnoses for late readmission. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Post-birth discharge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Late preterm infants appear to be at increased risk for long-term neurodevelopmental impairment compared with term infants. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Neurodevelopmental outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The infant mortality rate for late preterm infants is at least threefold greater than that of term infants. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strategies to decrease the morbidity and mortality associated with late preterm infants include prevention of late preterm delivery, successful establishment of breastfeeding, and management to prevent and treat the associated complications of late preterm birth. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/1\">",
"      Escobar GJ, Gonzales VM, Armstrong MA, et al. Rehospitalization for neonatal dehydration: a nested case-control study. Arch Pediatr Adolesc Med 2002; 156:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/2\">",
"      Escobar GJ, McCormick MC, Zupancic JA, et al. Unstudied infants: outcomes of moderately premature infants in the neonatal intensive care unit. Arch Dis Child Fetal Neonatal Ed 2006; 91:F238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/3\">",
"      Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004; 114:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/4\">",
"      Kramer MS, Demissie K, Yang H, et al. The contribution of mild and moderate preterm birth to infant mortality. Fetal and Infant Health Study Group of the Canadian Perinatal Surveillance System. JAMA 2000; 284:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/5\">",
"      Raju TN, Higgins RD, Stark AR, Leveno KJ. Optimizing care and outcome for late-preterm (near-term) infants: a summary of the workshop sponsored by the National Institute of Child Health and Human Development. Pediatrics 2006; 118:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/6\">",
"      Hamilton BE, Hoyert DL, Martin JA, et al. Annual summary of vital statistics: 2010-2011. Pediatrics 2013; 131:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/7\">",
"      Khashu M, Narayanan M, Bhargava S, Osiovich H. Perinatal outcomes associated with preterm birth at 33 to 36 weeks' gestation: a population-based cohort study. Pediatrics 2009; 123:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/8\">",
"      Spong CY, Mercer BM, D'alton M, et al. Timing of indicated late-preterm and early-term birth. Obstet Gynecol 2011; 118:323.",
"     </a>",
"    </li>",
"    <li>",
"     Hamilton BE, Martin JA, Ventura SJ, et al. Births: Final data for 2007. Natl Vital Stat Rep 2010; 58:24. Available at file://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_24.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/10\">",
"      Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet 2008; 371:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/11\">",
"      Schieve LA, Ferre C, Peterson HB, et al. Perinatal outcome among singleton infants conceived through assisted reproductive technology in the United States. Obstet Gynecol 2004; 103:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/12\">",
"      Davidoff MJ, Dias T, Damus K, et al. Changes in the gestational age distribution among U.S. singleton births: impact on rates of late preterm birth, 1992 to 2002. Semin Perinatol 2006; 30:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/13\">",
"      Ananth CV, Joseph KS, Oyelese Y, et al. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstet Gynecol 2005; 105:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/14\">",
"      American College of Obstetricians and Gynecologists. Committee Opinion No. 560. Medically indicated late-preterm and early-term deliveries. Obstet Gynecol 2013; 121:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/15\">",
"      Lee YM, Cleary-Goldman J, D'Alton ME. The impact of multiple gestations on late preterm (near-term) births. Clin Perinatol 2006; 33:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/16\">",
"      Lee YM, Cleary-Goldman J, D'Alton ME. Multiple gestations and late preterm (near-term) deliveries. Semin Perinatol 2006; 30:103.",
"     </a>",
"    </li>",
"    <li>",
"     Martin JA, Hamilton BE, Sutton PD, et al. Births: Final data for 2006. Natl Vital Stat Rep 2009; 57:1 www.cdc.gov/nchs/data/nvsr/nvsr57/nvsr57_07.pdf (Accessed on March 13, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/18\">",
"      Reddy UM, Wapner RJ, Rebar RW, Tasca RJ. Infertility, assisted reproductive technology, and adverse pregnancy outcomes: executive summary of a National Institute of Child Health and Human Development workshop. Obstet Gynecol 2007; 109:967.",
"     </a>",
"    </li>",
"    <li>",
"     Behrman RE, Butler AS. Preterm Birth, Causes, Consequences, and Prevention, The National Academies Press, Washington, DC 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/20\">",
"      Engle WA, Kominiarek MA. Late preterm infants, early term infants, and timing of elective deliveries. Clin Perinatol 2008; 35:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/21\">",
"      Shapiro-Mendoza CK, Tomashek KM, Kotelchuck M, et al. Effect of late-preterm birth and maternal medical conditions on newborn morbidity risk. Pediatrics 2008; 121:e223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/22\">",
"      McLaurin KK, Hall CB, Jackson EA, et al. Persistence of morbidity and cost differences between late-preterm and term infants during the first year of life. Pediatrics 2009; 123:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/23\">",
"      Bird TM, Bronstein JM, Hall RW, et al. Late preterm infants: birth outcomes and health care utilization in the first year. Pediatrics 2010; 126:e311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/24\">",
"      Engle WA, Tomashek KM, Wallman C, Committee on Fetus and Newborn, American Academy of Pediatrics. \"Late-preterm\" infants: a population at risk. Pediatrics 2007; 120:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/25\">",
"      Leone A, Ersfeld P, Adams M, et al. Neonatal morbidity in singleton late preterm infants compared with full-term infants. Acta Paediatr 2012; 101:e6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/26\">",
"      Melamed N, Klinger G, Tenenbaum-Gavish K, et al. Short-term neonatal outcome in low-risk, spontaneous, singleton, late preterm deliveries. Obstet Gynecol 2009; 114:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/27\">",
"      Teune MJ, Bakhuizen S, Gyamfi Bannerman C, et al. A systematic review of severe morbidity in infants born late preterm. Am J Obstet Gynecol 2011; 205:374.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/28\">",
"      Vachharajani AJ, Dawson JG. Short-term outcomes of late preterms: an institutional experience. Clin Pediatr (Phila) 2009; 48:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/29\">",
"      Laptook A, Jackson GL. Cold stress and hypoglycemia in the late preterm (\"near-term\") infant: impact on nursery of admission. Semin Perinatol 2006; 30:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/30\">",
"      Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late preterm births. JAMA 2010; 304:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/31\">",
"      Rubaltelli FF, Bonafe L, Tangucci M, et al. Epidemiology of neonatal acute respiratory disorders. A multicenter study on incidence and fatality rates of neonatal acute respiratory disorders according to gestational age, maternal age, pregnancy complications and type of delivery. Italian Group of Neonatal Pneumology. Biol Neonate 1998; 74:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/32\">",
"      Jain L. Respiratory morbidity in late-preterm infants: prevention is better than cure! Am J Perinatol 2008; 25:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/33\">",
"      Engle WA, American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics 2008; 121:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/34\">",
"      Ramachandrappa A, Rosenberg ES, Wagoner S, Jain L. Morbidity and mortality in late preterm infants with severe hypoxic respiratory failure on extra-corporeal membrane oxygenation. J Pediatr 2011; 159:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/35\">",
"      Steinhorn RH. Every week matters. J Pediatr 2011; 159:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/36\">",
"      Hunt CE. Ontogeny of autonomic regulation in late preterm infants born at 34-37 weeks postmenstrual age. Semin Perinatol 2006; 30:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/37\">",
"      Ramanathan R, Corwin MJ, Hunt CE, et al. Cardiorespiratory events recorded on home monitors: Comparison of healthy infants with those at increased risk for SIDS. JAMA 2001; 285:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/38\">",
"      Henderson-Smart DJ, Pettigrew AG, Campbell DJ. Clinical apnea and brain-stem neural function in preterm infants. N Engl J Med 1983; 308:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/39\">",
"      Sarici SU, Serdar MA, Korkmaz A, et al. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. Pediatrics 2004; 113:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/40\">",
"      Bhutani VK, Johnson L. Kernicterus in late preterm infants cared for as term healthy infants. Semin Perinatol 2006; 30:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/41\">",
"      Bhutani VK, Maisels MJ, Stark AR, et al. Management of jaundice and prevention of severe neonatal hyperbilirubinemia in infants &gt;or=35 weeks gestation. Neonatology 2008; 94:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/42\">",
"      Radtke JV. The paradox of breastfeeding-associated morbidity among late preterm infants. J Obstet Gynecol Neonatal Nurs 2011; 40:9.",
"     </a>",
"    </li>",
"    <li>",
"     Academy of Breastfeeding Medicine Clinical Protocol #10: Breastfeeding the Late Preterm Infant file://www.bfmed.org/Media/Files/Protocols/Protocol%2010%20Revised%20English%206.11.pdf (Accessed on June 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/44\">",
"      Burgos AE, Schmitt SK, Stevenson DK, Phibbs CS. Readmission for neonatal jaundice in California, 1991-2000: trends and implications. Pediatrics 2008; 121:e864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/45\">",
"      Escobar GJ, Joffe S, Gardner MN, et al. Rehospitalization in the first two weeks after discharge from the neonatal intensive care unit. Pediatrics 1999; 104:e2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/46\">",
"      Tomashek KM, Shapiro-Mendoza CK, Weiss J, et al. Early discharge among late preterm and term newborns and risk of neonatal morbidity. Semin Perinatol 2006; 30:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/47\">",
"      Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol 2007; 27:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/48\">",
"      B&eacute;rard A, Le Tiec M, De Vera MA. Study of the costs and morbidities of late-preterm birth. Arch Dis Child Fetal Neonatal Ed 2012; 97:F329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/49\">",
"      Morse SB, Zheng H, Tang Y, Roth J. Early school-age outcomes of late preterm infants. Pediatrics 2009; 123:e622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/50\">",
"      Petrini JR, Dias T, McCormick MC, et al. Increased risk of adverse neurological development for late preterm infants. J Pediatr 2009; 154:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/51\">",
"      Chyi LJ, Lee HC, Hintz SR, et al. School outcomes of late preterm infants: special needs and challenges for infants born at 32 to 36 weeks gestation. J Pediatr 2008; 153:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/52\">",
"      Talge NM, Holzman C, Wang J, et al. Late-preterm birth and its association with cognitive and socioemotional outcomes at 6 years of age. Pediatrics 2010; 126:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/53\">",
"      Moster D, Lie RT, Markestad T. Long-term medical and social consequences of preterm birth. N Engl J Med 2008; 359:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/54\">",
"      McGowan JE, Alderdice FA, Holmes VA, Johnston L. Early childhood development of late-preterm infants: a systematic review. Pediatrics 2011; 127:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/55\">",
"      Gurka MJ, LoCasale-Crouch J, Blackman JA. Long-term cognition, achievement, socioemotional, and behavioral development of healthy late-preterm infants. Arch Pediatr Adolesc Med 2010; 164:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/56\">",
"      Goyal NK, Fiks AG, Lorch SA. Persistence of underweight status among late preterm infants. Arch Pediatr Adolesc Med 2012; 166:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/57\">",
"      Kinney HC. The near-term (late preterm) human brain and risk for periventricular leukomalacia: a review. Semin Perinatol 2006; 30:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/58\">",
"      Billiards SS, Pierson CR, Haynes RL, et al. Is the late preterm infant more vulnerable to gray matter injury than the term infant? Clin Perinatol 2006; 33:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/59\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2007 period linked birth/infant death data set. Natl Vital Stat Rep 2011; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/60\">",
"      Tomashek KM, Shapiro-Mendoza CK, Davidoff MJ, Petrini JR. Differences in mortality between late-preterm and term singleton infants in the United States, 1995-2002. J Pediatr 2007; 151:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/61\">",
"      Young PC, Glasgow TS, Li X, et al. Mortality of late-preterm (near-term) newborns in Utah. Pediatrics 2007; 119:e659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/62\">",
"      Pulver LS, Guest-Warnick G, Stoddard GJ, et al. Weight for gestational age affects the mortality of late preterm infants. Pediatrics 2009; 123:e1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22713/abstract/63\">",
"      Committee on Obstetric Practice. ACOG committee opinion No. 404 April 2008. Late-preterm infants. Obstet Gynecol 2008; 111:1029.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5034 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22713=[""].join("\n");
var outline_f22_11_22713=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Factors associated with increased late preterm birth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Improved obstetrical surveillance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Multiple births",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Birth hospitalization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Respiratory morbidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Apnea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Feeding difficulties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Post-birth discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Neurodevelopmental outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neonatal management and discharge criteria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6764455\">",
"      DISCLAIMER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5034\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5034|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/9/37022\" title=\"figure 1\">",
"      US preterm birth rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/14/224\" title=\"figure 2\">",
"      Temporal change prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/62/39908\" title=\"figure 3\">",
"      Timing of late preterm or early term birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/24/19854\" title=\"figure 4\">",
"      Twin birth gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/31/39422\" title=\"figure 5\">",
"      Distribution of live births and infant deaths by gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5034|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/40/7819\" title=\"table 1\">",
"      Proportion of preterm birth by etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/10/2220\" title=\"table 2\">",
"      Preterm birth rates US",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/48/28428\" title=\"table 3\">",
"      Risk factors for preterm birth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/36/29262\" title=\"table 4\">",
"      Guidelines for timing of delivery after 34 weeks gestation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/12/36040?source=related_link\">",
"      Breastfeeding the preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/5/8282?source=related_link\">",
"      Cesarean delivery: Preoperative issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/36/31306?source=related_link\">",
"      Incidence, etiology, and prevention of stillbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17673?source=related_link\">",
"      Neonatal hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26346?source=related_link\">",
"      Neonatal resuscitation in the delivery room",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36105?source=related_link\">",
"      Overview of the routine management of the healthy newborn infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/3/39992?source=related_link\">",
"      Pathogenesis and etiology of unconjugated hyperbilirubinemia in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/4/12360?source=related_link\">",
"      Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19656?source=related_link\">",
"      Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/37/31322?source=related_link\">",
"      Principles of labor induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37194?source=related_link\">",
"      Sudden infant death syndrome: Risk factors and risk reduction strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/59/21434?source=related_link\">",
"      Treatment of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22714="Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid";
var content_f22_11_22714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22714/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22714/contributors\">",
"     Kristin M Leiferman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22714/contributors\">",
"     John J Zone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/11/22714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/11/22714/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/11/22714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H590249\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid and mucous membrane pemphigoid (MMP) are autoimmune blistering diseases that most commonly arise in older adults. These disorders are characterized by subepithelial blister formation and the deposition of immunoglobulins and complement within the epidermal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucosal basement membrane zone.",
"   </p>",
"   <p>",
"    Although both bullous pemphigoid and MMP may affect skin and mucosa, the classical clinical findings in bullous pemphigoid are tense, fluid-filled bullae on skin whereas the prevailing clinical feature in MMP is mucosal involvement. In MMP, inflamed and eroded mucosa is characteristic, involving any or all of the oral cavity, ocular conjunctiva, nose, pharynx, larynx, esophagus, anus, and genital mucous membranes.",
"   </p>",
"   <p>",
"    The clinical features and diagnosis of bullous pemphigoid and MMP will be reviewed here. The epidemiology, pathogenesis, and treatment of these disorders as well as greater detail on the ocular form of MMP (ocular cicatricial pemphigoid) and other autoimmune blistering disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3770?source=see_link\">",
"     \"Management and prognosis of bullous pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39544?source=see_link\">",
"     \"Management of mucous membrane pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link\">",
"     \"Ocular cicatricial pemphigoid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link&amp;anchor=H2#H2\">",
"     \"Dermatoses of pregnancy\", section on 'Pemphigoid gestationis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H784094\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53290498\">",
"    <span class=\"h2\">",
"     Bullous pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prodromal phase lasting weeks to months may precede the development of cutaneous bullae in patients with bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The prodromal phase may present with pruritic eczematous, papular, or urticaria-like skin lesions (",
"    <a class=\"graphic graphic_picture graphicRef80385 \" href=\"UTD.htm?41/50/42788\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/3\">",
"     3",
"    </a>",
"    ]. Some patients with bullous pemphigoid never develop blistering.",
"   </p>",
"   <p>",
"    When blisters develop, the classical lesion is a 1 to 3 cm tense bulla on an erythematous, urticarial, or noninflammatory base, and blisters may be numerous and widespread (",
"    <a class=\"graphic graphic_picture graphicRef54541 graphicRef70352 graphicRef79112 \" href=\"UTD.htm?33/1/33818\">",
"     picture 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/4\">",
"     4",
"    </a>",
"    ]. Associated pruritus is common and can be severe. The tense quality of the bullae differentiates the lesions of bullous pemphigoid from the flaccid bullae of pemphigus vulgaris (",
"    <a class=\"graphic graphic_picture graphicRef53425 \" href=\"UTD.htm?26/56/27526\">",
"     picture 3A",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Eventually, the bullae rupture, leaving moist erosions and crusts that resolve without scarring. When mainly erosions are present, it may be difficult to clinically distinguish bullous pemphigoid and pemphigus (",
"    <a class=\"graphic graphic_picture graphicRef63170 \" href=\"UTD.htm?39/35/40502\">",
"     picture 3B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The trunk, extremity flexures, and axillary and inguinal folds are common sites for cutaneous involvement (",
"    <a class=\"graphic graphic_picture graphicRef72866 graphicRef78910 graphicRef59590 \" href=\"UTD.htm?37/37/38490\">",
"     picture 4A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/6\">",
"     6",
"    </a>",
"    ]. Mucosal lesions, which typically are erosions of the oral mucosa, are present in 10 to 30 percent of patients (",
"    <a class=\"graphic graphic_picture graphicRef66179 \" href=\"UTD.htm?31/58/32675\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Localized forms of bullous pemphigoid also occur, and account for up to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/7\">",
"     7",
"    </a>",
"    ]. Examples include disease limited to the lower legs (",
"    <a class=\"graphic graphic_picture graphicRef71249 \" href=\"UTD.htm?0/28/452\">",
"     picture 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/7-11\">",
"     7-11",
"    </a>",
"    ], anogenital region [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/12,13\">",
"     12,13",
"    </a>",
"    ], peristomal skin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/14,15\">",
"     14,15",
"    </a>",
"    ], or sites of incidental or iatrogenic trauma (eg, radiation therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/16-21\">",
"     16-21",
"    </a>",
"    ]. Disease that begins in localized areas may remain localized or may progress to generalized involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/7,22\">",
"     7,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other reported clinical variants of bullous pemphigoid include eczematous, urticarial, and prurigo-like presentations; in such cases the diagnosis is based upon consistent laboratory findings (see",
"    <a class=\"local\" href=\"#H20007014\">",
"     'Laboratory tests'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/1,23\">",
"     1,23",
"    </a>",
"    ]. Rare variants include pemphigoid vegetans, which manifests with verruciform plaques in intertriginous areas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], dyshidrosiform pemphigoid, which occurs on palmar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plantar skin (resembling dyshidrotic eczema) and often is hemorrhagic (",
"    <a class=\"graphic graphic_picture graphicRef50357 \" href=\"UTD.htm?26/23/26997\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/26,27\">",
"     26,27",
"    </a>",
"    ], and vesicular bullous pemphigoid, in which lesions resemble dermatitis herpetiformis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lichen planus pemphigoides is another rare variant of bullous pemphigoid. It is postulated that the cellular inflammatory process that occurs at the basement membrane zone in lichen planus results in exposure of basement membrane zone antigens leading to subsequent development of basement membrane zone antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients with lichen planus pemphigoides typically present with bullae in sites of previously normal-appearing skin or mucosa. The bullae usually appear weeks to months after the onset of lichen planus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/3\">",
"     3",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53290512\">",
"    <span class=\"h2\">",
"     Mucous membrane pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMP represents a group of heterogeneous, chronic subepithelial blistering disorders that primarily affect mucosal surfaces [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/30\">",
"     30",
"    </a>",
"    ]. Historically, the term cicatricial pemphigoid also referred to these disorders. Some authors also consider cases of linear IgA bullous dermatosis and epidermolysis bullosa acquisita that primarily involve the mucous membranes as forms of MMP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/30\">",
"     30",
"    </a>",
"    ]. However, our approach is to view these diagnoses as distinct entities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"     \"Linear IgA bullous dermatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"     \"Epidermolysis bullosa acquisita\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MMP typically presents as relapsing and remitting mucosal inflammation and erosions (",
"    <a class=\"graphic graphic_picture graphicRef73874 graphicRef52208 graphicRef63997 \" href=\"UTD.htm?38/6/39017\">",
"     picture 8A-C",
"    </a>",
"    ). The oral cavity is the most common site of involvement, and cutaneous involvement also may be present. In a report that summarized the sites of involvement in 457 patients with MMP, the frequency of affected sites was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral mucosa (85 percent)",
"     </li>",
"     <li>",
"      Ocular conjunctiva (64 percent)",
"     </li>",
"     <li>",
"      Skin (24 percent)",
"     </li>",
"     <li>",
"      Pharynx (19 percent)",
"     </li>",
"     <li>",
"      External genitalia (17 percent)",
"     </li>",
"     <li>",
"      Nasal mucosa (15 percent)",
"     </li>",
"     <li>",
"      Larynx (8 percent)",
"     </li>",
"     <li>",
"      Anus (4 percent)",
"     </li>",
"     <li>",
"      Esophagus (4 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the oral cavity, the gingival and buccal mucosae are most commonly affected. Gingival disease usually manifests as a desquamative or erosive gingivitis (",
"    <a class=\"graphic graphic_picture graphicRef73874 \" href=\"UTD.htm?33/7/33905\">",
"     picture 8A",
"    </a>",
"    ), and, in mild cases, may manifest only with gingival erythema and edema [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"     32",
"    </a>",
"    ]. The detection of intact vesicles or bullae on mucosa is uncommon. Compared to the mucosal lesions of pemphigus, pain associated with oral MMP lesions is usually less intense [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Scarring is a common consequence of MMP that distinguishes this variant from mucosal involvement in bullous pemphigoid, which typically does not scar. Reticulated, white striations representing mucosal fibrosis often are present at sites of healed lesions, and functional limitations secondary to scarring may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]. As examples, MMP involving the ocular mucosa can lead to symblepharon, ankyloblepharon, and eventual blindness, and progressive laryngeal and tracheal involvement can result in asphyxiation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913497#H2913497\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cutaneous involvement in patients with MMP typically involves the scalp, face, or upper trunk. The bullous lesions resemble those seen in bullous pemphigoid, but, similar to mucosal lesions of MMP, often heal with scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3867557\">",
"    <span class=\"h1\">",
"     ASSOCIATED DISORDERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3867564\">",
"    <span class=\"h2\">",
"     Neurologic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Associations between bullous pemphigoid and neurologic disorders have been reported in several observational studies and case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/33-43\">",
"     33-43",
"    </a>",
"    ]. In a hospital-based prospective case-control study of 201 patients with bullous pemphigoid and 345 matched controls, dementia, Parkinson&rsquo;s disease, and unipolar or bipolar disorder were among the identified independent risk factors for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/38\">",
"     38",
"    </a>",
"    ]. In addition, a population-based case-control study of 868 patients with bullous pemphigoid and more than 3400 controls found that patients with preexisting diagnoses of dementia, Parkinson&rsquo;s disease, or stroke were significantly more likely to develop bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/37\">",
"     37",
"    </a>",
"    ]. Further, a case-control study with more than 5000 patients with multiple sclerosis and over 26,000 controls supported an association of bullous pemphigoid and this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Homology between bullous pemphigoid antigens in the skin and neuronal antigens in the central nervous system has been proposed as a cause for the observed link between bullous pemphigoid and neurologic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. However, further studies are necessary to explore the relationship between these disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link&amp;anchor=H590428#H590428\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Epitope spreading'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3867571\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMP with antibodies directed against laminin 332 (also known as laminin 5 or epiligrin) has been associated with an increased risk for internal malignancy (",
"    <a class=\"graphic graphic_figure graphicRef67891 \" href=\"UTD.htm?3/63/4086\">",
"     figure 1",
"    </a>",
"    ). In a cohort of 35 patients with this type of MMP, 10 (29 percent) developed solid organ malignancies, 7 of which were diagnosed within 14 months after a diagnosis of MMP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/49\">",
"     49",
"    </a>",
"    ]. Occurrences of non-Hodgkin lymphoma and cutaneous T cell lymphoma have also been reported in individual patients with anti-laminin 332 MMP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/50\">",
"     50",
"    </a>",
"    ]. The pathophysiological relationship of this subtype of MMP to cancer is unknown. However, expression of laminin 332 has been detected in malignant cells, and laminin 332 appears to be capable of promoting tumor cell growth, invasion, and metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since diagnostic laboratory testing for laminin 332 antibodies is not commercially available, suspicion for laminin 332 is primarily based upon immunofluorescence microscopy findings. Although not exclusive to laminin 332 MMP, the detection of antibodies bound to the dermal side of basement membrane zone-split (salt-split) skin suggests the possibility of this diagnosis. (See",
"    <a class=\"local\" href=\"#H53290540\">",
"     'Indirect immunofluorescence of serum'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Until definitive testing for laminin 332 antibodies becomes available, we suggest that patients with MMP in whom serum indirect immunofluorescence (IIF) studies reveal antibodies bound to the dermal side of basement membrane zone-split skin undergo age and gender appropriate cancer screening. Additional evaluation for malignancy should be performed as indicated based upon a review of symptoms, physical examination, and the results of age-appropriate screening.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785112\">",
"    <span class=\"h1\">",
"     DISEASE COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bullous pemphigoid is a chronic disorder characterized by exacerbations and remissions over the course of months to years. However, in some patients the disease is self-limited, resulting in disease remissions within a few years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3770?source=see_link&amp;anchor=H24368306#H24368306\">",
"     \"Management and prognosis of bullous pemphigoid\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of treatment, MMP is usually a chronic, progressive disease that results in functionally limiting or, in some cases (such as those with airway involvement), life-threatening disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"     32",
"    </a>",
"    ]. The clinical course and prognosis of ocular MMP is reviewed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913497#H2913497\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913561#H2913561\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Prognosis and cessation of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20007006\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinical findings may strongly suggest bullous pemphigoid or MMP, other disorders present with similar mucocutaneous lesions, and atypical presentations can occur (",
"    <a class=\"graphic graphic_table graphicRef69192 \" href=\"UTD.htm?1/0/1036\">",
"     table 1",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H20007021\">",
"     'Differential diagnosis'",
"    </a>",
"    below). Thus, confirmation of the diagnosis requires the careful interpretation of both clinical and laboratory findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H587825\">",
"    <span class=\"h2\">",
"     Clinical assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features that suggest bullous pemphigoid or MMP in patients over the age of 60 years include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blistering skin disease characterized by the presence of tense blisters and erosions that occur without another identifiable cause",
"     </li>",
"     <li>",
"      Desquamative gingivitis or mucositis involving oral, ocular, nasal, genital, anal, pharyngeal, laryngeal,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      esophageal mucosae",
"     </li>",
"     <li>",
"      Unexplained pruritic eczematous eruptions or urticarial plaques",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possibility of bullous pemphigoid or MMP also should be considered in the evaluation of younger individuals (including children) with suggestive symptoms in the absence of another identifiable cause (",
"    <a class=\"graphic graphic_picture graphicRef58359 \" href=\"UTD.htm?15/29/15827\">",
"     picture 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/52\">",
"     52",
"    </a>",
"    ]. In patients with signs or symptoms of these disorders, laboratory assessment is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link&amp;anchor=H589244#H589244\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20007014\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal studies used in the evaluation of patients with lesions suspicious for bullous pemphigoid or MMP include (",
"    <a class=\"graphic graphic_table graphicRef57402 \" href=\"UTD.htm?3/57/3997\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A",
"      <strong>",
"       lesional",
"      </strong>",
"      skin biopsy from",
"      <strong>",
"      </strong>",
"      the edge of",
"      <strong>",
"      </strong>",
"      an intact blister (or other",
"      <span class=\"nowrap\">",
"       inflamed/affected",
"      </span>",
"      tissue, urticarial or eczematous) for hematoxylin and eosin (H&amp;E) staining and a skin biopsy from",
"      <strong>",
"       perilesional",
"      </strong>",
"      tissue for direct immunofluorescence (DIF).The latter, DIF, is considered",
"      <strong>",
"       the gold standard",
"      </strong>",
"      for diagnosis (see",
"      <a class=\"local\" href=\"#H554282\">",
"       'Skin biopsy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714350#H4714350\">",
"       \"Approach to the patient with cutaneous blisters\", section on 'Skin biopsy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum specimens for indirect immunofluorescence (IIF) and enzyme linked immunosorbent assay (ELISA) to detect circulating basement membrane zone antibodies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H320553#H320553\">",
"       \"Approach to the patient with cutaneous blisters\", section on 'Serological tests'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H404213\">",
"    <span class=\"h3\">",
"     Our approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with clinical findings suggestive of bullous pemphigoid or MMP, we begin the laboratory assessment by obtaining both a",
"    <strong>",
"     lesional",
"    </strong>",
"    tissue specimen for routine (fixed tissue) histology and a",
"    <strong>",
"     perilesional",
"    </strong>",
"    tissue specimen for DIF. Bullous pemphigoid antigens may be sparse in distal anatomical locations; therefore, when possible, choosing a proximal anatomical site for the perilesional DIF specimen is preferred. Obtaining a lesional specimen often is difficult in MMP involving the mouth and vulva, because affected mucosa is friable and easily erodes. When this occurs, perilesional tissue should still be obtained for DIF.",
"   </p>",
"   <p>",
"    Serological studies provide additional information that can be useful for diagnosis and patient management. IIF performed on basement membrane zone-split skin aids in distinguishing bullous pemphigoid from epidermolysis bullosa acquisita and can identify patients with MMP who are at risk for malignancy-associated laminin 332 (epiligrin) MMP. Because of its value, we perform IIF in all patients with histological and DIF findings consistent with bullous pemphigoid or MMP. (See",
"    <a class=\"local\" href=\"#H3867571\">",
"     'Malignancy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H53290540\">",
"     'Indirect immunofluorescence of serum'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link&amp;anchor=H316627112#H316627112\">",
"     \"Epidermolysis bullosa acquisita\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, serological studies can be of value when DIF is negative in a patient with clinical and histological findings that are consistent with bullous pemphigoid or when it is not possible to obtain adequate biopsy tissue. The combination of IIF and ELISA serum testing is useful to support a clinical diagnosis of bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An algorithm depicting our approach to the diagnosis of patients who present with skin lesions suspicious for bullous pemphigoid and oral lesions suggestive of MMP is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef76558 \" href=\"UTD.htm?29/8/29827\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H554282\">",
"    <span class=\"h3\">",
"     Skin biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Separate specimens are optimal for H&amp;E (light microscopy of fixed tissue) and DIF because of differences in the requirements for the preferred biopsy location and tissue handling. We typically obtain two 4 mm punch biopsies. However, careful splitting of a 5 or 6 mm punch biopsy specimen or a shave biopsy specimen into lesional and perilesional specimens is an additional option. If only one small specimen can be obtained, the preferred test to perform is DIF. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=see_link&amp;anchor=H12#H12\">",
"     \"Skin biopsy techniques\", section on 'Punch biopsy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714350#H4714350\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Skin biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4988524\">",
"    <span class=\"h4\">",
"     Light microscopy of formalin-fixed tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies for H&amp;E staining should be taken from lesional skin, preferably from an intact vesicle or the edge of an intact bulla (",
"    <a class=\"graphic graphic_table graphicRef57402 \" href=\"UTD.htm?3/57/3997\">",
"     table 2",
"    </a>",
"    ). The specimen should include the blister edge and the immediately adjacent tissue. Care should be taken to avoid excessive torsion and crushing, which may alter tissue cleavage planes and increase the difficulty of pathological interpretation. Specimens obtained for H&amp;E are placed in formalin for processing.",
"   </p>",
"   <p>",
"    Common histopathological findings in cutaneous lesions of bullous pemphigoid include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eosinophilic spongiosis (particularly in early lesions) (",
"      <a class=\"graphic graphic_picture graphicRef79687 \" href=\"UTD.htm?25/18/25895\">",
"       picture 10",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Subepidermal blister formation (often with numerous eosinophils within cleft) (",
"      <a class=\"graphic graphic_picture graphicRef66267 \" href=\"UTD.htm?43/15/44279\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A superficial dermal inflammatory cell infiltrate of variable intensity with lymphocytes, eosinophils, and neutrophils (",
"      <a class=\"graphic graphic_picture graphicRef66267 \" href=\"UTD.htm?43/15/44279\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Histopathological examination of mucosal lesions of MMP typically shows epithelium-subepithelium cleavage and a mixed submucosal inflammatory cell infiltrate composed of lymphocytes, histiocytes, neutrophils, and eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"     32",
"    </a>",
"    ]. Additional findings may include plasma cell infiltration and subepidermal fibrosis; the latter is a finding consistent with the scarring nature of MMP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53290533\">",
"    <span class=\"h4\">",
"     Direct immunofluorescence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Direct immunofluorescence (DIF) studies are considered the gold standard for the diagnosis of pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/54\">",
"     54",
"    </a>",
"    ]. The procedure utilizes labeled antibodies to detect immunoglobulin binding and complement deposits in tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714358#H4714358\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Direct immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to biopsy specimens for H&amp;E histological evaluation, biopsy specimens for DIF should be obtained from",
"    <strong>",
"     perilesional",
"    </strong>",
"    , not lesional skin (",
"    <a class=\"graphic graphic_table graphicRef57402 \" href=\"UTD.htm?3/57/3997\">",
"     table 2",
"    </a>",
"    ). For affected skin, this can be an erythematous or urticarial area adjacent to a blister. For affected mucosa, in which tissue immediately adjacent to an erosion can be friable, a tissue specimen from normal-appearing mucosa several millimeters away from the edge of a lesion can be obtained.",
"   </p>",
"   <p>",
"    The tissue specimen for DIF",
"    <strong>",
"     should NOT be placed in formalin",
"    </strong>",
"    , rather a tissue transport medium compatible with the performance of immunofluorescence studies such as Michel&rsquo;s medium or Zeus medium should be used for specimen transport. Specimens for DIF should be transported promptly to an immunodermatology laboratory for receipt within seven days of obtaining the specimen; transport medium does not preserve a specimen indefinitely. Some immunodermatology laboratories also will accept specimens transported on normal saline soaked gauze (provided they are received during laboratory working hours within six hours of obtaining them; sooner is better) or specimens that are flash-frozen with liquid nitrogen and transported on dry ice (",
"    <a class=\"graphic graphic_table graphicRef57402 \" href=\"UTD.htm?3/57/3997\">",
"     table 2",
"    </a>",
"    ). Specimens should not be immersed in saline solution or solutions other than Michel&rsquo;s or Zeus medium.",
"   </p>",
"   <p>",
"    The classical DIF findings in bullous pemphigoid and MMP include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32,55,56\">",
"     32,55,56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Bullous pemphigoid",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Linear IgG",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      linear C3 staining along the basement membrane zone is present in virtually all cases (",
"      <a class=\"graphic graphic_picture graphicRef86372 graphicRef86950 \" href=\"UTD.htm?37/57/38808\">",
"       picture 12A-B",
"      </a>",
"      ); less intense linear basement membrane zone staining for IgM, IgA,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      IgE may be present.",
"     </li>",
"     <li>",
"      <strong>",
"       Mucous membrane pemphigoid",
"      </strong>",
"      &ndash; Linear IgG, linear IgA,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      linear C3 staining along the basement membrane zone is detected in approximately 80 to 100 percent of cases; linear IgE basement membrane zone staining can be detected in specimens from some patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A modified DIF technique has been described utilizing basement membrane zone-split perilesional skin or mucosa from patients with suspected pemphigoid. Ideally, this allows for more precise localization of antibody binding within the epithelial basement membrane zone of diseased tissue and, therefore, additional information for diagnosis. However, the technique is infrequently utilized with DIF because of its technical difficulty. In particular, basement membrane zone separation often is difficult with inflamed skin and is frequently impossible to perform on mucosal specimens. Performing IIF with the patient&rsquo;s serum on basement membrane zone-split skin substrate is a more practical test. The diagnostic value of IIF is reviewed below. (See",
"    <a class=\"local\" href=\"#H53290540\">",
"     'Indirect immunofluorescence of serum'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Additional clues for diagnosis may be provided by analysis of the linear pattern of basement membrane zone antibody staining detected in DIF. Whereas an n-serrated pattern has been associated with bullous pemphigoid, MMP, anti-laminin &gamma;1 pemphigoid, and linear IgA dermatosis (",
"    <a class=\"graphic graphic_picture graphicRef86951 \" href=\"UTD.htm?5/56/6022\">",
"     picture 13",
"    </a>",
"    ), a u-serrated pattern has been described in epidermolysis bullosa acquisita and bullous systemic lupus erythematosus (",
"    <a class=\"graphic graphic_picture graphicRef86952 \" href=\"UTD.htm?37/5/37971\">",
"     picture 14",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. A true linear pattern is commonly observed along with the characteristic n-serrated and u-serrated patterns in all of these immunobullous diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53290540\">",
"    <span class=\"h3\">",
"     Indirect immunofluorescence of serum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect immunofluorescence (IIF) testing is used to detect circulating basement membrane zone antibodies in patients with pemphigoid (",
"    <a class=\"graphic graphic_picture graphicRef82836 \" href=\"UTD.htm?16/21/16722\">",
"     picture 15A",
"    </a>",
"    ). To perform this test, the patient&rsquo;s serum is overlaid on an epithelial tissue substrate, incubated, and then stained for fluorescent detection of antibodies (",
"    <a class=\"graphic graphic_table graphicRef57402 \" href=\"UTD.htm?3/57/3997\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=see_link&amp;anchor=H4714372#H4714372\">",
"     \"Approach to the patient with cutaneous blisters\", section on 'Indirect immunofluorescence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4989279\">",
"    <span class=\"h4\">",
"     Bullous pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various tissue substrates containing epithelial basement membrane zones have been used to perform IIF in bullous pemphigoid. Monkey esophagus is a useful substrate because it can broadly categorize immunobullous diseases based on antibody staining patterns (",
"    <a class=\"graphic graphic_algorithm graphicRef76558 \" href=\"UTD.htm?29/8/29827\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"     \"Paraneoplastic pemphigus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"     \"Linear IgA bullous dermatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link\">",
"     \"Dermatitis herpetiformis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human skin (from cadavers or surgical waste) that is artificially split at the level of the lamina lucida (",
"    <strong>",
"     basement membrane zone-split skin",
"    </strong>",
"    ) using prolonged (48 to 72 hours) exposure to 1 M sodium chloride (",
"    <strong>",
"     salt-split skin",
"    </strong>",
"    ) or short (30 minutes) exposure to ethylenediaminetetraacetic acid (EDTA) is a useful substrate, particularly when basement membrane zone antibodies are known. This is because of high test sensitivity that exceeds 80 percent and the value of the test for distinguishing between certain subepithelial immunobullous diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/53,59,60\">",
"     53,59,60",
"    </a>",
"    ]. In a study of 23 patients with bullous pemphigoid, IIF on basement membrane zone-split skin was positive in 22 out of 23 patients (96 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/53\">",
"     53",
"    </a>",
"    ]. A separate study in which sera from 20 patients with bullous pemphigoid were evaluated yielded similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IIF with a basement membrane zone-split skin substrate aids in distinguishing between certain subepithelial immunobullous diseases because the test allows for localization of antibody deposition within the basement membrane zone. Specimens from patients with bullous pemphigoid typically demonstrate",
"    <strong>",
"     antibody deposition localized to the epidermal side of basement membrane zone-split skin",
"    </strong>",
"    , whereas in specimens from patients with epidermolysis bullosa acquisita, bullous lupus erythematosus, anti-laminin 332 pemphigoid, and anti-laminin &gamma;1 pemphigoid, antibodies are typically found on the dermal side (",
"    <a class=\"graphic graphic_picture graphicRef82836 graphicRef86374 \" href=\"UTD.htm?18/10/18599\">",
"     picture 15A-B",
"    </a>",
"    ). Combined epidermal-dermal staining patterns on basement membrane zone-split skin also are found in bullous pemphigoid and bullous lupus erythematosus (",
"    <a class=\"graphic graphic_picture graphicRef87135 \" href=\"UTD.htm?30/18/31011\">",
"     picture 16",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4989293\">",
"    <span class=\"h4\">",
"     Mucous membrane pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early studies of MMP, IIF was positive in fewer than one-third of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"     32",
"    </a>",
"    ]. However, the use of human basement membrane zone-split skin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concentrated serum may increase the likelihood of detecting circulating antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/32,59,61\">",
"     32,59,61",
"    </a>",
"    ]. In one series of eight patients with MMP, IIF on basement membrane zone-split skin was positive in 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/59\">",
"     59",
"    </a>",
"    ]. A larger series of 67 patients found that IIF on a basement membrane zone-split skin substrate yielded detectable antibodies in 84 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In MMP, basement membrane zone split-skin IIF is particularly useful for recognizing patients at risk for malignancy-associated laminin 332 MMP; in this condition, antibodies are found along the dermal side of the split [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Specific testing to confirm a diagnosis of anti-laminin 332 MMP remains limited to specialized centers and research settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20007021\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53290547\">",
"    <span class=\"h3\">",
"     Antigen-specific serological testing",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4989456\">",
"    <span class=\"h4\">",
"     Bullous pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequent presence of detectable circulating IgG antibodies against bullous pemphigoid antigen 180 (BP180) and bullous pemphigoid antigen 230 (BP230) in patients with bullous pemphigoid has led to the use of antigen-specific serological testing as an adjunctive test for the diagnosis of this disorder. The most common technique used for this purpose is enzyme-linked immunosorbent assay (ELISA). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link&amp;anchor=H589258#H589258\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Bullous pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    ELISA for bullous pemphigoid antibodies is commercially available. This testing detects circulating IgG that reacts with BP180 (specifically, the NC16A domain of BP180, which is the most common antigenic target) and with BP230 (specifically, fused antigenic targets from the N-terminal domain, central rod domain, and C-terminal domain of human BP230).",
"   </p>",
"   <p>",
"    ELISA for the BP180 NC16A domain is useful for the diagnosis of bullous pemphigoid; studies have documented sensitivity and specificity numbers of 79 to 90 percent and 90 to 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/60,65,66\">",
"     60,65,66",
"    </a>",
"    ]. Since BP180 NC16A antibody levels also correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/67\">",
"     67",
"    </a>",
"    ], many clinicians (including ourselves) utilize ELISA testing, not only to support the diagnosis of bullous pemphigoid, but also as a measure of the response to therapy. &nbsp;",
"   </p>",
"   <p>",
"    ELISA for BP230 is less likely to be positive in bullous pemphigoid than ELISA testing for BP180 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/60,68\">",
"     60,68",
"    </a>",
"    ]. In a retrospective study that evaluated ELISA results in 190 patients with bullous pemphigoid, the sensitivity and specificity of the assay for BP230 were 61 and 96 percent compared with 79 and 90 percent for BP180 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/60\">",
"     60",
"    </a>",
"    ]. Moreover, combined testing for BP180 and BP230 was only slightly more sensitive than BP180 alone; the sensitivity and specificity of conjoint testing were 87 and 88 percent. Although this finding suggests that testing for BP230 should be reserved for patients who test negatively for BP180, immunodermatology laboratories, including ours, test for antibodies to both antigens in diagnostic panels for bullous pemphigoid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/60\">",
"     60",
"    </a>",
"    ]. We have observed a small subset of pemphigoid patients who have strong epidermal pattern basement membrane zone IgG antibodies by IIF and relatively high levels of IgG BP230 antibodies by ELISA, but normal IgG BP180 antibody levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link&amp;anchor=H589251#H589251\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also, in our experience, approximately 10 percent of patients with bullous pemphigoid demonstrate characteristic epidermal pattern IgG basement membrane zone antibodies by IIF and normal levels of both IgG BP180 and IgG BP230 antibodies by ELISA. These patients likely have antibodies to epitopes of BP180 or BP230 that are not recognized by commercial ELISA tests or may have antibodies to basement membrane zone antigens other than BP180 and BP230. This finding supports the importance of performing both IIF and ELISA testing to identify patients with bullous pemphigoid.",
"   </p>",
"   <p>",
"    Of note, the detection of BP180",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    BP230 antibodies in serum does not definitively confirm a diagnosis of bullous pemphigoid. In one series of 337 people without bullous pemphigoid, 25 (7 percent) tested positively for one or both autoantibodies via ELISA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/69\">",
"     69",
"    </a>",
"    ]. Correlation of ELISA findings with DIF will reduce the risk for misdiagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other techniques that have been utilized for the detection of antibodies in bullous pemphigoid include immunoblotting and immunoprecipitation. However, these tests are technically demanding and generally are not utilized in the clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/2,53\">",
"     2,53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4989441\">",
"    <span class=\"h4\">",
"     Mucous membrane pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;MMP may present with autoantibodies directed against a variety of antigens, including BP180, BP230, laminin 332 (also known as epiligrin and laminin 5), &alpha;6&beta;4 integrin, and type VII collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/30,70-72\">",
"     30,70-72",
"    </a>",
"    ]. Antigen specific testing for basement membrane zone antibodies other than BP180 and BP230 primarily is limited to research laboratories, limiting the value of this testing mode in the MMP population. However, additional tests may be available in the future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=see_link&amp;anchor=H589279#H589279\">",
"     \"Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid\", section on 'Mucous membrane pemphigoid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588056\">",
"    <span class=\"h3\">",
"     Other laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood eosinophilia is common in patients with bullous pemphigoid, but is not a diagnostic finding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Increased serum IgE levels also are commonly found [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20007021\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical findings in bullous pemphigoid and MMP may resemble a variety of other diseases, including other variants of pemphigoid and additional blistering or non-blistering diseases (",
"    <a class=\"graphic graphic_table graphicRef69192 \" href=\"UTD.htm?1/0/1036\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467777\">",
"    <span class=\"h2\">",
"     Other pemphigoid variants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467836\">",
"    <span class=\"h3\">",
"     Pemphigoid gestationis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pemphigoid gestationis is an autoimmune subepidermal blistering disorder that develops during pregnancy and the postpartum period. Patients typically develop intensely pruritic papules, urticarial plaques, vesicles, and bullae that begin on the abdomen prior to spreading to other areas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. The face and mucous membranes are usually spared.",
"   </p>",
"   <p>",
"    Like bullous pemphigoid, patients with pemphigoid gestationis have circulating BP180 antibodies that are detected by ELISA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/78\">",
"     78",
"    </a>",
"    ]. On DIF, complement deposition predominates at the basement membrane zone. Pemphigoid gestationis is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=see_link&amp;anchor=H2#H2\">",
"     \"Dermatoses of pregnancy\", section on 'Pemphigoid gestationis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467889\">",
"    <span class=\"h3\">",
"     Laminin &gamma;1 pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laminin &gamma;1 pemphigoid (previously known as anti-p200 pemphigoid) is a more recently described variant of pemphigoid that is characterized by antibodies to a 200 kilodalton component of the dermal-epidermal junction. IIF on basement membrane zone-split skin demonstrates dermal localization of basement membrane zone antibodies IIF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/79\">",
"     79",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H53290533\">",
"     'Direct immunofluorescence'",
"    </a>",
"    above). The antigenic target is the &gamma;1 subunit of laminin 311.",
"   </p>",
"   <p>",
"    Patients with this type of pemphigoid are usually younger than those with bullous pemphigoid, but present with similar clinical features. In one series of 29 patients with this disorder, 25 patients were male, and the mean age of patients was 61 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/80\">",
"     80",
"    </a>",
"    ]. Additionally, 14 patients had coexistent psoriasis.",
"   </p>",
"   <p>",
"    Specific testing to confirm the presence of anti-laminin &gamma;1 pemphigoid via immunoblotting or ELISA remains primarily limited to specialized centers and research settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467264\">",
"    <span class=\"h3\">",
"     Brunsting-Perry pemphigoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brunsting-Perry pemphigoid is a cicatricial (scarring) form of pemphigoid that most commonly occurs in older men. Affected patients develop subepidermal blisters localized to the head or neck (",
"    <a class=\"graphic graphic_picture graphicRef54769 \" href=\"UTD.htm?5/47/5876\">",
"     picture 17",
"    </a>",
"    ). A variety of basement membrane zone antibodies have been detected in this variant [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/82-84\">",
"     82-84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12467920\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examples of non-pemphigoid disorders in the differential diagnosis for patients with cutaneous lesions are included below (",
"    <a class=\"graphic graphic_table graphicRef69192 \" href=\"UTD.htm?1/0/1036\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef76558 \" href=\"UTD.htm?29/8/29827\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Urticaria and eczematous dermatitis",
"      </strong>",
"      &ndash; The prodromal phase lesions of bullous pemphigoid may resemble the erythematous and edematous plaques of urticaria or the erythematous papules or plaques of eczematous dermatitis. Unlike true urticaria, the lesions of bullous pemphigoid are not transient. DIF studies of biopsy specimens are useful for distinguishing both of these disorders from bullous pemphigoid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=see_link\">",
"       \"New onset urticaria\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Skin-predominant epidermolysis bullosa acquisita",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Epidermolysis bullosa acquisita is a rare disorder characterized by subepidermal blister formation involving the skin and mucous membranes (",
"      <a class=\"graphic graphic_picture graphicRef62505 \" href=\"UTD.htm?21/36/22085\">",
"       picture 18",
"      </a>",
"      ). Unlike bullous pemphigoid, immunofluorescence on basement membrane zone-split skin demonstrates antibody bound to the dermal side of the split, and residual scarring and milia are common. Specific ELISA testing for antibodies to type VII collagen is useful for making this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"       \"Epidermolysis bullosa acquisita\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pemphigus",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Pemphigus is a group of autoimmune blistering disorders characterized by autoantibodies directed against epithelial cell surface antigens (also known as intercellular substance antigens). The flaccid nature of blisters in pemphigus contrasts with the tense, subepidermal bullae in pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef53425 graphicRef63170 \" href=\"UTD.htm?17/14/17642\">",
"       picture 3A-B",
"      </a>",
"      ). DIF studies are essential for diagnosis. Several pemphigus variants exist, including paraneoplastic pemphigus, which may show basement membrane zone antibodies in addition to cell surface antibodies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"       \"Paraneoplastic pemphigus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"       \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Linear IgA bullous dermatosis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Linear IgA bullous dermatosis is an autoimmune subepithelial blistering disorder that usually presents with annular and grouped tense vesicles arising on inflamed skin (",
"      <a class=\"graphic graphic_picture graphicRef56434 \" href=\"UTD.htm?15/62/16359\">",
"       picture 19",
"      </a>",
"      ). The skin lesions often are described as resembling a cluster of jewels. Mucosal sites also may be affected. The DIF finding of linear IgA antibody staining at the basement membrane zone in a perilesional skin biopsy specimen is essential for this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"       \"Linear IgA bullous dermatosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dermatitis herpetiformis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Intensely pruritic inflammatory papules, vesicles, or crusts with a predilection for the elbows, knees, and buttocks are characteristic of dermatitis herpetiformis, another autoimmune subepidermal blistering disorder (",
"      <a class=\"graphic graphic_picture graphicRef78315 \" href=\"UTD.htm?23/38/24163\">",
"       picture 20",
"      </a>",
"      ). The histopathological finding of neutrophilic microabscesses in dermal papillary tips by H&amp;E and the immunohistological detection of granular",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrillar IgA deposits in the papillary dermis by DIF are consistent with this diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=see_link\">",
"       \"Dermatitis herpetiformis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bullous lupus erythematosus",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Bullous systemic lupus erythematosus is a rare disorder. The development of subepidermal blisters with neutrophilic infiltrates in a patient with systemic lupus erythematosus suggests this disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=see_link&amp;anchor=H10#H10\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Bullous skin lesions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H588016\">",
"    <span class=\"h2\">",
"     Mucosal lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of mucosal erosions that must be distinguished from those associated with MMP and bullous pemphigoid include pemphigus variants (",
"    <a class=\"graphic graphic_picture graphicRef57924 graphicRef59594 \" href=\"UTD.htm?39/61/40918\">",
"     picture 21A-B",
"    </a>",
"    ), linear IgA bullous dermatosis or epidermolysis bullosa acquisita with mucosal involvement, oral lichen planus (",
"    <a class=\"graphic graphic_picture graphicRef54143 graphicRef60224 \" href=\"UTD.htm?3/28/3527\">",
"     picture 22A-B",
"    </a>",
"    ), erythema multiforme (",
"    <a class=\"graphic graphic_picture graphicRef68153 graphicRef58969 \" href=\"UTD.htm?18/31/18936\">",
"     picture 23A-B",
"    </a>",
"    ), Stevens-Johnson syndrome (",
"    <a class=\"graphic graphic_picture graphicRef73805 \" href=\"UTD.htm?30/7/30836\">",
"     picture 24",
"    </a>",
"    ), HIV-associated mucosal lesions, Beh&ccedil;et's syndrome, and aphthous ulcers (",
"    <a class=\"graphic graphic_picture graphicRef63475 \" href=\"UTD.htm?13/25/13713\">",
"     picture 25",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/11/22714/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=see_link\">",
"     \"Paraneoplastic pemphigus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=see_link\">",
"     \"Linear IgA bullous dermatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=see_link\">",
"     \"Epidermolysis bullosa acquisita\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=see_link\">",
"     \"Oral lichen planus: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of erythema multiforme\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=see_link&amp;anchor=H16#H16\">",
"     \"Oral lesions\", section on 'Aphthous ulcerations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of pemphigus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis for ocular involvement is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H378908#H378908\">",
"     \"Ocular cicatricial pemphigoid\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H785956\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bullous pemphigoid and mucous membrane pemphigoid (MMP) are uncommon autoimmune subepithelial blistering disorders that affect skin and mucous membranes. (See",
"      <a class=\"local\" href=\"#H784094\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Features of bullous pemphigoid",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The onset of blistering lesions in bullous pemphigoid is frequently preceded by a prodromal phase characterized by pruritic inflammatory plaques that resemble eczematous dermatitis or urticaria. Once the bullous phase develops, patients exhibit multiple tense 1 to 3 cm bullae as well as erosions and crusts at sites of ruptured bullae (",
"      <a class=\"graphic graphic_picture graphicRef54541 graphicRef70352 graphicRef79112 \" href=\"UTD.htm?33/1/33818\">",
"       picture 2A-C",
"      </a>",
"      ). The lesions of bullous pemphigoid usually heal without scarring. (See",
"      <a class=\"local\" href=\"#H53290498\">",
"       'Bullous pemphigoid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The trunk and extremities are typically involved in bullous pemphigoid; localized presentations also may occur. Mucosal disease is present in 10 to 30 percent of patients. (See",
"      <a class=\"local\" href=\"#H53290498\">",
"       'Bullous pemphigoid'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Features of MMP",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      MMP most commonly presents as desquamative gingivitis or erosions of the oral mucosa. Other potential sites of mucosal involvement include the ocular conjunctiva, skin, pharynx, genitalia, nasal mucosa, larynx, anus, and esophagus (",
"      <a class=\"graphic graphic_picture graphicRef73874 graphicRef52208 graphicRef63997 \" href=\"UTD.htm?38/6/39017\">",
"       picture 8A-C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H53290512\">",
"       'Mucous membrane pemphigoid'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=see_link&amp;anchor=H2913497#H2913497\">",
"       \"Ocular cicatricial pemphigoid\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unlike bullous pemphigoid, lesions of MMP tend to scar. Scarring may result in serious functional impairment. (See",
"      <a class=\"local\" href=\"#H53290512\">",
"       'Mucous membrane pemphigoid'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with the anti-laminin 332 (anti-laminin 5 or anti-epiligrin) form of MMP have an increased risk for internal malignancy. An evaluation for associated malignancy should be performed in patients with immunohistological findings that suggest this disorder. Specific testing for antibodies against laminin 332 is not yet widely available. (See",
"      <a class=\"local\" href=\"#H3867571\">",
"       'Malignancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Diagnosis",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The evaluation of patients with clinical findings suggestive of bullous pemphigoid or MMP begins with obtaining skin or mucous membrane biopsy specimens from both lesional tissue for H&amp;E (light microscopic histology) and perilesional tissue for direct immunofluorescence (DIF) (",
"      <a class=\"graphic graphic_algorithm graphicRef76558 \" href=\"UTD.htm?29/8/29827\">",
"       algorithm 1",
"      </a>",
"      ). DIF is the gold standard for diagnosis and demonstrates characteristic basement membrane zone antibody localization in virtually all patients with bullous pemphigoid and the majority of patients with MMP (",
"      <a class=\"graphic graphic_picture graphicRef86372 graphicRef86950 \" href=\"UTD.htm?37/57/38808\">",
"       picture 12A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H554282\">",
"       'Skin biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serological studies to detect circulating basement membrane zone antibodies by indirect immunofluorescence (IIF) and enzyme-linked immunoassay (ELISA) also are useful for the diagnosis of bullous pemphigoid (",
"      <a class=\"graphic graphic_picture graphicRef82836 \" href=\"UTD.htm?16/21/16722\">",
"       picture 15A",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef76558 \" href=\"UTD.htm?29/8/29827\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H53290540\">",
"       'Indirect immunofluorescence of serum'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H53290547\">",
"       'Antigen-specific serological testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of bullous pemphigoid and MMP is broad (",
"      <a class=\"graphic graphic_table graphicRef69192 \" href=\"UTD.htm?1/0/1036\">",
"       table 1",
"      </a>",
"      ). The possibility of other pemphigoid disorders, other blistering disorders, and nonbullous diseases must be considered. (See",
"      <a class=\"local\" href=\"#H20007021\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/1\">",
"      Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/2\">",
"      Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Dermatol Clin 2011; 29:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/3\">",
"      Kasperkiewicz M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity 2012; 45:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/4\">",
"      Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol 2007; 23:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/5\">",
"      Uzun S, Durdu M. The specificity and sensitivity of Nikolskiy sign in the diagnosis of pemphigus. J Am Acad Dermatol 2006; 54:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/6\">",
"      Yancey KB, Egan CA. Pemphigoid: clinical, histologic, immunopathologic, and therapeutic considerations. JAMA 2000; 284:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/7\">",
"      Tran JT, Mutasim DF. Localized bullous pemphigoid: a commonly delayed diagnosis. Int J Dermatol 2005; 44:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/8\">",
"      Borradori L, Prost C, Wolkenstein P, et al. Localized pretibial pemphigoid and pemphigoid nodularis. J Am Acad Dermatol 1992; 27:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/9\">",
"      Kitajima Y, Suzuki M, Johkura Y, Yaoita H. Localized bullous pemphigoid: report of a case with an immunofluorescence and electron microscopical studies on the lesional distribution of 180-KD bullous pemphigoid antigen, beta 4 integrin, and type VII collagen. J Dermatol 1993; 20:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/10\">",
"      Kakurai M, Demitsu T, Azuma R, et al. Localized pemphigoid (pretibial type) with IgG antibody to BP180 NC16a domain successfully treated with minocycline and topical corticosteroid. Clin Exp Dermatol 2007; 32:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/11\">",
"      Kohroh K, Suga Y, Mizuno Y, et al. Case of localized bullous pemphigoid with unique clinical manifestations in the lower legs. J Dermatol 2007; 34:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/12\">",
"      Urano S. Localized bullous pemphigoid of the vulva. J Dermatol 1996; 23:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/13\">",
"      Saad RW, Domloge-Hultsch N, Yancey KB, et al. Childhood localized vulvar pemphigoid is a true variant of bullous pemphigoid. Arch Dermatol 1992; 128:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/14\">",
"      Batalla A, Pe&oacute;n G, De la Torre C. Localized bullous pemphigoid at urostomy site. Indian J Dermatol Venereol Leprol 2011; 77:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/15\">",
"      Vande Maele DM, Reilly JC. Bullous pemphigoid at colostomy site: report of a case. Dis Colon Rectum 1997; 40:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/16\">",
"      Sheerin N, Bourke JF, Holder J, et al. Bullous pemphigoid following radiotherapy. Clin Exp Dermatol 1995; 20:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/17\">",
"      Mul VE, van Geest AJ, Pijls-Johannesma MC, et al. Radiation-induced bullous pemphigoid: a systematic review of an unusual radiation side effect. Radiother Oncol 2007; 82:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/18\">",
"      Baykal C, Okan G, Sarica R. Childhood bullous pemphigoid developed after the first vaccination. J Am Acad Dermatol 2001; 44:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/19\">",
"      Quartey-Papafio CM, Hudson PM. Bullous pemphigoid initially localized to sites of burns (scalds) in a patient on sulphasalazine for ulcerative colitis. Clin Exp Dermatol 1994; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/20\">",
"      Macfarlane AW, Verbov JL. Trauma-induced bullous pemphigoid. Clin Exp Dermatol 1989; 14:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/21\">",
"      Salomon RJ, Briggaman RA, Wernikoff SY, Kayne AL. Localized bullous pemphigoid. A mimic of acute contact dermatitis. Arch Dermatol 1987; 123:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/22\">",
"      Kaplan RP. Cutaneous involvement in localized forms of bullous pemphigoid. Clin Dermatol 1987; 5:43.",
"     </a>",
"    </li>",
"    <li>",
"     Alonso-Llamazares J, Peters MS, Leiferman KM. Bullous Pemphigoid. In: Atlas of Bullous Disease, Jordon RE (Ed), Churchill Livingstone, San Francisco 2000. p.43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/24\">",
"      Kim J, Chavel S, Girardi M, McNiff JM. Pemphigoid vegetans: a case report and review of the literature. J Cutan Pathol 2008; 35:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/25\">",
"      Chan LS, Dorman MA, Agha A, et al. Pemphigoid vegetans represents a bullous pemphigoid variant. Patient's IgG autoantibodies identify the major bullous pemphigoid antigen. J Am Acad Dermatol 1993; 28:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/26\">",
"      Gharami RC, Kumar P, Mondal A, Ghosh K. Dyshidrosiform Pemphigus vulgaris: Report of an unusual case. Dermatol Online J 2010; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/27\">",
"      Kim YJ, Kim MY, Kim HO, Park YM. Dyshidrosiform bullous pemphigoid. Acta Derm Venereol 2004; 84:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/28\">",
"      Lai FJ, Sheu HM, Lee JY, et al. Vesicular pemphigoid with circulating autoantibodies against 230-kDa and 180-kDa proteins, and additional autoantibodies against 97-kDa and 45-kDa proteins. Int J Dermatol 2007; 46:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/29\">",
"      Zillikens D, Caux F, Mascaro JM, et al. Autoantibodies in lichen planus pemphigoides react with a novel epitope within the C-terminal NC16A domain of BP180. J Invest Dermatol 1999; 113:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/30\">",
"      Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/31\">",
"      Ahmed AR, Hombal SM. Cicatricial pemphigoid. Int J Dermatol 1986; 25:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/32\">",
"      Fleming TE, Korman NJ. Cicatricial pemphigoid. J Am Acad Dermatol 2000; 43:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/33\">",
"      Long CC, Lever LR, Marks R. Unilateral bullous pemphigoid in a hemiplegic patient. Br J Dermatol 1992; 126:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/34\">",
"      Bunker CB, Brown E. Unilateral bullous pemphigoid in a hemiplegic patient. Br J Dermatol 1993; 129:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/35\">",
"      Foureur N, Descamps V, Lebrun-Vignes B, et al. Bullous pemphigoid in a leg affected with hemiparesia: a possible relation of neurological diseases with bullous pemphigoid? Eur J Dermatol 2001; 11:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/36\">",
"      Stinco G, Codutti R, Scarbolo M, et al. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol 2005; 85:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/37\">",
"      Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol 2011; 131:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/38\">",
"      Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Invest Dermatol 2011; 131:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/39\">",
"      Masouy&eacute; I, Schmied E, Didierjean L, et al. Bullous pemphigoid and multiple sclerosis: more than a coincidence? Report of three cases. J Am Acad Dermatol 1989; 21:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/40\">",
"      Kirtschig G, Walkden VM, Venning VA, Wojnarowska F. Bullous pemphigoid and multiple sclerosis: a report of three cases and review of the literature. Clin Exp Dermatol 1995; 20:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/41\">",
"      Stinco G, Mattighello P, Zanchi M, Patrone P. Multiple sclerosis and bullous pemphigoid: a casual association or a pathogenetic correlation? Eur J Dermatol 2002; 12:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/42\">",
"      Nielsen NM, Frisch M, Rostgaard K, et al. Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult Scler 2008; 14:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/43\">",
"      Chosidow O, Doppler V, Bensimon G, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol 2000; 136:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/44\">",
"      Langer-Gould A, Albers KB, Van Den Eeden SK, Nelson LM. Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study. Mult Scler 2010; 16:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/45\">",
"      Bouras C, Riederer BM, K&ouml;vari E, et al. Humoral immunity in brain aging and Alzheimer's disease. Brain Res Brain Res Rev 2005; 48:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/46\">",
"      Laffitte E, Burkhard PR, Fontao L, et al. Bullous pemphigoid antigen 1 isoforms: potential new target autoantigens in multiple sclerosis? Br J Dermatol 2005; 152:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/47\">",
"      Chen J, Li L, Chen J, et al. Sera of elderly bullous pemphigoid patients with associated neurological diseases recognize bullous pemphigoid antigens in the human brain. Gerontology 2011; 57:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/48\">",
"      Li L, Chen J, Wang B, et al. Sera from patients with bullous pemphigoid (BP) associated with neurological diseases recognized BP antigen 1 in the skin and brain. Br J Dermatol 2009; 160:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/49\">",
"      Egan CA, Lazarova Z, Darling TN, et al. Anti-epiligrin cicatricial pemphigoid and relative risk for cancer. Lancet 2001; 357:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/50\">",
"      Sadler E, Lazarova Z, Sarasombath P, Yancey KB. A widening perspective regarding the relationship between anti-epiligrin cicatricial pemphigoid and cancer. J Dermatol Sci 2007; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/51\">",
"      Miyazaki K. Laminin-5 (laminin-332): Unique biological activity and role in tumor growth and invasion. Cancer Sci 2006; 97:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/52\">",
"      Lara-Corrales I, Pope E. Autoimmune blistering diseases in children. Semin Cutan Med Surg 2010; 29:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/53\">",
"      Chan YC, Sun YJ, Ng PP, Tan SH. Comparison of immunofluorescence microscopy, immunoblotting and enzyme-linked immunosorbent assay methods in the laboratory diagnosis of bullous pemphigoid. Clin Exp Dermatol 2003; 28:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/54\">",
"      Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev 2010; 10:84.",
"     </a>",
"    </li>",
"    <li>",
"     Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, 2010. p.123.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/56\">",
"      Yayli S, Pelivani N, Beltraminelli H, et al. Detection of linear IgE deposits in bullous pemphigoid and mucous membrane pemphigoid: a useful clue for diagnosis. Br J Dermatol 2011; 165:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/57\">",
"      Vodegel RM, Jonkman MF, Pas HH, de Jong MC. U-serrated immunodeposition pattern differentiates type VII collagen targeting bullous diseases from other subepidermal bullous autoimmune diseases. Br J Dermatol 2004; 151:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/58\">",
"      Terra JB, Pas HH, Hertl M, et al. Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients. Br J Dermatol 2011; 165:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/59\">",
"      Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol 1988; 118:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/60\">",
"      Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol 2011; 147:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/61\">",
"      Setterfield J, Shirlaw PJ, Kerr-Muir M, et al. Mucous membrane pemphigoid: a dual circulating antibody response with IgG and IgA signifies a more severe and persistent disease. Br J Dermatol 1998; 138:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/62\">",
"      Domloge-Hultsch N, Anhalt GJ, Gammon WR, et al. Antiepiligrin cicatricial pemphigoid. A subepithelial bullous disorder. Arch Dermatol 1994; 130:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/63\">",
"      Domloge-Hultsch N, Gammon WR, Briggaman RA, et al. Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease. J Clin Invest 1992; 90:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/64\">",
"      Bekou V, Thoma-Uszynski S, Wendler O, et al. Detection of laminin 5-specific auto-antibodies in mucous membrane and bullous pemphigoid sera by ELISA. J Invest Dermatol 2005; 124:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/65\">",
"      Sitaru C, D&auml;hnrich C, Probst C, et al. Enzyme-linked immunosorbent assay using multimers of the 16th non-collagenous domain of the BP180 antigen for sensitive and specific detection of pemphigoid autoantibodies. Exp Dermatol 2007; 16:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/66\">",
"      Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci 2002; 30:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/67\">",
"      Schmidt E, Obe K, Br&ouml;cker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000; 136:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/68\">",
"      Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol 2011; 147:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/69\">",
"      Wieland CN, Comfere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol 2010; 146:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/70\">",
"      Rashid KA, G&uuml;rcan HM, Ahmed AR. Antigen specificity in subsets of mucous membrane pemphigoid. J Invest Dermatol 2006; 126:2631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/71\">",
"      Chan LS, Majmudar AA, Tran HH, et al. Laminin-6 and laminin-5 are recognized by autoantibodies in a subset of cicatricial pemphigoid. J Invest Dermatol 1997; 108:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/72\">",
"      Lazarova Z, Yee C, Lazar J, Yancey KB. IgG autoantibodies in patients with anti-epiligrin cicatricial pemphigoid recognize the G domain of the laminin 5 alpha-subunit. Clin Immunol 2001; 101:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/73\">",
"      Kulthanan K, Chularojanamontri L, Tuchinda P, et al. Prevalence and clinical features of Thai patients with bullous pemphigoid. Asian Pac J Allergy Immunol 2011; 29:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/74\">",
"      Bushkell LL, Jordon RE. Bullous pemphigoid: a cause of peripheral blood eosinophilia. J Am Acad Dermatol 1983; 8:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/75\">",
"      Arbesman CE, Wypych JI, Reisman RE, Beutner EH. IgE levels in sera of patients with pemphigus or bullous pemphigoid. Arch Dermatol 1974; 110:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/76\">",
"      Ambros-Rudolph CM, Black MM. From prurigo gestationis Besnier to atopic eruption of pregnancy: the confusing nosology of the less well-defined dermatoses of pregnancy has been largely clarified. Clin Dermatol 2006; 24:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/77\">",
"      Ambros-Rudolph CM, M&uuml;llegger RR, Vaughan-Jones SA, et al. The specific dermatoses of pregnancy revisited and reclassified: results of a retrospective two-center study on 505 pregnant patients. J Am Acad Dermatol 2006; 54:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/78\">",
"      Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol 1994; 102:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/79\">",
"      Zillikens D, Kawahara Y, Ishiko A, et al. A novel subepidermal blistering disease with autoantibodies to a 200-kDa antigen of the basement membrane zone. J Invest Dermatol 1996; 106:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/80\">",
"      Dilling A, Rose C, Hashimoto T, et al. Anti-p200 pemphigoid: a novel autoimmune subepidermal blistering disease. J Dermatol 2007; 34:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/81\">",
"      Groth S, Recke A, Vafia K, et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/82\">",
"      Mart&iacute;n JM, Pinazo I, Molina I, et al. Cicatricial pemphigoid of the Brunsting-Perry type. Int J Dermatol 2009; 48:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/83\">",
"      Jedlickova H, Niedermeier A, Zga��arov&aacute; S, Hertl M. Brunsting-Perry pemphigoid of the scalp with antibodies against laminin 332. Dermatology 2011; 222:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/11/22714/abstract/84\">",
"      Fukuda S, Tsuruta D, Uchiyama M, et al. Brunsting-Perry type pemphigoid with IgG autoantibodies to laminin-332, BP230 and desmoplakins I/II. Br J Dermatol 2011; 165:433.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16176 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-E8883028DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22714=[""].join("\n");
var outline_f22_11_22714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H785956\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H590249\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H784094\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53290498\">",
"      Bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53290512\">",
"      Mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3867557\">",
"      ASSOCIATED DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3867564\">",
"      Neurologic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3867571\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H785112\">",
"      DISEASE COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20007006\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H587825\">",
"      Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20007014\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H404213\">",
"      - Our approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H554282\">",
"      - Skin biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4988524\">",
"      Light microscopy of formalin-fixed tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H53290533\">",
"      Direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53290540\">",
"      - Indirect immunofluorescence of serum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4989279\">",
"      Bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4989293\">",
"      Mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53290547\">",
"      - Antigen-specific serological testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4989456\">",
"      Bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H4989441\">",
"      Mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H588056\">",
"      - Other laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20007021\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12467777\">",
"      Other pemphigoid variants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12467836\">",
"      - Pemphigoid gestationis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12467889\">",
"      - Laminin &gamma;1 pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12467264\">",
"      - Brunsting-Perry pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12467920\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H588016\">",
"      Mucosal lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H785956\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16176\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16176|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/8/29827\" title=\"algorithm 1\">",
"      Clinical testing for pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16176|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/63/4086\" title=\"figure 1\">",
"      Epidermal basement membrane zone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16176|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/50/42788\" title=\"picture 1\">",
"      Bullous pemphigoid eczematous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/57/36758\" title=\"picture 2A\">",
"      Bullous pemphigoid tense bullae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/24/21892\" title=\"picture 2B\">",
"      Bullous pemphigoid tense bullae 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/33/31251\" title=\"picture 2C\">",
"      Bullous pemphigoid on urticarial plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/56/27526\" title=\"picture 3A\">",
"      Pemphigus vulgaris bullae and erosions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/35/40502\" title=\"picture 3B\">",
"      Pemphigus vulgaris large erosions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/16/26885\" title=\"picture 4A\">",
"      Bullous pemphigoid multiple lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/53/24406\" title=\"picture 4B\">",
"      Bullous pemphigoid axillae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/47/14070\" title=\"picture 4C\">",
"      Bullous pemphigoid trunk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/58/32675\" title=\"picture 5\">",
"      Bullous pemphigoid oral mucosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/28/452\" title=\"picture 6\">",
"      Bullous pemphigoid on lower legs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/23/26997\" title=\"picture 7\">",
"      Dyshidrosiform bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/7/33905\" title=\"picture 8A\">",
"      Mucous membrane pemphigoid gingivitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20226\" title=\"picture 8B\">",
"      Mucous membrane pemphigoid lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/49/38674\" title=\"picture 8C\">",
"      Mucous membrane pemphigoid palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/29/15827\" title=\"picture 9\">",
"      Bullous pemphigoid in childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/18/25895\" title=\"picture 10\">",
"      Bullous pemphigoid eosinophilic spongiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/15/44279\" title=\"picture 11\">",
"      Bullous pemphigoid pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/58/33700\" title=\"picture 12A\">",
"      Bullous pemphigoid direct immunofluorescence 400X",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/7/7283\" title=\"picture 12B\">",
"      Bullous pemphigoid direct immunofluorescence C3 deposits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/56/6022\" title=\"picture 13\">",
"      N-serrated pattern on direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/5/37971\" title=\"picture 14\">",
"      U-serrated pattern on direct immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/21/16722\" title=\"picture 15A\">",
"      Bullous pemphigoid IIF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/9/40081\" title=\"picture 15B\">",
"      Epidermolysis bullosa acquisita split skin immunofluorescence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/18/31011\" title=\"picture 16\">",
"      Indirect immunofluorescence on basement membrane zone-split skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/47/5876\" title=\"picture 17\">",
"      Brunsting-Perry pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/36/22085\" title=\"picture 18\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/62/16359\" title=\"picture 19\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/38/24163\" title=\"picture 20\">",
"      Dermatitis herpetiformis elbows",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/48/769\" title=\"picture 21A\">",
"      Pemphigus vulgaris - oral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/26/6562\" title=\"picture 21B\">",
"      Paraneoplastic pemphigus oral findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/10/27808\" title=\"picture 22A\">",
"      Oral lichen planus - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/37/40530\" title=\"picture 22B\">",
"      Erosive lichen planus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/62/21474\" title=\"picture 23A\">",
"      Erythema multiforme lip",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/4/9284\" title=\"picture 23B\">",
"      Erythema multiforme tongue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/7/30836\" title=\"picture 24\">",
"      Mucosal changes in Stevens-Johnson syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/25/13713\" title=\"picture 25\">",
"      Aphthous ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16176|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/0/1036\" title=\"table 1\">",
"      Differential diagnosis of pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/57/3997\" title=\"table 2\">",
"      Diagnostic pemphigoid testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/54/14186?source=related_link\">",
"      Approach to the patient with cutaneous blisters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35369?source=related_link\">",
"      Dermatitis herpetiformis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15273?source=related_link\">",
"      Epidemiology and pathogenesis of bullous pemphigoid and mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4858?source=related_link\">",
"      Epidermolysis bullosa acquisita",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/36/14922?source=related_link\">",
"      Linear IgA bullous dermatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/43/3770?source=related_link\">",
"      Management and prognosis of bullous pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/39/39544?source=related_link\">",
"      Management of mucous membrane pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/24/21898?source=related_link\">",
"      New onset urticaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/2/4138?source=related_link\">",
"      Ocular cicatricial pemphigoid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/11/25786?source=related_link\">",
"      Oral lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/11/41144?source=related_link\">",
"      Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/44/18121?source=related_link\">",
"      Paraneoplastic pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37672?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of erythema multiforme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19146?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of pemphigus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/20/40264?source=related_link\">",
"      Skin biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_11_22715="Sx CNS tumor elev ICP child";
var content_f22_11_22715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67480&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonspecific signs and symptoms of increased intracranial pressure in children with central nervous system tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased head circumference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spayed sutures or tense fontanel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head tilt",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of developmental milestones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Older children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intermittent headaches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nausea and vomiting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palliedema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Declining academic performance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Personality changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weight loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anorexia",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22715=[""].join("\n");
var outline_f22_11_22715=null;
var title_f22_11_22716="HRCT patterns in ILD";
var content_f22_11_22716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    HRCT patterns in interstitial lung disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bronchiolitis obliterans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asbestosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Distribution of disease within the lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Peripheral lung zone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asbestosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Bronchiolitis obliterans with organizing pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Eosinophilic pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Central disease (bronchovascular thickening)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lymphangitic carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Upper zone predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Granulomatous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pulmonary histiocytosis X (eosinophilic granuloma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic infectious diseases (eg, tuberculosis, histoplasmosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pneumoconiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Silicosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Berylliosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Coal miners' pneumoconiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Lower zone predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Idiopathic pulmonary fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rheumatoid arthritis (associated with usual interstitial pneumonia)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Asbestosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22716=[""].join("\n");
var outline_f22_11_22716=null;
var title_f22_11_22717="Zofenopril in anterior MI";
var content_f22_11_22717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Zofenopril lowers mortality after anterior MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 272px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative mortality after acute anterior myocardial infarction in 1556 patients randomized to therapy with the ACE inhibitor zofenopril or placebo given within 24 hours after the onset of symptoms and continued for six weeks. Zofenopril was associated with a significant reduction in mortality that was apparent within six weeks (p = 0.011).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Ambrosioni E, Borghi C, Magnani B. N Engl J Med 1995; 332:80.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22717=[""].join("\n");
var outline_f22_11_22717=null;
var title_f22_11_22718="Contents: Pancreatic surgery";
var content_f22_11_22718=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?5/48/5902\">",
"       General Surgery",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pancreatic surgery",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pancreatic surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Pancreatic cancer",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/20/15686\">",
"           Classification of pancreatic cysts",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/49/41753\">",
"           Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/37/33370\">",
"           Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/18/3368\">",
"           Pancreatic cystic neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/27/44472\">",
"           Pathology of exocrine pancreatic neoplasms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/32/33288\">",
"           Pathophysiology and clinical manifestations of intraductal papillary mucinous neoplasm of the pancreas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8746\">",
"           Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic endocrine tumors",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/57/18330\">",
"           Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/10/14504\">",
"           Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/57/31640\">",
"           Glucagonoma and the glucagonoma syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/30/12777\">",
"           Insulinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/51/6968\">",
"           Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/34/3623\">",
"           Somatostatinoma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/59/16311\">",
"           The VIPoma syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatic surgery",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/40/41610\">",
"           Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/32/2569\">",
"           Distal pancreatectomy: Techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/57/38809\">",
"           Pancreatic debridement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/44/43721\">",
"           Pancreaticoduodenectomy (Whipple procedure): Techniques",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/34/8746\">",
"           Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pancreatitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/22/3431\">",
"           Anatomy and clinical significance of pancreas divisum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/14/28903\">",
"           Clinical features, diagnosis, and prevention of pancreatic fistulas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/5/20569\">",
"           Clinical manifestations and diagnosis of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35572\">",
"           Complications of chronic pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/32/17928\">",
"           Diagnosis and management of pseudocysts of the pancreas",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/5/42072\">",
"           Overview of pancreatic stenting and its complications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/46/44774\">",
"           Pathogenesis of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/29/44504\">",
"           Predicting the severity of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/35/7738\">",
"           Treatment of acute pancreatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/58/15271\">",
"           Treatment of pancreas divisum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/20/23878\">",
"           Treatment of pancreatic fistulas",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/19/41272\">",
"           Benefits and complications associated with kidney-pancreas transplantation in diabetes mellitus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/16/7434\">",
"           Patient selection for and immunologic issues relating to kidney-pancreas transplantation in diabetes mellitus",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-704E9158E0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_11_22718=[""].join("\n");
var outline_f22_11_22718=null;
var title_f22_11_22719="Uterus didelphys and vag sept";
var content_f22_11_22719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterus didelphys, bicollis, with complete vaginal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 271px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_11_22719=[""].join("\n");
var outline_f22_11_22719=null;
